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ABSTRACT 
 
 
 
Female Genital Schistosomiasis (FGS) is a clinical manifestation linked to the parasite 
Schistosoma haematobium. Studies have shown that parasite ova can lodge in genital tract tissue 
and cause increased contact bleeding and mucosal lesions called sandy patches. It is also 
hypothesised that FGS is associated with human immunodeficiency virus (HIV) acquisition and 
possible squamous cell atypia (SCA) of the cervix. The aim of this study was to investigate 
whether there is a link between FGS and cervical SCA using non-invasive diagnostic tools and to 
also investigate the effect of mass treatment among participants. 
 
 
This study was nested in a large school based clinical FGS study among girls aged 10-12 (n=708) 
and young women aged 16-23 from two regions in the north (n=833) and south coast (n=394) of 
rural KwaZulu-Natal between 2009 and 2014. Non-invasive diagnostic tests used included Pap 
smear cytology and Liquid-based cytology (LBC), (only among young women) and Schistosoma 
PCR in urine (in girls and young women) and vaginal lavage (among young women only). Urine 
microscopy was also conducted. HPV genotyping was done in a subsample of young women from 
the north coast. Ethical considerations were adhered to. 
 
 
Among the girls, the overall mean prevalence of S. haematobium in urine samples collected on 
three consecutive days was 31.8% and the Schistosoma PCR prevalence was 25.0%. Microscopy 
and PCR results were significantly associated with a history of gynaecologic symptoms among 
the girls. Highly focal distribution of urogenital schistosomiasis was found in the 18 primary 
schools based on PCR, (median= 27.0%, IQR=12.0-38.7%). 
 
 
Among the young women, the prevalence of S. haematobium ova detected in cytology was 8/394 
(2.0%) from the south coast and 12/833 (1.4%) from the north coast. Schistosoma-specific DNA 
was found in 38/394 (9.6%) of vaginal lavages and in 91/394 (23.1%) of the urine from the south 
coast.  There was a significant association between S. haematobium eggs in Pap smears and the 
presence of Schistosoma DNA in lavage (p<0.001). The prevalence of SCA in the south coast was 
107/394 (27.1%) and this was not significantly associated with schistosomiasis. The Schistosoma 
PCR urine and vaginal lavage results from the south coast were included in a comparison of two 
other countries in Africa (Tanzania and Madagascar) each with distinct S. haematobium and S. 
mansoni transmission patterns. In the north coast however, there was a significant association 
between SCA and genital and urinary Schistosoma ova (p=0.005). Additionally 19/833 (2.2%) of 
the young women had high grade squamous intraepithelial lesion 
xvii  
 
(HSIL). Possible risk factors for schistosomiasis and SCA were river water contact, age at sexual 
debut and having at least one child. LBC samples had an improved diagnostic yield compared to 
Pap smears and also enabled HPV genotyping to be done in a subsample of 10 cases with HSIL. 
HPV genotyping revealed at least one or more carcinogenic types of HPV. 
 
 
The outcome of anti-schistosomal treatment on SCA was a challenge to analyze since mass drug 
administration (MDA) did not occur within the study population as planned. Despite this, the 
questionnaire data on reported anti-schistosomal treatment were described in relation to 
schistosomiasis and SCA. The findings of this study reveal that FGS does exist among girls and 
young women in Schistosoma endemic areas. Among the young women, Schistosoma PCR in 
vaginal lavage was an improved method to diagnose FGS rather than conventional cytology. There 
was a statistically significant association between ova in Pap smears and the other diagnostic 
methods used. LBC sampling should be used in FGS populations to detect schistosomiasis and 
SCA, since a single sample can be used for cytology, HPV genotyping as well as possibly 
Schistosoma PCR testing. The high prevalence of HSIL detected in this young population at risk 
for HIV and schistosomiasis raises concern that the screening programme commencing at 30 years 
of age in our study area might be starting too late. The preliminary results for the outcome of 
treatment require further investigation. 
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1.0 CHAPTER ONE 
 
 
1.1 Introduction 
 
Female Genital Schistosomiasis (FGS) refers to the presence and effects of Schistosoma ova 
within the female genital tract.  Ova from the parasite Schistosoma haematobium lodge in 
genital tissues and can cause lesions which result in increased susceptibility to contact bleeding 
and alterations to the mucosa, leading to FGS (Kjetland et al. 2008; Norseth et al. 2014). This 
study focuses on the association between FGS and squamous cell atypia (SCA). SCA 
encompasses a spectrum of atypical changes to cervical cells including pre-cancerous or 
dysplastic changes as well as invasive cervical cancer diagnosed cytologically. An important 
carcinogenic agent in almost all cervical cancers is Human papillomavirus (HPV) (Schiffman 
et al. 2007). There is interest in FGS due to alterations in the mucosa caused by Schistosoma 
ova. Studies have shown that there is a possible link to SCA of the cervix (Petry et al. 2003; 
Kjetland et al. 2009a) and also to HIV acquisition (Mbabazi et al. 2011). Furthermore it has 
also been suggested that anti-schistosomal treatment with Praziquantel could have a positive 
effect on reducing genital lesions (Richter et al. 1996; Downs et al. 2013). 
 
 
The aim of this study was to investigate whether there is a link between FGS and SCA. This 
thesis presents the findings of the prevalence and risk factors for FGS and cervical atypia that 
may lead to cancer. The preliminary findings on the effects of anti-schistosomal treatment on 
cervical atypia are also discussed. The analyses which form the basis of the five included 
manuscripts were conducted in three sub-samples, one among girls and two sub-samples among 
the young women over the five-year study period from two schistosomiasis endemic districts 
in KwaZulu-Natal, South Africa. 
 
 
My link to this research is explained through a brief synopsis of my professional and academic 
background. My post-graduate qualification is a Master of Public Health degree. This has been 
the source of my motivation and grounding for wanting to investigate the public health aspects 
of this research. My undergraduate qualification is laboratory based, and since I was a student 
technologist, I have always had an interest in cytologically diagnosable parasites. As a qualified 
Cytotechnologist, I have a further interest in investigating cytology as a diagnostic tool 
for genital schistosomiasis and cervical atypia. I strongly believe that the girls and women 
of South Africa face much hardship and often bear the scourge of ill health due to preventable 
diseases like schistosomiasis, cervical cancer and HIV. I hope that through this research I am 
able to provide new knowledge and contribute to improving the plight of 
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girls and women in South Africa and globally to reduce their suffering from these preventable 
diseases. An area of new knowledge and technology that was brought into this research was 
the inclusion of Schistosoma PCR in cervico-vaginal lavage sampling and HPV DNA 
genotyping among young women from Schistosoma endemic regions. 
1.2 Aims and Objectives 
 
 
 
Aims                                                                                                                                         To 
determine if FGS is associated with current Human papillomavirus (HPV) and squamous cell 
atypia (SCA) in young women. 
 
To determine if early treatment for schistosomiasis reverses the cytologic indicators of 
gynaecological damage (cervical atypia) caused by S. haematobium ova and if this treatment 
has an impact on HPV and squamous cell atypia. 
 
 
Objectives 
 
The First Objective was to determine the prevalence of SCA and other cytopathology of the 
cervix in the presence of FGS, in young women aged 16-23 of rural KwaZulu-Natal. (Paper 
2, 4 and 5). 
 
 
 
The Second Objective was to determine the epidemiological risk factors for SCA of the cervix 
with special reference to FGS. (Papers 2 and 4). 
 
 
The Third Objective was to develop early diagnostic tools for FGS. In girls aged 10-12 years 
and among young women aged 16-23 years. (Papers 1, 2, 3 and 4). 
 
 
The Fourth Objective was to explore the effect of mass-treatment with Praziquantel on early 
stages of genital disease in the young women. (Paper 5-Short communication). 
 
 
The Fifth Objective was to make recommendations for health policy and health services 
interventions that would reduce the prevalence and incidence of SCA and FGS. (Papers 1, 2, 
3, 4 and 5). 
 
Hypothesis 
 
We hypothesize that genital schistosomiasis in young women is associated with squamous cell 
atypia of the cervix and HPV infection. 
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1.3 List of Manuscripts 
 
Paper 1 
 
Real-time PCR detection of Schistosoma-DNA in small volume urine samples reflects focal 
distribution of urogenital schistosomiasis in primary school girls of KwaZulu-Natal, South 
Africa. 
 
 
Pavitra Pillay, Myra Taylor, Siphosenkosi G. Zulu, Svein. G. Gundersen, Jaco J. Verweij, Pytsje 
Hoekstra, Eric A.T.  Brienen, Elisabeth Kleppa, Eyrun F. Kjetland, and Lisette van Lieshout. 
Status: Published in American Journal Tropical Medicine and Hygiene, 2014. 90 (3) 546-552. 
 
 
Paper 2 
 
Cervical Cytology as a diagnostic tool for Female Genital Schistosomiasis. Correlation to 
cervical atypia and Schistosoma PCR. 
 
 
Pavitra Pillay, Lisette van Lieshout, Myra Taylor, Motshedisi Sebitloane, Siphosenkosi G. Zulu, 
Elisabeth Kleppa, Borghild Roald and Eyrun F. Kjetland 
Status: Provisionally accepted for publication in CytoJournal 21st November 2015. 
 
 
 
Paper 3 
 
Detection of Schistosoma DNA by real-time PCR in vaginal lavages and urine: a comparison 
between five female African study populations originating from three countries with distinct S. 
haematobium and S. mansoni transmission patterns. 
 
Pavitra Pillay, Jennifer Downs, Eric AT Brienen, Myra Taylor, Eyrun F Kjetland and Lisette 
 
Van Lieshout. (2 additional co-authors from Madagascar and Tanzania) 
 
In manuscript anticipated submission American Journal of Tropical Medicine and Hygiene 
 
 
Paper 4 
 
Liquid-based cytology as a tool for a more precise diagnosis and risk-assessment of cervical 
squamous cell atypia among young women from Schistosoma and HIV endemic populations in 
South Africa. 
 
Pavitra Pillay, Myra Taylor, Hashini N Galappaththi-Arachchige, Siphosenkosi G Zulu, Irene 
 
K Christiansen, Ole-Herman Ambur, Borghild Roald and Eyrun F Kjetland 
 
In manuscript. 
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Paper 5 -Short Communication 
 
 
Preliminary findings of the effect of prior treatment with Praziquantel on squamous atypia are 
described in young women at risk for female genital schistosomiasis. 
 
Pillay Pavitra, Myra Taylor, Hashini N Galappaththi-Arachchige, Borghild Roald, Lisette Van 
 
Lieshout, Eyrun F Kjetland. 
In manuscript. 
 
1.4 Summary of Chapters 
 
Chapter One:  Provides the setting of the study in relation to the health and social context, as 
well as where the researcher fits into this context. The aims and objectives as well as a list of 
manuscripts are provided. 
 
Chapter Two: Review of Literature: This chapter includes current literature on FGS. It covers 
the epidemiology, burden, history and developments of FGS research, the risk factors for and the 
development of cervical cancer. Possible diagnostic tools for FGS are also discussed. HPV 
genotyping in Liquid based cytology (LBC) samples is also discussed. Alternative diagnostic 
tools and new technology are also introduced. In addition, the issue of treatment for 
schistosomiasis is discussed as well as the public health issues pertaining to FGS. In addition, 
the gaps in the literature are highlighted. 
 
Chapter Three: Materials and Methods: This chapter focuses on the implementation of the study 
and includes the protocol that was followed in order for the study to be conducted. It also includes 
background information on the study area, population and the ethical considerations. This 
research undertook a study of females living in communities from areas in which access to clean 
water and adequate sanitation remains a problem. Information on the two main cohorts that is 
included in this study, namely the primary-school girls in which microscopy and urine 
Schistosoma PCR results are compared with self-reported genital symptoms. This has been 
detailed in Paper 1. The cohort of young women in whom Pap smear cytology, microscopy and 
Schistosoma PCR in urine and vaginal lavage was conducted is discussed in detail in Papers 2, 
3 and 4. The effect of treatment has been discussed in the Short Communication (Paper 5). 
 
Chapters Four, Five, Six, Seven and Eight: In each of these chapters, one of the five manuscripts 
is presented. This is preceded by a synopsis of the manuscript indicating how it relates to the 
aims and objectives of the study. 
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Chapter 9: Unpublished Results 
 
The cytology results which were not included in any of the manuscripts are presented in this 
chapter. 
 
 
Chapter 10: Synthesis, Conclusions and Recommendations 
 
Key findings are discussed in this chapter. The main purpose of this chapter is to reveal the 
current status of FGS and how it was evaluated in terms of the objectives of this study. The 
findings are critiqued in the light of similar studies and the strengths and weaknesses of the 
data are presented. 
 
Chapter 11: Conclusions and Recommendations 
 
This  chapter  also  draws  conclusions  and  recommendations  from  the  manuscripts  and 
recommendations are made. Areas for improvement for further studies are also highlighted. 
 
 
 
Appendices 
 
The appendices contain the letters of permission and ethical approval, as well as the 
questionnaire and supporting documents used in the data collection. 
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2.0 CHAPTER TWO 
 
 
 
2.1 Introduction 
 
In this chapter, current literature on FGS and the research questions in this study are discussed. 
The discussion includes the epidemiology and burden of schistosomiasis, the history and 
developments of FGS research, cervical cancer and the link to FGS. The risk factors are 
presented. Diagnostic tools for urogenital schistosomiasis are also reviewed, including urine 
microscopy, Schistosoma PCR in urine and vaginal lavage samples and cytology. Alternative 
diagnostic techniques that are available but were not used in this study are also discussed. 
 
 
2.2 Epidemiology of schistosomiasis 
 
Schistosomiasis is one of the 17 neglected tropical diseases (NTDs) that has been prioritised 
by the World Health Organisation (WHO) (World Health Organisation 2015). These diseases 
include a variety of entities that affect the majority of the population who comprise the world’s 
poorest communities and collectively affect more than 1.4 billion people (World Health 
Organisation 2015). Schistosomiasis, affects approximately 261 million people world-wide, 
46% of whom are children aged (5-14) years (World Health Organisation 2015). Africa has 
the highest distribution of schistosomiasis (Figure 1.1.) (World Health Organisation 2015) 
 
 
The genus Schistosoma is made up of several species, those that most commonly infect humans 
are S. haematobium, S. mansoni and S. japonicum. The S .haematobium and S. mansoni 
parasites are mainly found in Africa and the Middle East, S. mansoni in South America, while 
S. japonicum is found in Asia (Colley et al. 2014). Schistosomiasis is known to cause several 
complications in the human host, depending on the parasite species involved, ranging from 
portal hypertension which can lead to death via bleeding in the gastrointestinal tract, to 
increased risks of developing urinary bladder cancer (Vennervald and Polman 2009). S. 
mansoni and S. japonicum are associated with intestinal schistosomiasis and S. haematobium 
is associated with urinary and genital schistosomiasis (DeMay.R 1996; King 2009) 
 
 
 
Schistosomiasis is a neglected tropical disease that remains a global burden despite the efforts 
to eliminate this disease in the 1980’s using the anti-schistosomal drug Praziquantel. Infection 
peaks within the first two decades of life, thereafter the prevalence and intensity decline. 
However  in  endemic  areas,  schistosomiasis  can  cause  lasting  pathology  and  morbidity. 
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Children are predisposed to infection due to factors such as poor hygiene related to excretion 
and their tendency to play in infested water (Wright 1986). 
 
 
 
 
Figure1.1. Global prevalence of schistosomiasis (World Health Organisation 2015) 
 
 
 
2.3 Life Cycle and Pathology 
 
Schistosomiasis, or “Bilharzia” as this disease is commonly known was named after Dr 
Theodor Bilharz who elucidated the life cycle. Schistosomiasis is acquired through parasite 
infected water-contact mainly among the poor, who rely on rivers for their livelihood and water 
source for washing and cooking (Colley et al 2014). Each species of schistosomiasis has its own 
specific snail host; the Bulinus snail is the intermediate host for S. haematobium (Figure1.2.). 
This snail is found in vegetation surrounding water sources where it sheds thousands of 
infective cercariae, which can penetrate the skin of the human host. Once within the human host 
cercariae can take up to six or seven weeks to develop into adult worms that favour living in 
the venules of the host (Colley et al 2014). The adult worms copulate and produce thousands 
of fertilised ova excreted by the humans through urine and faeces, and because of the lack 
of sanitation, into fresh water such as rivers or dams. Here, these ova hatch to release miracidia 
which infect the snail host and the life cycle continues (Colley et al. 2014). 
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Adult worms can live for an average of 3 to 5 years but some may live for up to 30 years within the 
human host. The male and female worm pair remain as a “monogamous couple” together for their 
lifetime, with the female producing eggs and the male fertilizing them (Gryseels et al. 2006; 
Colley et al. 2014). Schistosomiasis can cause various phases of infection; initially the host has 
an immune response to antigenic secretions from the miracidia which clinically is presented as a 
rash at the site of penetration from cercariae. It is also known as “swimmers itch”. A condition 
called Katayama fever due to parasite related hypersensitivity could ensue (Gryseels et al. 2006). 
This usually resolves within a few weeks and is not very common in endemic populations. In 
high risk populations, chronic pathology can occur in the genito- urinary tracts of both males 
and females because of S. haematobium, which is due to the eggs that are trapped in the mucosa 
(Leutscher et al. 2000; Gryseels et al. 2006; Stecher et al. 2015) It is not the adult worms that cause 
much damage to the host, but rather the viable and dead ova (Wright 1986). 
 
 
Schistosomiasis has a complicated life cycle and while treatment efforts were made to kill the 
parasites using the anti-schistosomal drug Praziquantel, there was little control over re- infection 
nor the irreversible damage that this disease had caused within the human host. Eliminating the 
definitive snail host has also been a challenge for eco-systems, which compound this problem 
(King 2009). 
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Figure1.2 Life cycle of S. haematobium adapted from (Gryseels et al 2006; and Colley et 
al 2014). 
 
 
2.4 Schistosoma in the urogenital tracts 
 
Genital schistosomiasis has been studied in the African population for several years as seen in 
Table 1.1. (Page 14). Early studies by Gelfand et al. and others reported sites where evidence 
of schistosomal infections was found other than the urinary tract.  In men the sites were the 
prostate and testes and in women the sites included the uterus, fallopian tubes, ovaries, cervix 
and vagina. These studies dating back decades shed light on the organ preference and 
pathological changes due to S. haematobium and S. mansoni (Gelfand 1967). Studies focussing 
on the debate around the presence of schistosomiasis in the genital tract with or without 
involvement of the urinary tract have revealed that urinary and genital schistosomiasis can co- 
exist and also that genital schistosomiasis can occur in the absence of urinary schistosomiasis 
(Poggensee et al. 1998; Kjetland et al. 2005; Randrianasolo et al. 2015). Up to 75% of the 
women who excrete S. haematobium eggs in the urine may have schistosome eggs in the 
uterine, cervix, vagina or vulva (Renaud et al. 1989; Kjetland et al. 2005). In a study that was 
conducted among 547 women aged between 20-49 years to determine the morphologic effects 
Ashali Pillay ‘15 
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of schistosomiasis on the lower genital tract, it was found that 58% of women with urinary 
schistosomiasis had genital schistosomiasis (Kjetland et al. 2005). 
 
 
In 2009, at a Schistosomiasis Working Group Meeting, consensus was reached that since the 
Schistosoma parasite is responsible for the development of lesions in the urinary and genital 
tracts of both males and females, this condition was renamed from urinary schistosomiasis to 
urogenital schistosomiasis (WHO 2009). 
 
 
 
Urinary Tract: Pathological changes to the urinary bladder are usually associated with the 
intensity of infection, in humans with high egg loads, eggs are excreted via the urine. Over 
half the eggs produced by the parasite remain trapped in the host’s tissues and never leave the 
body (King 2009). The eggs secrete enzymes that trigger an inflammatory response; the extent 
of the inflammation is dependent on the immune system of the host (Gryseels et al. 2006). 
This disruption to the tissues caused by ova is characterised initially by neutrophils and 
macrophages, then lymphocytes and finally eosinophils which result in a granulomatous 
reaction. Red blood cells are also a common finding. Giant epithelioid cells and plasma cells 
may also be found around the granuloma (Wright 1986). The ova are able to trigger an 
inflammatory reaction that can progress to erosion of the mucosa. Erosion is manifested 
clinically by painful micturition and haematuria among males and females. This common 
clinical symptom when seen among male children was termed “male menstruation” (Wright 
1986). On cystoscopic examination, the bladder appears granular, which is due to 
inflammation and urothelial hyperplasia around the ova. While some eggs are degraded within 
the granulomas, others resist and become calcified. Within affected organs, fibrosis and 
scarring can be found as a result of trapped ova. The cellular reaction may progress from 
hyperplasia to metaplasia and then in some cases to dysplasia and bladder cancer (Herrera and 
Ostrosky-Wegman 2001; Vennervald and Polman 2009). In the present study, diagnostic tools 
are used to determine the presence of schistosomiasis in the urinary tract as well as in genital 
samples to further explore the existence of infection within the urinary and genital tracts. 
 
Genital Tract: While there is evidence that S. haematobium is the causative agent for FGS, 
little is known about the effect of S. mansoni. The two Schistosoma parasites, S. haematobium 
and S. mansoni are prevalent in Africa and in the Middle East, whereas S. mansoni can also be 
found in South America (Colley et al. 2014). In some regions in Africa, there is overlap 
between the geographical areas in which both species are endemic (Meurs et al. 2012). The S. 
haematobium worm is known to prefer residence in the pelvic venous plexus therefore the ova 
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tend to become lodged in urogenital tissues, while S. mansoni prefers the portal venous system 
and is usually found in the intestinal tract. It has been suggested that while S. mansoni ova are 
usually lodged in the liver or intestines, this parasite can also be found in the genital tract 
(Feldmeier et al. 1998). In the following studies conducted in Tanzania and Brazil, S. mansoni 
was found with FGS (Poggensee et al. 2001a; Cavalcanti et al. 2011). 
 
Community based studies have linked S. haematobium as the more frequent parasitic agent in 
FGS (Kjetland et al. 2005). FGS is a neglected entity and has recently only gained interest in 
Africa through community based studies (Leutscher et al. 1997; Kjetland et al. 2005; Downs 
et al. 2011) despite being studied for many years prior to this (Table 1.1), (page 14). In other 
studies the genital changes as seen on macroscopic examination of the cervix, via 
histopathology and cytology have been reported over the last five decades (Berry 1976; 
Wright, Chipangwi and Hutt 1982; Poggensee et al. 2001b; Kjetland et al. 2005). The genital 
tract is affected when eggs are excreted into the venous system where they become trapped in 
surrounding organs, it is suggested that there is an overflow of eggs into the genital tract from 
other pelvic organs. The exact extent of damage that can occur within the organs is related to 
the host’s response to the deposited ova. Ova have been found throughout the female genital 
tract: in the ovaries; fallopian tubes; uterus and placenta; cervix and vagina    (Poggensee et 
al. 2001b; Kjetland, Leutscher and Ndhlovu 2012). 
 
 
The genital manifestations may mimic cancer-looking lesions and different sexually 
transmitted diseases, such as ulcers, genital warts, polyps, and also cause mucosal immune 
activation and blood vessel friability (El-Zeneiny, Badawy and Iskander 1968; Edington, 
Nwabuebo and Junaid 1975; Leutscher et al. 1998; Poggensee et al. 2001b). Genital biopsies 
from thirty three women from Malawi were used in the study to examine the histopathologic 
and clinical changes seen in FGS. In this study it was found that sandy patches and vaginal 
tumours were mostly associated with FGS (Helling-Giese et al. 1996). In a recent expert 
committee meeting, a general consensus of clinical findings from several large community 
based FGS studies was in summary, the colposcopic findings of sandy patches, homogenous 
sandy patches, abnormal mucosal blood vessels and more recently rubbery papules in the 
cervico-vaginal region  (Kjetland et al. 2005; Norseth et al. 2014; Randrianasolo et al. 2015). 
Classification of the clinical findings are also of importance since FGS is an under diagnosed 
entity which needs to be made known to health care workers (Norseth et al. 2014) 
 
 
In histological sections of the cervix, ova have been described as few or numerous, and are 
usually seen in the connective tissue below the epithelium of the squamo-columnar junction. 
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It has been reported that ova could gain access from the stroma into the epithelial lining by 
either of the following mechanisms: hyperaemia within the egg containing venules resulting 
in eggs “piercing” into the epithelial lining with their spines, or through areas of ulceration 
within the epithelium (Berry 1966). The response to ova within cervical biopsies have been 
described as follows: in some biopsies no reaction to the ova was detected, while in others, 
varying degrees of changes similar to those in the bladder, including inflammation, 
granulation and ulceration were noted (Berry 1966; Poggensee et al. 2001b). In 
granulomatous inflammation, giant multinucleated histiocytes, epithelioid cells, 
lymphocytes, plasma cells and eosinophils may be seen. The ova can be detected in varying 
stages of maturity containing immature or mature miracidia or as calcified or dead ova. Empty 
shells may also be seen (Berry 1966). 
 
 
In cytology Pap smears varying stages of inflammation may be seen depending on the stage, 
from acute (with mainly neutrophils), to chronic (mainly lymphocytes and histiocytes) and 
granulomatous inflammation (Wikeley 1989). Granulomatous inflammation is characterized 
by the presence of aggregates of macrophages and small lymphocytes. Macrophages become 
large with pale nuclei and abundant foamy cytoplasm and epithelioid cells have narrowed 
elongated/oval nuclei with soft frayed cytoplasm outlining the nuclei. Giant multinucleated 
histiocytes are also seen (Berry 1966). Freshly passed ova are oval with a chitinous shell. S. 
haematobium has a terminal spine whilst S. mansoni has a lateral one. Ova of S. haematobium 
range from 80-170 µm long and from 30-70 µm broad whilst those of S. mansoni are 
marginally larger and S. mathee are longer and narrower (Berry 1976). Inside the ovum an 
embryo miracidium may be seen in an under-developed or well-developed stage and 
emergent miracidia are not uncommon. In cytological samples of the female genital tract the 
following presentations of Schistosoma species as seen in histological sections have been 
described, including empty shells which are refractile, folded and crumpled with no visible 
internal structure; degenerative ova which have a variable appearance dependent upon the 
length of time they have been dead (Wikeley 1989) Partially blackened and completely black 
and opaque forms may also be seen. Immature ova have a granular appearance inside the 
refractile, chitinous shell. Mature ova may be seen with a visible miracidium. Emergent free- 
lying miracidia are oval, round and could also appear in elongated shapes with the exterior 
surface of miracidia being finely ciliated (Berry 1976). 
 
 
In the present study, cytology is used as a diagnostic tool in young women who are at risk for 
schistosomiasis, since cytology has the advantage over cervical biopsies because it is a 
technique that causes minimal disruption to the epithelium.  In addition to the detection of 
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parasites, it can be used for the detection of other entities like inflammation and cervical 
atypia. In the present study, the presence of Schistosoma ova in Pap smears or Schistosoma 
DNA detected in vaginal lavage samples, has been used as a proxy for FGS because 
demonstration of Schistosoma-egg derived pathology is not feasible in the study population. 
 
 
 
2.5 Female genital schistosomiasis and cervical cancer 
 
 
There has been a controversial relationship between genital schistosomiasis and squamous cell 
atypia of the cervix which has been studied over decades. Studies either supporting or rejecting 
this association may be seen in Table 1.1. (Page 14). It has been hypothesised that Schistosoma 
haematobium may play a role in the development of cervical cancer probably indirectly by 
increasing the susceptibility to HPV infection (Kjetland et al. 2009a). Others however question 
the aetiologic role of schistosomiasis in the development of cervical cancer (Moubayed et al. 
1994). The causal relationship between schistosomiasis and cervical cancer is complex and 
hence may be difficult to determine since both entities occur in the genital tract and females 
may be asymptomatic for several years. In a study analysing the relationship between parasites 
and cancer, it was found that helminths can cause genetic instability and affect cellular 
communication mechanisms, through inflammation and alteration to the immune modulators 
which could promote tumour formation (Herrera and Ostrosky-Wegman 2001). 
 
 
 
Similarly, several histopathological reports indicate that there may be inflammatory reactions 
around dead ova, which continue to pose a clinical problem (Kjetland et al. 2008). In a study 
conducted in Malawi it was found that several lesions including epithelial hyperplasia, basal 
cell activity and leukoplakia were frequently seen in genital Schistosoma infection. It has been 
suggested that these changes may induce chronic irritation and possible premalignant 
conditions (Helling-Giese et al. 1996). In the present study the association of FGS and 
squamous atypia has been investigated. 
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Table 1.1 Summary of literature on Female Genital Schistosomiasis in relation to symptoms and distribution, squamous cell atypia, HIV, 
and treatment 
 
 
Focus of studies: Distribution of FGS and Clinical Symptoms 
AUTHOR,YEAR AIMS OF STUDY POPULATION RESULTS COUNTRY 
(Randrianasolo et al. 2015) To compare Schistosoma PCR, histopathology 
and gynaecological findings among women 
with different intensities of urinary 
schistosomiasis 
118 women aged 15-35 
years 
This study adds an additional clinical finding called 
“rubbery papule” to the previously classified sandy 
patches. It also confirms that live and dead ova can 
cause pathology in the mucosa. It confirms that 
women with Schistosoma negative urines may have 
Schistosoma positive genital samples. 
Madagascar 
(Hegertun et al. 2013) An investigation of genital symptoms in young 
girls with urinary schistosomiasis 
1057 school girls aged 
10-12 years 
Genital symptoms were significantly associated 
with urinary schistosomiasis and water contact 
South Africa 
(Yirenya-Tawiah et al. 2011) To determine the prevalence of FGS in Ghana 420 women, aged 15-49 Prevalence of FGS was 10.6% and the women 
infected had associated reproductive health 
symptoms 
Ghana 
(Kjetland et al. 2005) To investigate the FGS induced pathology in 
the lower genital tract 
527 Women aged 20-49 Genital homogenous sandy grainy patches found in 
46% of women with schistosomiasis also mucosal 
bleeding and abnormal blood vessels were found 
Zimbabwe 
(Poggensee et al. 2000) To investigate the occurrence of and morbidity 
caused by genital schistosomiasis 
134 women Morbidity caused to the genital mucosa in women 
infected with schistosomiais could increase the risk 
of acquiring HIV 
Tanzania 
(Helling-Giese et al. 1996) To examine the histopathologic and clinical 
changes seen in FGS 
33 women Sandy patches and vaginal tumours were mostly 
associated with FGS 
Malawi 
(Gelfand et al. 1971) Histopathological analyses of Schistosoma 
infections from the uterus, and its adnexa and 
vagina. 
64 Autopsies from 
African women aged 
17-70 
Most infections were due to S. haematobium. 
Heaviest egg loads were found in the bladder, 
similar egg loads were found in the cervix, fallopian 
tubes and ovaries 
South Africa and 
Zimbabwe 
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Focus of studies: Female Genital Schistosomiasis Association with Cancer 
AUTHOR,YEAR AIMS OF STUDY POPULATION RESULTS COUNTRY 
(Toller et al. 2015) Case report CIN3 and schistosomiasis eggs 44 year old HIV 
positive woman 
Diagnostic features described. FGS must be 
included in the differential diagnosis in routine 
gynaecological investigations to prevent 
misdiagnosis 
Angola 
2013(Van Bogaert 2014) To investigate urogenital schistosomiasis and 
HIV and cervical cancer 
227 cervical biopsies, 
50 were from HIV 
infected women and177 
were non- HIV infected 
No association of cervical schistosomiasis and HIV 
and also no HIV-schistosome co- infection with 
cervical cancer or its precursors 
South Africa 
(Kjetland et al. 2009a) To investigate the impact of HPV and 
schistosomiasis in a 5 year follow up study 
37 women Schistosomiasis was associated with high grade 
intraepithelial lesions but not with persistent high 
risk HPV. Further studies warranted. 
Zimbabwe 
. 
(Moubayed et al. 1994) 
To investigate carcinoma of the cervix and 
schistosomiasis 
Retrospective study- 
4520 histopathology 
cervical cancer cases 
76 (1.7%) of the cases had schistosomiasis, 
schistosomiasis was not associated with cervical 
atypia 
Tanzania 
(Szela et al. 1993) To investigate the possible association of FGS 
with cervical dysplasia and cervical cancer 
2 groups of 24 women 
each- one Schistosoma 
endemic area and the 
other from a non- 
endemic region 
46% schistosoma prevalence in the endemic group 
but no association with cervical dysplasia or cancer. 
No association from the non-endemic group. HPV 
was most likely the cause of cancer of the cervix 
rather than schistosomiasis 
Ghana 
(El Tabbakh and Hamza 1989) To investigate the relationship bet cervical 
cancer and schistosomiasis 
Case report well 
differentiated 
adenocarcinoma and 
schistosomiasis 
Schistosomiasis and squamous carcinoma of the 
cervix is controversial- 
schistosomiasis associated with precancerous 
epithelial changes like basal cell hyperplasia, 
leukoplakia 
Regarding the Schistosoma squamous carcinoma 
relationship: association does not prove causality- 
since it is very complex to prove causality 
Egypt 
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Focus of studies: Female Genital Schistosomiasis Association with Cancer 
AUTHOR,YEAR AIMS OF STUDY POPULATION RESULTS COUNTRY 
(Wright,  Chipangwi and Hutt 1982) To investigate the histopathology of FGS 176 histopathological 
sections 
60% had genital schistosomiasis, no conclusive 
evidence that this was linked to cervical cancer 
Malawi 
(Youssef,  Fayad and Shafeek 1970) To investigate the association of FGS with 
genital atypia 
121 cases of cervical 
schistosomiasis 
Possible association of schistosomiasis with 
premalignant conditions- epithelial and basal cell 
hyperplasia and other changes. One case of CIS and 
16 cases of invasive squamous carcinoma 
associated with schistosomiasis 
Egypt 
(Berry 1966) To describe the cytopathology and 
histopathology of genital schistosomiasis 
139 cytology smears 
140 histological 
sections from the 
genital tract 
Genital schistosomiasis was confirmed and should 
be considered in the diagnosis of populations at 
risk. FGS was not associated with cancer of the 
cervix, but further investigation necessary. Cervical 
smears can be of value in the diagnosis if properly 
collected. 
South Africa 
Focus of studies: Clinical Manifestations of Urinary Schistosomiasis 
AUTHOR,YEAR AIMS OF STUDY POPULATION RESULTS COUNTRY 
(Swai et al. 2006) To review retrospective histopathological 
samples in order to determine the occurrence 
and features of FGS. 
423 organ specimens in 
which schistosomiasis 
was diagnosed were 
reviewed in conjunction 
with age, clinical and 
other symptoms 
172 (40.7%) had urinary schistosomiasis Genital 
schistosomiasis diagnosed in 176 cases, from 
peritoneum, uterus, ovary, cervix, vulva, labia, 
cervix, fallopian tubes, women aged between 5-61 
years. Also evidence of cancer or precancerous 
lesions in 20% of the cervical biopsies with 
schistosomiasis 
Tanzania 
(Leutscher et al. 1998) To assess morbidity due to schistosomiasis 
among women of reproductive age 
176 women aged 
between 15-49 
Schistosomiasis causes symptoms in both urinary 
and genital tracts and needs further investigation- 
small sample size and many confounders 
Madagascar 
(Poggensee et al. 1998) To investigate genital schistosomiasis without 
egg excretion in urine 
533 women, aged 
between 15-45 years 
Urinary Schistosoma prevalence was 40%, Genital 
schistosomiasis was 32%. Co-existence of genital 
and urinary schistosomiasis was 62%. Genital 
schistosomiasis without egg detection in urine was 
23%. FGS link to HIV possibly increased 
Tanzania 
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Focus of studies: FGS and its Association to HIV 
AUTHOR,YEAR AIMS OF STUDY POPULATION RESULTS COUNTRY 
(Kleppa et al. 2014) To investigate the relationship between FGS 
and HIV using HIV target cell density and HIV 
expression of the HIV CCR5 co receptor in 
blood and cervical mucus at baseline and post 
anti-schistosomal treatment. 
14  young women 
attending high school 
CD14+ cells were elevated blood and CD4+ cells 
expressing the CCR5 HIV co-receptor were 
increased in FGS+ women. Post anti-schistosomal 
treatment, only the CD14+ levels decreased. FGS 
may increase HIV acquisition and alter HIV target 
cells as well as due to genital damage. Anti- 
schistosomal treatment can modify this. 
South Africa 
(Downs et al. 2011) To determine female urogenital schistosomiasis 
(FUS) among women of reproductive age 
457 women aged 18-50 
years 
Prevalence of FUS was 5% and HIV was 5.9% 
overall, but found in 17% of women with FUS- 
conclusion- FUS may increase acquisition of HIV 
Tanzania 
(Kjetland et al. 2006) To determine the association between FGS and 
HIV 
547 women aged 
between 20-49 
Women with genital schistosomiasis had almost a 
3-fold risk of HIV 
Zimbabwe 
Focus of studies: FGS and the Effect of Anti-schistosomal Treatment 
AUTHOR,YEAR AIMS OF STUDY POPULATION RESULTS COUNTRY 
(Downs et al. 2013) To explore the response of a single dose of 
praziquantel in women with schistosomiasis 
33 women aged 18-50 6 months after a single dose of PZQ (8) 24% had 
persistent schistosomiasis and (11) 33% had genital 
abnormalities attributed to schistosomiasis. 
Treatment with PZQ more frequently than 6 month 
intervals and in younger women may help reduce 
genital pathology, and risk of HIV acquisition. 
Tanzania 
(Kjetland et al. 2006) To study the effect of treatment with 
praziquantel 
527 women aged 20-49 
years 
Results were analyzed at baseline and within 3-12 
months post treatment. Genital lesions and bleeding 
did not reduce after treatment. 
Zimbabwe 
(Richter et al. 1996) To investigate the reversibility of lower genital 
tract abnormalities in women with Schistosoma 
infections after treatment with praziquantel 
21 women at 2-9 weeks 
after PZQ treatment 
Although the sample size was small, and the 
follow-up time was short, there was partial 
resolution of genital pathology- more research is 
required. 
Malawi 
 
 
 
2.6 Epidemiology of Cervical Cancer 
 
 
Cervical cancer is a serious public health concern and was ranked the second most common 
cancer among women after breast cancer in developing countries and third most common in 
developed countries (Arbyn and Dillner 2007). The highest prevalence is among  developing 
countries from South and Central America, sub-Saharan Africa, and South and South East 
Asia as (Anorlu 2008; Ferlay et al. 2010). Cervical cancer in the developing world was 
estimated to account for approximately 79% of cancers that occurred in the world in 2002. 
About 80% of these cases are in developing countries where screening programmes are not 
well established or minimally effective (Sankaranarayanan, Budukh and Rajkumar 2001). In 
2008, it was reported that more than 85% of the deaths due to cervical cancer occurred in 
developing countries (Jemal et al. 2011). 
 
Estimated Cervical Cancer Mortality Worldwide in 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estimated age-standardised rates (World) per 100,000 
 
 
Figure1.3. Global cervical cancer mortality rates. (WHO 2015) 
 
 
 
Cervical cancer is one of the few cancers that pass through a stage where it is confined to the 
epithelium before it invades through the basement membrane and into the stroma (Schiffman 
et al. 2007). The uterine cervix is lined on the outer region or ectocervix by non-keratinized 
stratified squamous epithelium and the endocervix is lined by a single layer of columnar cells. 
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The Female Genital Tract 
 
 
The point at which the two epithelia meet is known as the squamo-columnar junction or 
transformation zone (TZ) (Figure 1.4). The TZ is found within the endocervical canal before 
puberty, at the onset of menstruation or at the first pregnancy, this zone “rolls” out into the 
ectocervix. This is the site where squamous metaplasia occurs in most women (Singer 1975). 
Squamous metaplasia is a benign proliferative reaction in which the fragile columnar 
epithelium becomes replaced by a more resilient squamous-like epithelium. During menopause, 
the TZ once again reverts into the ectocervix. The TZ is the most common site where cells 
become infected by viral infections like HPV and also where cancers develop (Schiffman et al. 
2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.4 Anatomy of the Female Genital Tract adapted from (Wheater P 1985) 
 
The cervical lesions in the pre-invasive stage were initially described as “incipient cancer”, 
“dysplasia” or “carcinoma in situ”. Later these lesions were designated "cervical intraepithelial 
lesion" (CIN) and most recently they have been re-classified according to the Bethesda System 
of reporting as squamous intraepithelial lesions (SIL) (Solomon et al. 2002). The primary 
function of diagnostic terminology is to communicate to the physician the interpretation of a 
cervical smear in descriptive terms that will have clear universal implications for appropriate 
patient management. The Bethesda System (TBS) of reporting was adopted in 1991(Solomon 
et al. 2002). TBS was designed to be flexible so that it could evolve in response to changing 
needs in cervical cancer screening. TBS is divided into three main categories as depicted in 
Table 1.2. Since HPV is so strongly associated with dysplasia and often cannot be distinguished 
from CIN1/mild dysplasia it has been put in the same category under low-grade squamous 
intraepithelial lesion (LSIL). Early detection and treatment in the pre-invasive stage can in most 
cases lead to total eradication of this disease (Sankaranarayanan, Budukh and Rajkumar 2001). 
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The evolution of invasive squamous cell cancer involves a number of stages with increasing 
intraepithelial abnormality which steadily progresses from mild to moderate to severe to 
carcinoma in situ (CIS) and then to micro-invasive carcinoma (Vooijs 1991). Although it is not 
cytologically possible to predict the malignant potential of a pre-malignant lesion, evidence 
suggests that mild dysplasias are more prone to regress spontaneously. Conversely, severe 
dysplasia and carcinoma-in-situ dysplasia also known as high grade squamous intraepithelial 
lesion (HSIL) is more likely to persist and progress to invasive cancer. This can progress over 
a period of up to ten years (Vooijs 1991). Another important predictor of progression is the 
strain or genotype of HPV that is found with the intraepithelial lesion, there are some strains 
that are highly carcinogenic and associated with invasive cancer (Schiffman et al. 2007). 
 
 
 
Table1.2 Terminology for cervical atypia (Solomon and Nayar 2004) 
 
Bethesda System Cervical Intraepithelial 
Neoplasia (CIN) 
Dysplasia Terminology 
 
Atypical Squamous Cells of Unknown 
Significance (ASCUS) 
 
Cellular Atypia Unspecified cellular changes 
 
Low grade squamous intraepithelial 
lesions (LSIL) 
 
High grade squamous intraepithelial 
lesion (HSIL) 
 
HPV 
CIN1 
CIN2 
CIN3 (including carcinoma 
in situ /CIS) 
 
HPV 
 
Mild Dysplasia 
 
Moderate Dysplasia 
Severe Dysplasia/CIS 
 
 
 
In South Africa a small proportion of women have been opportunistically over-screened in an 
uncoordinated and unscientific manner, while the vast majority of high risk and especially rural 
women have had no access to cervical screening (Anorlu 2008). Many women only present in 
the advanced stage of the disease, when the cancer is often untreatable (Anorlu 2008). Thus the 
lack of or poor implementation of screening has been a contributory factor in the development 
of cervical cancer. In 2000, the South African Department of Health launched the National 
Guideline on Cervical Screening which offers women three free Pap smears in their lifetime 
commencing at the age of 30. There are 10 year intervals between each smear, if women are 
found negative (Health 2000) 
 
 
 
 
 
2.7 Risk Factors for cervical cancer 
 
Sexually transmitted HPV infection of the cervix has been reported as the risk factor implicated 
in 99.7% of invasive cervical cancers in both developed and developing countries (Walboomers 
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et al. 1999). More specifically, the HPV types 16, 18, 31, 39, 45, 52 and 58 have been reported 
as “carcinogenic to humans” (Walboomers et al. 1999). The list of HPV types is updated by 
the International Agency for Research in Cancer (IARC) as those types with “sufficient” 
evidence for carcinogenicity and those with “limited” evidence for being carcinogenic (IARC, 
2007). In addition, the following risk factors were identified from the results of the re-analysis 
of twelve invasive cervical cancer studies (Berrington and Green 2007). Early onset of sexual 
activity, a greater number of lifetime sexual partners, parity, younger age at full term pregnancy, 
use of oral contraceptives, immunosuppression and smoking were the most common risk 
factors (Berrington and Green 2007). In a South African survey among 20-25 year old women 
it was found that the average age at which they first had sex was 16.9 years (Fonn et al. 2002). 
 
It is known, that women are generally infected with HPV in their teens, 20s, or 30s and cervical 
cancer can take up to 20 years after the initial HPV infection to develop (Schiffman et al. 2007). 
Studies also show that at least 96% of low grade lesions of the cervix in young women tend to 
regress within 36 months of acquisition (Szarewski and Sasieni 2004; Schiffman et al. 2007). 
Cervical screening amongst young women is therefore a topic of much debate in light of the 
theory that lesions tend to clear. There is concern about over diagnosis and over-treatment 
among young women (Szarewski and Sasieni 2004). The incidence of cervical cancer has been 
noted to increase in women between the ages of 35 to 40 years and reaches a maximum in 
women in their fifties and sixties (Denny, Quinn and Sankaranarayanan 2006). A Zimbabwean 
study, found the high-risk HPV prevalence to be 36% in young women aged 15-24 years (Baay 
et al. 2004). In developing countries like South Africa where young women are at risk for both 
HIV and schistosomiasis, and cervical cancer is the second common cancer, raising awareness 
of the effects of HPV among young women at risk for these diseases is important. 
 
 
 
2.8 Implications for cervical cancer and HIV 
 
Recent studies have shown that women with HIV have a higher risk of progressing faster to 
invasive cervical cancer (Ferlay et al. 2010; Firnhaber et al. 2012). In a cross-sectional study 
that was conducted in KwaZulu-Natal among 466 rural women to establish the relationship 
between HIV infection and cervical dysplasia, where the mean age among the women was 24.3 
(range 15 to 55 years), it was found that there was a significant association with HIV and 
abnormal Pap smear findings (Karim et al. 2007). Of importance in this study was the age 
distribution of the subgroup of women with HSIL in which 5/6 cases occurred under the age of 
30 and almost all these cases were from women co-infected with HIV (Karim et al. 2007). In a 
cross-sectional study conducted in Cape Town to determine the risk of pre-cervical cancer and 
cancer among HIV positive women, it was found that there was a 66,3% prevalence of 
abnormal Pap smears in women 18 years and older  (Moodley et al. 2006). In a recent 
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exploratory study investigating screening South African women under the age of 30, since the 
current screening programme does not cater for this age group who have high grade lesions that 
could progress and also are at risk for HPV and HIV, it was suggested that policy makers should 
reassess the risk factors as well as the psychosocial impact of cervical cancer to ensure that 
health infrastructure supporting the prevention and management is provided for women at the 
onset of sexual activity (Learmonth and Learmonth 2014). 
 
 
2.9 Association of schistosomiasis with HIV 
 
This association has been investigated in several studies, as seen in Table1 (page 14). In a 
study among the same Zimbabwean population to determine the association between FGS and 
HIV, it was found that women with genital schistosomiasis had almost a 3-fold risk of having 
HIV (Kjetland et al. 2006). In a study investigating the immune cells in relation to HIV and 
schistosomiasis, it has been found that HIV target cells which are CD4+ T lymphocytes found 
in genital mucosa from Schistosoma induced lesions may contribute to HIV transmission 
(Jourdan et al. 2011). It has been recently suggested that increased vascularity which makes the 
mucosa more prone to lesions within in the vagina and uterine cervix, caused by S. 
haematobium may also increase the risk of HIV (Jourdan et al. 2011). It has been shown that 
there is a significant overlap in the prevalence of HIV and schistosomiasis in Sub-Saharan 
Africa, supporting the hypothesis that schistosomiasis infection may be linked to increased risk 
for HIV (Mbabazi et al. 2011). 
 
 
 
2.10 Anti-schistosomal Treatment 
 
Praziquantel was developed in the 1970’s and was found to be safe and easily administered via 
school or community based mass treatment campaigns (Gönnert and Andrews 1977; Ming- 
Gang 2005). The current WHO resolution is to eradicate schistosomiasis in multiple countries 
by 2020 and globally by 2025 (World Health Organisation 2015).The WHO mass treatment 
strategy includes all risk groups with school age children being a primary target (World Health 
Organisation 2015). Mass treatment for schistosomiasis is therefore done through schools in 
endemic areas and has already been implemented in many African countries (Gundersen et al. 
1990; Fenwick and Webster 2006). In South Africa mass treatment was implemented in schools 
in KwaZulu Natal in 2001, however this programme was not sustained (Appleton and Kvalsvig 
2006). While it was reported that there was a reduction in Schistosomiasis from this 
programme, it is also known that in populations at risk, there is the possibility of re-infection 
(Randjelovic et al. 2015). In South Africa a huge challenge has been the high cost of anti- 
schistosomal drugs (Berge et al. 2011). South Africa is one of the five remaining countries in 
Africa where mapping has to occur in accordance with the WHO resolution. 
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The mass treatment is known to be effective in killing the Schistosoma parasites, however this 
has not completely eliminated this disease because of various implementation, monitoring and 
re-infection challenges in high risk communities (King 2009). The WHO mass treatment 
strategy includes all risk groups with school age children being a primary target (World Health 
Organisation 2006). 
 
 
Diagnostic tools for schistosomiasis detection are available, and for mass drug administration 
(MDA) it has been suggested that there are distinct stages in which infection is monitored, the 
first stage being the mapping and surveillance in which the prevalence of infection is 
determined, thereafter diagnostic tools are required for monitoring where the effect of treatment 
interventions can be measured and finally to monitor re-infection after treatment interventions 
have ceased (Utzinger et al. 2015). 
 
 
While mass treatment is effective in killing adult worms responsible for laying eggs, it is not 
known what effect it has on FGS lesions. One study showed that treatment given to women 
with FGS lesions in adulthood appeared to leave the lesions unchanged (Kjetland et al. 2006). 
Similarly, several histopathological reports indicate that there may be inflammatory reactions 
also around dead ova, which are presumably PCR negative, yet continuing to pose a clinical 
problem (Kjetland et al. 2009b). The effect of treatment on FGS however requires further 
exploration. 
 
 
2.11 Diagnosing FGS 
 
In diagnosing genital schistosomiasis, visual inspection can be used whereby the cervix is 
magnified using a colposcope and the surface is examined for grainy sandy patches and other 
characteristic signs of egg-induced inflammation (Kjetland, Leutscher and Ndhlovu 2012). 
This procedure also has limitations since it is highly observer-dependent, requires extensive 
training and expensive equipment and cannot be used among children, since intra-vaginal 
inspections are normally not performed before the onset of sexual activity. Since FGS needs to 
be investigated among girls and young women due to their susceptibility to schistosomiasis, it 
is important to seek alternative and indirect mechanisms of investigating this disease. 
 
 
Alternate diagnostic mechanisms to visual inspection include the identification of parasite eggs 
in urine, stool, or biopsy specimens, Schistosoma PCR analysis and using immunological 
disease markers on blood or other samples. For the specific diagnosis of FGS histological 
examination of a cervical biopsy was considered to be the gold standard (Poggensee et al. 
2001b). In young populations who are risk for HIV, this procedure, searching for Schistosoma 
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eggs in biopsy tissue, is invasive and therefore not applicable. Urine microscopy may be used 
to diagnose schistosomiasis, however urine is an unspecific diagnostic tool for genital 
schistosomiasis, since it has been found that women may present with Schistosoma ova in their 
genital tract with or without ova in the urinary tract (Randrianasolo et al. 2015). Molecular 
techniques such as PCR in stool and urine have also been established (Verweij et al. 2007); 
(Aryeetey et al. 2013). In a Zimbabwean FGS study, Schistosoma PCR was done on cervico- 
vaginal lavage samples, however this aspect of diagnostics requires further investigation 
(Kjetland et al. 2009b). 
 
 
In attempts to gain more insight into FGS, Pap smears may also be used to detect Schistosoma 
ova, although routine investigations from previous studies thereof, have shown mainly low 
sensitivity with the exception of a study conducted in Madagascar among known positives 
(Feldmeier,  Helling-Giese and Poggensee 2001; Randrianasolo et al. 2015). 
 
 
Immunologic tests for the Schistosoma antigen are also available, two antigen tests that have 
been in use for schistosomiasis are the circulating anodic antigen (CAA) and the circulating 
cathodic antigen (CCA) (Van Lieshout, Polderman and Deelder 2000). Schistosoma antigens 
are secreted into the host’s circulatory system and are detectable within 3 to 5 weeks after 
infection (Van Dam et al. 1996). One of the methods of detection is thorough using the antibody 
sandwich enzyme-linked immunosorbent assays (ELISA) method (Van Lieshout, Polderman 
and Deelder 2000). In a study comparing direct parasitological methods and immunologic 
methods (using serum CAA and urine-CAA as well as antibodies) it was found that the results 
were comparable in populations with moderate to high intensity of infection (Van Lieshout 
2000). A challenge with immunological markers is that these could not be used to distinguish 
between past and present infections (Obeng et al. 2008). A rapid field applicable point of care 
(POC) assay using CCA in urine samples was developed to overcome some of the 
disadvantages of the ELISA, however this tool is unable to distinguish between Schistosoma 
species (Obeng et al. 2008). These immunologic tests could possibly be useful for FGS if these 
are done on samples from the genital tract, like cervico-vaginal lavage. Antibody tests have 
proven to be highly sensitive in individuals who might be infected but originate from non- 
endemic areas such as travellers but are not for people who live in endemic areas, since 
antibodies can be detected in light infections and in those who have had a short exposure but 
are of little value in areas with low transmission due to their lack of specificity (Van Lieshout, 
Polderman and Deelder 2000; Gryseels et al. 2006; Van Lieshout and Verweij 2010). Indirect 
markers include the identification of clinical findings (for example, haematuria), radiographic 
examinations and questionnaires can be used to assess prevalence (Van Lieshout and Verweij 
2010). 
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In populations at risk for schistosomiasis it is important to be able to identify those infected, 
ensure that they are treated accordingly and the measures are taken to reduce re-infection (Van 
Lieshout and Verweij 2010). A suitable diagnostic marker should not only provide information 
about the presence of a pathogen at the individual level but should also be able to provide 
additional information that will assist in the management of disease, such as intensity of 
infection or whether the infection is past or present. Schistosomiasis is a disease that can be 
viewed from two main perspectives, firstly from a health care perspective where infected 
individuals need treatment as well as from a public health perspective where diagnostic 
information provided can assist in managing populations at risk (Van Lieshout and Verweij 
2010; Colley et al. 2014; Utzinger et al. 2015). 
 
 
 
 
In the present study, the diagnostic tests used to determine Schistosoma prevalence at the 
population level included urine microscopy and Schistosoma DNA assays in urine and cervico- 
vaginal lavage and cervical cytology for detecting schistosomiasis in the urinary and genital 
tracts to map populations risk and to clarify trends and associations between FGS entities. These 
diagnostic tests will be discussed below in more detail. 
 
 
 
 
2.12 Urine and stool microscopy 
 
Traditionally, parasitology using urine microscopy and Kato-Katz for stool microscopy has 
been known to provide close to 100% specificity, whereas there is variation using the other 
methods (Gryseels et al. 2006). Sensitivity and specificity of the tests vary and depend on a 
range of factors such as the parasite species, host factors and epidemiologic characteristics of 
the area (Gryseels et al. 2006). The main goal in selecting a diagnostic method for 
schistosomiasis is to ensure that the test not only enables the parasite to be diagnosed, but is 
also helpful in providing additional information on whether the infection is past or present, the 
intensity of the infection and treatment (Van Lieshout and Verweij 2010). In endemic areas 
logistics of high tech laboratory analyses, and the lack of skilled personnel, as well as cost 
factors, need to be considered when selecting the appropriate laboratory test. Tests need to be 
reliable and reproducible (Van Lieshout and Verweij 2010). 
 
 
The sensitivity of urine microscopy is optimal when using samples that are collected at times 
during maximum egg excretion (usually between 10am-12am) since it has been found that 
variation in egg excretion can occur among individuals, the exception being among those who 
are highly infected with a median egg output of at least 100 eggs/10 ml (Doehring, Feldmeier 
and Daffalla 1983; Doehring et al. 1985b). This study confirmed that peak egg excretion was 
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around midday and that excretion could be enhanced at any time of day with physical exercise 
and fluid intake prior to micturition (Doehring et al. 1985a). However individuals with light 
infections with low egg counts require repeated sampling and careful examination to enable 
high sensitivity and specificity. Light infections are often missed and underestimated, but 
should be viewed with more seriousness, since it has been found that the host’s response to 
eggs and not the number of worm pairs determines pathology (van der Werf et al. 2003). It has 
been found that quantifying eggs is important in monitoring treatment programmes for 
schistosomiasis (Kosinski et al. 2011). 
 
 
Urine microscopy is a relatively cheap and easy diagnostic test, but requires repeated sampling 
and careful examination to enable high sensitivity and specificity especially in light infections 
(Obeng et al. 2008). A 10mL sample of urine is usually examined microscopically and eggs are 
counted manually. Intensity of infection is expressed as the number of eggs detected per 10mL 
of urine; 50eggs is the threshold distinguishing between light and heavy intensities (Utzinger 
et al. 2015). A positive diagnosis is made if one intact ovum is seen (Thomassen Morgas et al. 
2010). With urine microscopy, possible confounders include low egg counts, contaminants that 
can mimic eggs; the time the sample was collected (i.e. if the sample was collected when there 
was a low egg excretion) and also there may be variation in results due to human error (Braun- 
Munzinger and Southgate 1992). Urine samples must also be processed within 24 to 48 hours, 
and microscopic examination of a large volume of samples can be rather time consuming and 
tedious. An additional source of error in diagnosis is that some individuals can excrete variable 
numbers of eggs from day to day, so it is usually better to examine multiple samples (Van 
Lieshout and Verweij 2010). Using microscopy to detect schistosomiasis is used in many 
developing countries; however it is limited to monitoring the effect of treatment in cases where 
egg intensities are low and variable (Cavalcanti et al. 2013). 
 
 
 
 
2.13 Real-time polymerase chain reaction (PCR) in Urine and Cervico-vaginal lavage 
 
The use of PCR to detect schistosomiasis began with the amplification of DNA sequences in 
the detection of S. mansoni (Rabello, Pontes and Dias-Neto 2002). This approach was highly 
sensitive for the detection of the parasite DNA in stool samples. PCR for detecting the 
Schistosoma genus was compared to other diagnostic techniques and has been proven to 
overcome some of the drawbacks of the other detection techniques, especially in terms of 
sensitivity and specificity (Pontes, Dias-Neto and Rabello 2002). While the gold standard for 
the identification of parasites is via microscopy, PCR was found to be a more sensitive 
diagnostic test. DNA isolation and amplification was previously known to be a time consuming 
and laborious process, however in recent times, these processes have been simplified even with 
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the advent of real-time PCR. While conventional PCR has the advantage of being able to 
identify even minute quantities of parasite DNA, however it is unable to quantify the DNA 
(Gordon et al. 2011). 
 
 
Multiplex PCR assays are able to detect multiple species in an individual host, using multiple 
primer pairs (Verweij et al. 2007). An advantage of real-time PCR over conventional PCR is 
the fact that the infection can be quantified. Multiplex real-time PCR assays have been 
established for specific and sensitive detection of a broad range of parasites in clinical samples, 
including S. haematobium (Verweij et al. 2007; Obeng et al. 2008; Ten Hove et al. 2008). In a 
study comparing real-time PCR, urine microscopy and other techniques for the detection of 
schistosomiasis it was found that previous limitations with PCR in detecting parasitic infections 
such as low sensitivity, and problems with contamination have been reduced (Obeng et al. 
2008). Schistosoma PCR has also shown good specificity, sensitivity and reproducibility of 
results, especially in cases where no eggs were detected by microscopy in a study conducted 
among travellers (Cnops et al. 2012). Real-time PCR assays rely on samples collected and 
stored at optimal temperatures as well as require well defined laboratory facilities. 
 
 
PCR as a diagnostic technique does not have the same limitations of microscopy. While PCR 
has limitations of cost as well as being a specialized technique that requires specific equipment 
and processes that are not field applicable, it has the advantage of enabling a large number of 
samples to be processed in a short period of time and has a reduced risk of contamination and 
human error. This application might prove to be effective for use in settings where 
epidemiological mapping of schistosomiasis is required. Quantification of Schistosoma DNA 
in urine samples using real-time PCR may be a specific and sensitive alternative to microscopy 
to determine the urogenital distribution in preadolescent girls, despite the issues of field 
applicability in developing countries. We have explored this as part of this PhD and further 
details are provided in Paper 1. 
 
 
An earlier study has shown that genital schistosomiasis can occur among women while being 
negative in the urinary tract and that co-infection in both the urinary and genital tracts can occur 
(Poggensee et al. 1998). While urine and stool samples have been established assays for the 
detection of Schistosoma DNA using real-time PCR, a previous genital schistosomiasis study 
conducted among rural Zimbabwean women, investigated the use of cervico-vaginal lavage 
samples for Schistosoma DNA (Kjetland et al. 2009b). The results of this study revealed that 
positive Schistosoma ova detected in cervico-vaginal lavage PCR correlated with the clinical 
findings of bleeding and sandy patches. It was also found that younger women had increased 
schistosomal  DNA  compared  to  older  women  (Kjetland  et  al.  2009b).  Since  genital 
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schistosomiasis is more challenging to diagnose, it has been proposed that in resource poor 
settings, where rural gynaecological facilities and infrastructure are limited, this could be a 
complementary tool to gynaecologic examinations, especially for research purposes. The 
sample size in this study was small and further investigations are required to validate these 
assumptions (Kjetland et al. 2009b). PCR techniques used then have since evolved and 
improved. The PCR detection of schistosomiasis using cervico-vaginal washings or self- 
administered tampons or swabs would thus be beneficial in diagnosing FGS. Cervical washings 
for DNA detection are less traumatic to the cervical mucosa, and could be beneficial in early 
identification of disease. In this study, the use of PCR in the detecting of schistosomiasis is 
investigated in urine as well as vaginal lavage samples. The use of Schistosoma DNA in urine 
and cervico-vaginal lavage samples has been explored in Paper 2. 
 
 
 
 
2.14 Cytology 
 
The Pap smear was developed in the 1930’s and initiated by the father of Cytology, Dr George 
N Papanicolaou (Papanicolaou 1942; Papanicolaou and Traut 1997). The first screening tool 
was the vaginal smear which was introduced approximately 50 years ago and supported by the 
American Cancer Society (Koss 1993). Pap smear programmes, also known as cytologic 
screening programmes have achieved remarkable results in reducing cervical cancer incidence 
and mortality in some developed countries. It is reported that the incidence of cervical cancer 
and the associated mortality have both decreased substantially in Nordic countries after the 
introduction of organized screening programmes using the Pap test (Hakama and Louhivuori 
1987). 
 
 
 
A Pap smear is a cytological sample of the cervix, designed to detect abnormal cervical cells. 
This involves scraping cells from the squamo-columnar junction (this exact location is most 
representative of the cervix) and then fixing them onto a glass slide. The slides are then sent to 
a cytology laboratory stained and evaluated by a cytologist. Pap smears are widely used and 
they are valuable in detecting pre-invasive cancer of the cervix. Smears obtained with the 
original “Ayre” spatula are often easier to screen (Ayre 1947). A wooden spatula is preferable 
to a plastic spatula, because of its mildly rough surface that can collect more material. The 
collection device may play an important role in the sample adequacy. The shape, surface, 
texture and material of the device may determine how much of the scraped material is deposited 
on to the glass slide and is available for screening and analysis. Several methods of obtaining 
cytologic material from the uterine cervix are available (Koss 1993). 
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Liquid-based cytology (LBC) is a newer technique which entails collecting the samples with a 
broom-like device that is placed into a vial containing a buffered fixative solution (Hutchinson 
et al. 1999). The principle of the LBC technique is that cells are processed and stained using an 
automated system, concentrating the cells onto a microscopic slide in a monolayer with the 
removal of excess mucous, blood and inflammatory cells. For both conventional and LBC 
samples the Papanicolaou staining technique is used (Papanicolaou 1942). This is a 
polychromatic stain that has gained worldwide acceptance for cytologic samples. It is designed 
to display many variations of cellular morphology showing degrees of cellular maturity and 
metabolic activity (DeMay 1996). In the present study, both conventional and LBC were used 
to investigate FGS and SCA. 
 
 
 
 
2.15 Alternative cervical cancer screening tools to cytology 
 
 
While the Pap smear is known to be an effective tool for the prevention, detection and 
management of cervical cancer it is not the most accurate test due to sampling errors and 
diagnostic errors  (DeMay 1997; DeMay 1996)  For a Pap smear to be a valuable tool in the 
diagnosis of cervical cancer, the following steps need to be followed: the smear needs to be 
properly collected so that it is well preserved and adequate (having the correct representation 
of cells from the cervix). Thereafter, the smear must be properly prepared or stained for 
cytological assessment and finally it must be correctly diagnosed by the cytologist (DeMay 
1997). Three common diagnostic problems are that results from smears are issued without them 
being fully representative, or result are issued from an unsatisfactory smear and the issuing of 
“false negative” results (DeMay 1997). Cancer could be missed on a Pap smear if there are only 
few cells present or compared to the biopsy which is the gold standard, lesions may not be 
within reach of the sampling device used (Koss 1993). Cytology as a discipline requires 
concentration since screening many slides can lead to fatigue and human error (Koss 1993). 
Another common problem is the fact that there is a shortage of cytologists, and the capacity to 
provide results within a short period of time is limited in developing countries. Furthermore, it 
is a huge challenge in developing countries to get a woman to have a Pap smear, and expecting 
her to return for results after some time is also problematic. Not being able to interpret the cells 
correctly is another source of error. There are however, some alternatives to conventional 
cytology in addition to LBC cytology, which are available, and these include options such as 
visual examination and HPV testing and vaccination. 
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HPV DNA tests and genotyping: HPV originates from the papilloma virus family, there are 
several HPV types which have been identified in humans (Bibbo and Wilbur 2008). Some of 
these cause no symptoms in humans while others are sexually transmitted and potentially 
carcinogenic. Viral particles enter the body via small abrasions on the skin or mucous 
membranes. Viral replication occurs mainly in the nucleus, but the effects are seen in both the 
nucleus and cytoplasm. On the vulva, HPV causes multiple, warty, cauliflower-like (verrucous) 
lesions (Bibbo and Wilbur 2008). Histologically, HPV causes proliferation and thickening of 
the squamous epithelium. In the genital tract the following types of lesions have been identified: 
subclinical papillomavirus infection: flat warts, exophytic warts/ condyloma acuminatum, 
endophytic warts (Bibbo and Wilbur 2008). 
 
 
 
With the discovery that HPV is central to the development of cervical cancer, scientists have 
been developing molecular diagnostic tests for detecting HPV (Walboomers et al. 1999). There 
is potential for HPV testing in screening programmes, both as an adjunct to cytological 
screening and in primary screening (Schiffman et al. 2007). The proposed uses of HPV testing 
in cervical cancer prevention programmes include the identification of HPV in areas where Pap 
smear findings show ASCUS (cells that are atypical but not definitely dysplastic) and to test 
for high-risk types of HPV so that such women may be identified, monitored and treated 
accordingly. In addition, testing may be used as a means of surveillance for women after 
treatment for high grade lesions (Schiffman et al. 2007). 
 
 
 
HPV genotyping is an important tool in determining the oncogenic potential of the virus. Many 
strains of HPV, types 16, 18, 31, 33 and 45, are thought to have a high oncogenic potential 
(Clifford et al. 2006). The worldwide prevalence of HPV in cervical cancer is 99.7%, and the 
association of so-called high-risk (likely oncogenic) HPV with cervical cancer makes HPV the 
highest attributable factor that is specific for any major human cancer (Walboomers et al. 1999). 
A global review conducted to assess the age specific prevalence of HPV in females, found that 
the most high-risk oncogenic HPV are types 16 and 18 (Louie, De Sanjose and Mayaud 2009). 
HPV vaccines have been developed and are aimed at protecting against oncogenic strains of 
HPV with the stimulation of antibody production among humans. The introduction of HPV 
vaccines in developing countries where cervical cancer is a huge burden could be a possible 
solution, however HPV vaccination is only effective in prevention among women who have no 
present or past HPV infection. HPV vaccination would therefore be more effective in pre- 
adolescent girls (Cutts et al. 2007). 
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Molecular Markers p16: Immuno- markers may be used in order to identify oncogenic strains 
of HPV that are likely to progress, thus preventing over treatment or misdiagnosis by using the 
Pap diagnosis only (Lesnikova et al. 2009). The diagnostic test for the immune-marker p16 can 
be conducted on LBC samples as can the HPV DNA testing. HPV has been established as the 
common causative agent in cervical cancer since it is able to alter gene or protein expression in 
the host cells. There are different strains of HPV, some have a high risk oncogenic potential 
which results in cervical cancer. Two proteins caused by high risk HPV infection are E6 and 
E7 (Saqi et al. 2002). E7 binds to the retinoblastoma gene product (RB) resulting in its 
functional inactivation. The E7 HPV oncogenes inhibit the effect of tumour suppressive 
proteins, protein P53 and RBp respectively thus increasing the risk of mutations. Since the p16 
is under negative feedback control of functional RBp, overexpression of the p16 gene occurs 
in cells infected by high risk HPV (Cuschieri and Wentzensen 2008). Because the p16 protein 
is detectable by immunocytochemistry it is a surrogate marker for HPV since this protein is not 
expressed in normal tissue (Lesnikova et al. 2009). It is observed in the nucleus and the 
cytoplasm of cells. In young populations, such as the present study population such an assay 
may be of value in identifying those young women with high risk for cervical cancer. 
 
 
 
Visual inspection with acetic acid (VIA): Visual examination instead of cytology as the initial 
screening technique has been implemented in areas where resources are particularly scarce 
(World Health Organization 2012). The method entails a primary health care worker carrying 
out a visual examination of the cervix, using a speculum cervix which is swabbed with acetic 
acid, abnormal areas react with the acid and turn white. Once identified, these areas can be 
treated with cryotherapy or biopsy. This approach is advantageous since it is a “see and treat” 
approach. One of the limitations to this approach is that it is not always accurate in identifying 
pre-cancerous conditions. It has been found that VIA is promising in low-resource settings 
since it is a relatively simple, “low-tech” approach that is minimally dependent on infrastructure 
for its adequate performance, provided that treatment services are in place. Due to low cost, 
easy applicability and immediate results, it has been suggested that VIA could be a useful 
screening test in developing countries compared to Pap smear screening (World Health 
Organization 2012). Over-treatment may result in additional health risks to women as well as 
overburdening the health care system. VIA is less effective for screening women in their fifties 
because of the tendency for the squamo-columnar junction to recede into the cervical canal, 
making observation more difficult. Despite these drawbacks it is recommended that VIA be 
considered as an option for identifying pre-cancerous lesions in many settings, either in 
conjunction with or as an alternative to other screening approaches. 
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2.16 Management of Premalignant Cytologic Findings 
 
 
The form of patient management is based on a correct cytologic diagnosis. It is not usually 
necessary to biopsy lesions with minimal or moderate severity, since only a small proportion 
of these lesions will progress to a more marked abnormality, whereas the time it takes a lesion 
to progress provides ample time to detect a lesion at successive cytologic examinations 
(Lindeque 2005). Only after persistence of the lesion has been confirmed are follow-up 
procedures, including colposcopy warranted. A cytologic diagnosis of severe dysplasia or in 
situ carcinoma is usually followed by colposcopy and biopsy, which at confirmation of the 
process are followed by cautery, laser treatment, conization or hysterectomy (Lim 2002). In 
cases where HPV genotyping is available, this helps inform the course of treatment (Schiffman 
et al. 2007). 
 
 
 
2.17 Summary 
 
Many school going females have contact with contaminated water sources and are at risk of 
schistosomiasis and FGS. Young women in South Africa are also at risk of HIV and cervical 
cancer and the high prevalence of these infections place many women at risk of premature 
mortality. 
In this study we investigate the usefulness of diagnostic tools such as Pap smears and LBC 
samples together with Schistosoma PCR in urine and vaginal lavage samples which are 
ethically acceptable among women in the diagnosis of FGS. 
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3.0 CHAPTER THREE 
 
 
 
3.0. Materials and methods 
 
3.1. Study setting and design 
 
The study included a cross sectional design. The study had different components. The sample 
for this study was drawn from a larger sampling frame among young females (aged 10-12 years) 
in 18 primary and 81 high schools (aged 16-23 years) who took part in a clinical study on FGS 
to investigate if annual school-based chemotherapy could prevent the development of FGS (Ref 
BF029/07). In a sub-sample of the young women a cohort was followed up in a prospective 
study. 
 
 
Table1.3 Study areas and groups 
 
Paper Study Site Age 
 
(years) 
Sampling year - 
analyses 
Number of 
participants 
included in 
analysis 
1 18 Primary 10-12 2009-10 - Questionnaire 708 
 schools  Urine collected over 3  
 Ugu District  days: microscopy, PCR  
 Cross sectional    
2, 3 41 High schools 16-23 2011 - Questionnaire 394 
 Ugu District  Single urine, microscopy,  
 Cross sectional  PCR  
4, 5 40 High schools 16-23 2012-13 – Questionnaire 833 
(Short Ilembe and  Cervico-vaginal lavage  
Communication) Uthungulu 
Districts 
PCR, Pap smears and or 
LBC samples 
 
3.2 Inclusion and Exclusion Criteria: 
 
 
a)   Primary school girls were included in the study provided that assent was obtained 
from each participant as well as written permission from their parents or guardians. 
Participants who were absent from school on the day of sampling were excluded. 
b)  Young women were included in the study. Pregnant women and virgins were excluded 
as well as those young women who did not wish to participate in this study. Participants 
provided written consent. 
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3.3 General Characteristics and Demographics of the study populations 
 
The study was conducted in the KwaZulu-Natal province which is situated on the eastern 
coastline of Southern Africa. This province is made up of eleven districts and is the epicentre of 
the HIV epidemic in South Africa (South African Municipal Demarcation Board 2012; 
Directorate Epidemiology 2013). Two areas Ugu and Ilembe/Uthungulu situated alongside the 
Indian Ocean south and north of the city of Durban were included in the study. These districts 
are traversed by many rivers. The map below indicates the study areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study sites in 
north coast 
 
 
 
N 
Study site in south 
coast 
 
Total area 92,100km2 
 
Figure1.5 Map of KwaZulu-Natal showing study areas adapted from (South African 
 
Municipal Demarcation Board 2012) 
 
 
 
Study area 
 
Within the province of KwaZulu Natal, Ugu District is situated along the coast south of Durban 
and has a population of 710.000 people, 51% are below the age of 20 years, and 55% are female. 
The area is endemic for both schistosomiasis and HIV. Ilembe and Uthungulu Districts are 
situated on the north coast of KwaZulu-Natal and this area of the study, hosts a population of 
approximately 570 000 people. Those who are under the age of 19 account for 49% of the 
population. Those who are 34 years or younger comprise 72% of this population. There are low 
levels of employment in these districts, with only about 29% of this population being actively 
employed (Manzini 2001). Many of the population from these districts reside in areas, where 
access to water sanitation and other infrastructure is poor. HIV and AIDS is a major health 
burden in this population, the national South African HIV prevalence among antenatal women 
was reported in 2013 at 29.5% of which KwaZulu-Natal had the highest prevalence of 37.4%. 
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Individual district prevalences for HIV among antenatal women were as follows: 38.3% in Ugu 
District, and 37.4% and 38.5% in Ilembe and Uthungulu districts respectively (Directorate 
Epidemiology 2013). These are some of the poorest districts in South Africa, similar to other 
schistosomiasis endemic areas in other African contexts. These are mostly rural communities 
where women do their laundry and children play in Schistosoma infected rivers, but also include 
some urban and semi-urban centres (Appleton and Kvalsvig 2006; Saathoff et al. 2004; 
Kvalsvig 1988). Schools were selected that were situated below an altitude of 400 metres. 
 
 
 
3.4 Ethics and Permissions 
 
The processes of obtaining ethical approval and permissions were the same for both study 
populations. The study was initially discussed with the relevant stakeholders including the 
Provincial and District representation, Department of Health, Department of Education, school 
staff, parents, and pupils. Their permission was obtained at this time. In the first meetings, the 
focus of the project, its importance, and benefits were explained to the stakeholders. Written 
informed consent was obtained and sought at this time (Appendices 2, 3, 4, 5). For the young 
women  logistical arrangements were made with school principals and other relevant staff, for 
suitable times for transportation of the participants to the study clinics for gynaecological 
examinations and interviews. 
 
 
Ethical approval was obtained from the Biomedical Ethics Research Committee of the 
University of KwaZulu Natal for the main study entitled: “Schistosomiasis in young women 
and girls in KwaZulu-Natal, manifestations, effect of treatment, association with HIV” Ref 
BF029/07. Ethical approval was also received, Reference HRKM010-08. REK Øst-Norge and 
the Norwegian ethics committee, gave ethical clearance Ref 469-07066a1.2007.535, 
September 17th 2007. Permission was received from the Department of Health, 
Pietermaritzburg, KZN, February 3rd 2009. The Departments of Health and Education in Ugu, 
Ilembe and Uthungulu Districts, KwaZulu-Natal have also given permission. The present study 
protocol was submitted to the UKZN Biomedical Research Ethics Committee (BREC) and full 
approval was granted on the 19th of August 2011 and annual recertification approval has been 
received since then and to date, RefBF057/11. 
 
 
 
3.5 Data collection 
 
Teams of trained field assistants and school nurses visited the schools to give general 
information and recruit initially the primary school girls. 
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In the high school, a team of trained field assistants and school nurses visited the schools to 
give general information and recruit adolescent girls for laboratory investigations and 
treatment. After signed consent was received, participants were collected from school by 
research assistants and transported to the project clinic via clinic transport. Once all 
examinations were complete, the participants were transported back home. 
 
 
Data storage: Each participant was allocated a unique number to be used as a code for all 
samples and data. The participants’ names did not appear on any sample, container or interview 
sheet, only the code. Names and identity with codes were kept separately in a locked cupboard. 
Full confidentiality was maintained in all aspects of the research. 
 
 
Interview Process. 
 
Consenting participants underwent a private face-to-face semi-structured interview, conducted 
by research assistants in “isiZulu”, the local language, including history of water contact, red 
urine and genital symptoms. The young women were asked about sexual history and number 
of children as these variables possibly could have bearing on the correlation to cervical atypia. 
 
 
Urine storage and microscopy: Collected urine samples for microscopy were stored in dark 
cooler boxes to ensure sample quality. Urine samples were processed in the field site laboratory 
by a laboratory technician. Urine samples for microscopy were preserved with 1ml of 2% 
tincture of merthiolate in 5% formalin solution (Thomassen Morgas et al. 2010). The samples 
were spun for 10 minutes at 4000 rates per minute (rpm) and the sediment examined 
microscopically, magnification with objective 10, by trained field workers. The samples 
underwent quality control by an independent microscopist on 10% of randomly chosen 
samples. 
 
 
PCR analysis: For Schistosoma PCR analysis, an aliquot of 1 mL of each first day urine sample 
was transferred into cryotubes without any preservative. The aliquots were stored at 4 °C for a 
maximum of a week in the dark and thereafter stored at -80°C for several months, before being 
transported to the Netherlands in frozen conditions for DNA isolation and detection. For a sub- 
selection of 85 urines, 49 of them microscopy negative at all examinations, a second aliquot 
was PCR tested at a local laboratory in South Africa for quality control purposes. 
 
 
High school cohort- Gynaecological Examination: The protocol used was adapted from a 
previous FGS study conducted in Zimbabwe (Kjetland et al. 2005). Gynaecologic examination 
was done by trained clinicians (Kleppa et al. 2014). It was commenced by photocolposcopic 
examination of the cervix using an autoclaved metal speculum after which cervico-vaginal 
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lavage samples were collected followed by cytology Pap smears or LBC samples in all the 
consenting participants. Acetic acid or iodine application for colposcopic examination was 
done last. 
 
 
Collection of cervico-vaginal lavages Cervico-vaginal lavages were collected by spraying 10 
ml saline on the vaginal wall and cervix twice, and then drawn back into the syringe. Thereafter, 
1 mL of each sample was then dispensed into 6 labelled cryotubes.  The samples (cervico- 
vaginal lavage and urine) for Schistosoma DNA detection were stored at 4 °C for a maximum 
of a week in the dark and thereafter stored at -80°C for several months, before being transported 
to the Netherlands in frozen conditions for DNA isolation and detection. The laboratory staff 
was blinded to urine microscopy and the cytology results. 
 
 
3.6. Laboratory Analysis 
 
3.6.1 Schistosoma PCR analysis 
 
DNA analysis was conducted at the Leiden University Medical Center (LUMC) in the 
Netherlands, where colleagues from the Department of Parasitology have developed and 
perfected these assays. In order for samples to be transported abroad, permission was obtained 
from the Department of Health, South Africa, in addition to the initial ethical permission that 
was obtained from the University of KwaZulu-Natal’s Biomedical Research Ethics Committee. 
The samples were transported to the Netherlands via courier at -800 Celsius, in dry ice. 
 
 
The DNA isolation and the set-up of the PCR was performed with a custom-made automated 
liquid handling station (Hamilton®, Switzerland) (Figure 1.5). The protocols for urine and 
vaginal lavage were identical. In short, the DNA detection technique entails the following main 
steps: denaturation/isolation, annealing/hybridization and amplification. 
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Figure1.6 Automated liquid handling station (Hamilton®, Switzerland) with block 
containing 96 samples being processed in each run. 
 
 
DNA was isolated from a 200 µL subsample of each urine and vaginal lavage sample 
respectively using QIA Tissue Kit (QIAgen, Hilden, Germany) spin columns (Verweij et al. 
2007; Obeng et al. 2008). The principle of DNA isolation using spin columns entails the 
separation of DNA molecules which bind to silica surfaces in the presence of chaotropic salts 
under certain pH conditions. Carbohydrates and proteins are not absorbed and are removed. 
Nucleic acids are eluted under low-salt conditions- this process helps free the DNA. 
 
 
In the first step, the samples underwent the heating step after the addition proteinase K for 2 
hours at 550C. The heating step facilitates the removal inhibitory factors and helps to break up 
eggs if present. The tissue lysis buffer containing the internal control which is the Phocin 
Herpes Virus (PhHV-1) was then added and the samples were incubated for 10 minutes at 700C 
(Niesters 2002). The purpose of the tissue lysis buffer is to break down the peptide bridges and 
destroys the cell walls to release DNA. It also facilitates the removal of interactions between 
DNA and histones. 
 
 
For real-time PCR Schistosoma-specific primers Ssp48F and Ssp124R were used to amplify a 
 
77-base paired fragment of the internal-transcribed-spacer-2 (ITS2). The double-labeled probe 
 
Ssp78T was used to detect amplification (Obeng et al. 2008). For the internal control, PhHV- 
 
1-specific primers PhHV-267S and PhHV-337AS and the specific double-labeled probe PhHV- 
 
1-305TQ were included in each reaction mixture. The process of primers binding to DNA is 
called hybridization/ annealing. Resultant bonds are only strong if the base pairs of the primer 
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and the DNA match. Polymerases then begin to attach to additional complementary 
nucleotides. Polymerases are enzymes that link individual nucleotides to form long DNA 
chains. 
 
 
The amplification and detection of each DNA sample was achieved using the Bio-Rad CFX 
Manager (Figure 1.5). Amplification and detection commenced by using a 25ul reaction 
mixture containing PCR buffer (HotstarTaq mastermix QIAgen), 5mM MgCl2, 2,5ug buffer 
(HotstarTaq mastermix QIAgen), 5mM MgCl2, 2.5 μg bovine serum albumin (Roche 
Diagnostics Nederland BV, Almere, The Netherlands), 5 pmol of each Schistosoma-specific 
primers, 3.75 pmol of each PhHV-1-specific primers, 1.25 pmol of each of the Schistosoma- 
specific and PhHV-1-specific double labelled probes and 5μl of the DNA sample. In each 
amplification run, negative and positive controls were used. The thermocycler was set for 15 
min at 950C, followed by 50 cycles, each of 15s at 950C, 30 seconds at 600C, and 30 seconds at 
720C (Figure 1.6). 
 
 
 
The PCR output consisted of a cycle-threshold (Ct) value. This value represents the 
amplification cycle in which the level of fluorescent signal exceeded the background 
fluorescence and thereby indicating the presence of parasite-specific DNA in the sample that 
was tested. Based on microscopy, the infection was classified as high-intensity if the mean 
number of eggs of the three specimens was higher than 50 per 10 ml urine (Montresor et al. 
1998).Based on PCR, the infection was classified as high-intensity (Ct<30), medium-intensity 
(30<Ct<35), low intensity (35<Ct<50) or negative (Ct=50) (Pillay et al.2014). These categories 
were chosen arbitrarily, based on previous experiences with protozoal infections where DNA 
loads with a Ct-value below 30 could generally be confirmed by microscopy and DNA loads 
with a Ct-value higher than 35 were always microscopy negative(Van Lieshout and Verweij 
2010). 
 
 
Ct-values of the internal controls were within the expected range for all samples. Fluorescence 
data from PCR assays are collected from PCR cycles that occur in the linear amplification 
portion of the reaction. In ideal conditions, the fluorescence accumulates in proportion to the 
amplicon. Negative samples have no DNA, therefore have no threshold value. Weakly positive 
sample imply that not much DNA was present, therefore this would take a longer number of 
cycles to reach the Ct-value. A sample with a high load of DNA will take less cycles to reach 
the threshold than for those samples with less DNA. 
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Figure 1.7 Display screen of the amplification cycle. 
 
 
3.6.2 Pap smears and liquid-based cytology samples 
 
 
The Pap smears or LBC samples were collected after the cervico-vaginal lavage samples were 
taken. Traditional Pap smears were collected by scraping a wooden spatula of the cervix and 
the cervical surface of the fornices. The cervical smears were then spray-fixed using a 
commercial cytological fixative for preservation. Traditional Pap smears were collected from 
all of the participants from the Ugu District and 519 of the participants from the Ilembe district. 
 
Liquid-based cytology (LBC) is a newer technique, and entails collecting the samples with a 
broom-like device that is placed into a vial containing a buffered fixative solution. In this study 
the SurePathTM (Franklin Lakes, NJ, USA) LBC method was used. The principle of the 
processing of these samples is that on sample collection the cells are further processed and 
stained using an automated system concentrating the cells onto a microscopic slide in a 
monolayer with the removal of excess mucous, blood and inflammatory cells (Figure 1.8 A and 
B). LBC sampling was done for the remaining 327 participants from the Ilembe district. 
 
 
All cytological smears were examined using an Olympus BX43F microscope with 
magnification of 10 and 40 times. The screening was done blinded to any of the other laboratory 
results or clinical findings other than the sample type. Smears were examined microscopically 
for all cytological entities that are expected to be found in cervical smears and reporting was 
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done in accordance to the Bethesda System of Reporting (Solomon and Nayar 2004). Smears 
were reported in a systematic manner, ensuring that all cytological entities were taken into 
account. The cytology report consisted of the following broad areas: a) smear adequacy; b) 
inflammation and benign conditions; c) infective agents; and d) squamous cell atypia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
 
 
 
Figure 1.8 A) Pap 40x: showing cells which are not well preserved and there is excess 
background mucus and inflammatory cells. 
 
B) LBC 40x: excess background material is removed and cells are well preserved and 
easily visualized. 
 
Staining: For both conventional and LBC samples the Papanicolaou staining technique was 
used. It is designed to display many variations of cellular morphology showing degrees of 
cellular maturity and metabolic activity. Use of the Papanicolaou stain results in well stained 
nuclei, differential cytoplasmic counterstaining and cytoplasmic transparency (Figure 1.9). 
There are three main dyes used in this staining technique (DeMay 1996). The nuclear stain is 
Haematoxylin which stains the nucleus of cells blue. The first cytoplasmic counterstain is 
Orange G-6 (OG), which is a monochromatic stain. It stains keratin bright orange. Keratin is 
not a “normal” component of cells and is seen mainly in keratinizing squamous cell carcinoma. 
The other cytoplasmic stain is Eosin Azure-50 (EA). This is a polychrome stain and consists of 
eosin and light green. It stains the cytoplasm of metabolically active cells, intermediate 
squamous cells, parabasal cells, columnar cells, histiocytes and neutrophils. It also stains 
nucleoli. Superficial cells are stained pink or eosinophilic. Intermediate cells and parabasal cells 
are stained shades of blue or cyanophilic (DeMay.R 1996). 
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Figure1.9 Pap 40x: Showing different areas stained by the 
 
Papanicolaou stain 
 
Cytology screening in South Africa is based on the Bethesda System of reporting (Solomon 
and Nayar 2004). The smears were examined microscopically for all cytological entities that 
are expected to be found in cervical smears and reporting was done in accordance to the 
Bethesda System of Reporting (Solomon and Nayar 2004). Smears were reported in a 
systematic manner, ensuring that all cytological entities were taken into account. Adequacy 
was reported according to the Bethesda System, and entities such as the adequate number of 
well- preserved epithelial cells and cellular composition and sampling of the transformation 
zone as well as any other indicators that may impact on the quality of the smear were 
considered. Smears which met these criteria were deemed “satisfactory for evaluation”. Smears 
which did not meet all the criteria, but at the same time enabled a diagnosis were reported as 
“satisfactory for evaluation but limited by”, followed by whichever criteria were lacking for 
example inadequate endocervical cells, inflammation etc. Smears were deemed “unsatisfactory 
for evaluation” in instances where either obscuring blood, excessive inflammation, thick areas, 
poor preservation, poor staining, air drying artefact or contaminants compromised. The 
background contents were also reported on, these included blood and inflammatory cells 
(neutrophils, eosinophils, lymphocytes and histiocytes). Benign changes such as repair and 
regeneration or hyperkeratosis or parakeratosis or squamous metaplasia are also reported. 
Infective agents which are cytologically detectable were also reported. Epithelial dysplasias 
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were  graded  according  to  the  Bethesda  System  (Solomon  and  Nayar2004);(Figure1.10). 
 
 
 
 
Figure 1.10 LBC 40x epithelial cell abnormalities as seen in cervical cytology samples. 
 
 
ASCUS: This entity refers to cytopathologic changes that are not sufficiently clear-cut to permit 
a specific diagnosis. Cellular features include nuclear enlargement in squamous cells with 
mature, superficial/intermediate-type cytoplasm. Variation in nuclear size and shape, and 
binucleation, may be observed. The chromatin is slightly increased but still retains even 
distribution. Because the cellular changes in the ASCUS category may reflect as exuberant 
benign change or a potentially serious lesion, which cannot be unequivocally classified, they 
are interpreted as being of undetermined significance (Solomon and Nayar 2004). 
 
Low Grade Squamous Intraepithelial Lesion (LSIL)/Mild Dysplasia/ (CINI): This category 
encompasses those changes associated with HPV including koilocytosis as well as mild 
dysplasia changes. Cells are seen lying singly or in sheets. The nuclear abnormalities occur 
within “mature” or superficial-type cells (Figure 1.11 A). There is also mild variation in nuclear 
size and shape. Nuclear hyperchromasia mild and chromatin is uniformly distributed. The 
chromatin may appear degenerated or smudged if associated with the cytopathic changes of 
HPV. In LSIL, cells rarely exhibit nucleoli. Cells usually have plentiful, clear, translucent 
cytoplasm with well-defined angular borders (Figure 1.11B). Cells resemble intermediate and 
superficial type squamous cells with a somewhat reduced cytoplasmic body and a slightly 
enlarged nucleus, occupying less than one third of the total area of the cell. Cells that 
demonstrate a well-defined, optically clear perinuclear cavity and a peripheral dense rim of 
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cytoplasm with the accompanying nuclear abnormalities are consistent with HPV (Solomon 
and Nayar 2004); (DeMay 1996). 
 
 
 
Figure1.11 Pap 40 x A) Benign squamous epithelial cells with pyknotic nuclei. B) LSIL 
 
cell with slightly enlarged nucleus 
 
 
High Grade Squamous Intraepithelial Lesion (HSIL): High grade lesions encompass moderate 
dysplasia/CIN II, severe dysplasia/CINIII, and carcinoma in situ/CIS. This category 
encompasses a spectrum of cytological changes that are more likely to persist or progress than 
low-grade lesions. 
 
Moderate Dysplasia/ (CIN II): The size of abnormal cells is more variable. These abnormalities 
are usually confined to the “intermediate” squamous cells (Figure 1.12A). Most cells are round 
to oval, but occasionally spindle cells and elongated and bizarre shapes may be found. 
Cytoplasmic staining is usually cyanophilic, but some cells may show eosinophilia of the 
cytoplasm. Nuclei are enlarged and round to oval, sometimes elongated or irregularly shaped. 
Nuclear chromatin is evenly distributed and moderately hyperchromatic. Nucleoli are usually 
absent. The nucleocytoplasmic ratio is increased, both by nuclear enlargement and by reduction 
of the cytoplasmic volume. The nucleus generally occupies less than half of the total area of 
the cell (Abdel-Hadi and Talaat 2000; Solomon and Nayar 2004) (Figure 1.12B). 
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Figure1.12 Pap 40 x A) Benign intermediate squamous epithelial cells with nuclei have 
finely granular chromatin. B) HSIL- CIN2 Intermediate type cells with moderately 
enlarged nuclei and moderately hyperchromatic nuclei. 
 
Severe Dysplasia/ Carcinoma in Situ (CIN III/CIS): An area in which discrepancies in the 
grading of lesions still occurs is the discrimination between severe dysplasia and carcinoma in 
situ. Cytoplasm was usually sparse, typically forming a small rim around the nucleus. Cells are 
mainly round or oval often irregular or elongated. Cells occur singly as well as in aggregates. 
In the most severe intraepithelial lesions aggregates have a syncytial arrangement with 
indistinct cell borders and irregularly arranged nuclei. The nucleus occupies usually at least two 
thirds of the total area of the cell. Nuclei have a hyperchromatic, irregularly distributed, 
coarsely granular chromatin (Figure 1.13A and B). In actively proliferating lesions 
eosinophilic- staining nucleoli may be observed, but more often these are obscured by the 
dense, hyperchromatic chromatin. Some severe dysplasias show an extreme irregularity in 
shape and size of the composing cells. 
 
 
 
 
Figure 1.13 Pap 40 x A) HSIL- Cells from CIN2 and CIN3, B) HSIL- CIN3 Cells with 
marked hyperchromasia and a small volume of cytoplasm. 
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Cellular Morphology of schistosomiasis: 
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Pap and LBC 40x: Ova of Schistosoma haematobium were seen in varying 
presentations in the Pap smears and LBC samples as described in Paper 2, additional 
images are depicted. 
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3.1.7 Statistical analyses 
 
Data were stored and grouped in Microsoft Access database and imported into IBM SPSS 20.0 
(Chicago, Illinois, USA) and 23.0 (Armonk, NY, USA) for statistical analysis. Descriptive 
statistics were used in this exploratory study. Inferential statistics were done using the Fisher’s 
Exact Test. The odds and risks ratios and the corresponding 95% confidence intervals were 
determined for 2 x 2 cross-tabulations. All p-values were two-tailed values and p-values less 
than 0.05 considered as statistically significant. Categorical variables were summarized by 
frequency and percentage and presented using bar charts. Where the data were not normally 
distributed, results were described as the total number, range, interquartile ranges (IQR) and 
median value of positive subjects. The McNemar statistical test was used to analyze 
concordance between the different diagnostic procedures. For the diagnostic tests the 
continuous variable output was given for the positive cases only using the Mann-Whitney rank- 
sum test. 
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3.1.8     Linking of objectives and papers 
 
 
This study had five manuscripts, Papers 2 and 4 included the first three objectives. The papers 
are presented as follows: development of non-invasive diagnostic tools for FGS are included in 
Papers 1-4. Paper 1 describes the use of real-time PCR to diagnose schistosomiasis in girls 10- 
12 years of age and the sensitivity of the diagnostic tests were used to assess distribution of 
schistosomiasis in relatively large study populations by using small sample volumes. 
 
 
Paper 2 builds on the use of PCR and focused on an older cohort. The value of Cervical 
Cytology as a diagnostic tool for FGS and comparison with real-time PCR for Schistosoma 
specific DNA in vaginal lavage and urine samples and urine microscopy for S. haematobium 
ova has been described. . 
 
 
Paper 3 considers the generalisability of the use of real-time PCR for the detection of 
Schistosoma DNA in vaginal lavage and urine comparing populations from Tanzania, 
Madagascar and South Africa. 
 
 
Paper 4 further investigates the value of traditional Pap smears comparing with LBC for FGS. 
This paper presents the prevalence of cervical squamous atypia and the association with 
urogenital schistosomiasis, possible risk factors for cervical atypia and schistosomiasis are 
identified. 
 
 
Paper 5 considers whether treatment in young women with Praziquantel can reduce FGS and 
squamous cell atypia. 
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4.0 CHAPTER FOUR 
 
 
4.1 Paper 1 
 
Real-time PCR detection of Schistosoma-DNA in small volume urine samples reflects 
focal distribution of urogenital schistosomiasis in primary school girls of KwaZulu- 
Natal, South Africa. 
 
Pavitra Pillay, Myra Taylor, Siphosenkosi G. Zulu, Svein. G. Gundersen, Jaco J. Verweij, 
Pytsje Hoekstra, Eric A.T. Brienen, Elisabeth Kleppa, Eyrun F. Kjetland and Lisette van 
Lieshout. 2014. 
American Journal of Tropical Medicine and Hygiene 90: 546-552. (Published) 
 
 
 
 
This paper was written to address the challenge to find non-invasive diagnostic tools since in 
children who are risk for genital schistosomiasis since gynaecologic examinations are not 
ethical (Objective 2, 3).  The aim of this study was to investigate Schistosoma PCR in urine 
samples and compare results to microscopy and to investigate the association of genital 
symptoms using the laboratory and clinical data on a school level. 
 
Urine samples from 708 primary school girls aged 10-12 years from 13 schools were analysed 
for Schistosoma ova microscopically using 2 subsamples of 10mL of urine collected over three 
consequtive days and using a single 200µl urine sample for Schistosoma DNA analysis. The 
interview data collected provided information on the living conditions, water contact and 
genital symptoms. 
 
My role in this aspect of the research was to learn about the ITS-based real-time Schistosoma 
PCR assay, which was devised and developed at the Leiden University Medical Center 
(LUMC) and to process the urine samples with support and assistance from the staff at the 
LUMC. Performing the Schistosoma PCR laboratory work and analysing the data with 
assistance was new knowledgde gained. I was also first author in this publication with support 
and assistance from my supervisors and co-authors. 
 
This was the first study to explore the association between Schistosoma PCR and female genital 
symptoms in children at school level. It was also found that schistosomiasis was focal and 
differed among schools. Such tools may be of value in disease mapping at population level for 
the detection and management of schistosomiasis. 
 
Am. J. Trop. Med. Hyg., 90(3), 2014, pp. 546 –552 
doi:10.4269/ajtmh.13-0406 
Copyright  © 2014 by The American Society of Tropical  Medicine  and Hygiene 
 
 
Real-Time Polymerase Chain Reaction for Detection of Schistosoma DNA  in Small-Volume 
Urine  Samples Reflects  Focal Distribution of Urogenital Schistosomiasis 
in Primary  School Girls in KwaZulu Natal, South Africa 
 
Pavitra  Pillay,* Myra Taylor, Siphosenkosi G. Zulu, Svein G. Gundersen, Jaco J. Verweij, Pytsje Hoekstra, 
Eric A. T. Brienen, Elisabeth Kleppa,  Eyrun  F. Kjetland,  and Lisette  van Lieshout 
Department of Biomedical and Clinical Technology,  Durban University of Technology,  KwaZulu Natal, South Africa; School of Nursing and 
Public Health, University of KwaZulu Natal, KwaZulu Natal, South Africa; Research Unit, Sorlandet Hospital HF, Kristiansand, Norway; 
University of Agder, Kristiansand, Norway; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands; 
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Abstract.     Schistosoma haematobium eggs and Schistosoma DNA  levels were measured in urine samples from 708 girls 
recruited from 18 randomly  sampled primary schools in South Africa. Microscopic analysis of two 10-mL urine subsamples 
collected  on three  consecutive  days confirmed  high day-to-day variation;  103 (14.5%)  girls had  positive  results  at all 
six examinations, and at least one positive sample was seen in 225 (31.8%)  girls. Schistosoma-specific  DNA,  which was 
measured in a 200-mL urine subsample  by using real-time  polymerase chain reaction, was detected in 180 (25.4%) cases, 
and levels of DNA corresponded significantly with average urine egg excretion.  In concordance with microscopic results, 
polymerase chain  reaction  results  were  significantly  associated  with history  of gynecologic  symptoms  and  confirmed 
highly focal distribution of urogenital schistosomiasis.  Parasite-specific DNA  detection has a sensitivity comparable to 
single urine microscopy and could be used as a standardized high-throughput procedure to assess distribution of urogenital 
schistosomiasis  in relatively  large study populations by using small sample volumes. 
 
 
INTRODUCTION 
 
Schistosomiasis  is endemic  to 76 countries  and 85% of those 
infected  live in rural  areas  of sub-Saharan Africa,  where  at 
least 100 million women and girls are at risk of having this 
helminth  infection.1 Those  who are most vulnerable to infec- 
tion  are  pre-school  and  primary  school  children,  adolescent 
girls, and women of childbearing age. To reduce morbidity the 
World Health Organization recommends annual treatment of 
such as those with HIV or human papillomavirus.4 The colpo- 
scope for investigating gynecologic  morbidity  has limitations 
because  it is highly observer-dependent, requires  extensive 
training and expensive equipment, and cannot be used among 
children because  intra-vaginal inspections  are normally  not 
performed before  the onset of sexual activity. 
For  urinary  tract  infection  with  S. haematobium,  micro- 
scopic examination for eggs is considered the diagnostic  gold 
12
 
school-age children in areas of high endemicity.2 
standard. However,  the  extent  to  which the  presence  and 
In sub-Saharan Africa, Schistosoma haematobium is the pre- 
dominant species.3  Adult worms lodge in the venules surround- 
ing the pelvic organs,  where  they deposit  their  eggs. Some of 
intensity of excreted eggs in urine is associated  with the actual 
degree of genital morbidity  is still under  debate because  stud- 
ies have shown a substantial proportion of adult women with 
4
 
the eggs are released  into the urine whereas others get trapped 
genital  lesions  to  be  urine  microscopy  negative. In  adults, 
in the bladder  mucosa  where  they give rise to granulomatous 
gynecologic   symptoms   are   often   seen   many   years   after 
4
 
inflammation causing  hematuria and  urinary  symptoms.  Up 
reported water  exposure. Conversely,   in  school-age   girls, 
to 75% of the women who excrete S. haematobium eggs in the 
urine may also have Schistosoma eggs in the uterus, cervix, 
vagina,  or  vulva.4    The   genital   manifestations  may  mimic 
cancer-like lesions and the different sexually transmitted dis- 
eases,  such  as  ulcers,  genital  warts,  polyps,  and  also  cause 
mucosal   immune   activation  and  blood   vessel  friability.5–7 
Several studies have indicated that genital manifestation of 
schistosomiasis may make women susceptible  to human immu- 
nodeficiency virus (HIV)  infection and they may possibly also 
develop  infertility.8–10 Because  S. haematobium affects the 
urinary and genital tracts, urinary schistosomiasis has been 
renamed urogenital schistosomiasis.11 
The gold standard for diagnosing  gynecologic  schistosomi- 
asis has been  the demonstration of eggs in a crushed  biopsy 
specimen.6 However,  this procedure is controversial because  it 
is invasive and could make the cervical mucosa more  suscep- 
tible  to infections  with other  sexually transmitted infections, 
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one  would  expect  infections  to  be  more  recently  acquired, 
with adult  worms actively  producing  eggs that  are  deposited 
at different tissues in the pelvic region  and excreted into the 
urine in relatively  large quantities. 
The    association     between     urine    microscopy–detected 
S. haematobium infection  and genital symptoms has been 
recently  studied  on a group  of 10–12-year-old  school girls in 
South Africa.13 One third of the interviewed girls reported to 
have  a history  of genital  symptoms,  and multivariate regres- 
sion analysis showed a significant association with the urine 
microscopy  results. To avoid suboptimal diagnosis and not to 
miss light infections, intense microscopy was performed as 
generally  recommended, which required repeated urine  sam- 
ple collection and examination.12,13 Microscopy has the limi- 
tations  of  being  an  observer-dependent procedure, as  well 
as laborious,  when applied to large-scale population based 
surveys. For this purpose  there  is a clear need for more 
standardized  and  highly  sensitive  high-throughput  diagnos- 
tic procedures.14,15 
In recent  years, several  nucleic acid–based  diagnostic  tests 
have been established for specific and sensitive detection and 
quantification of a broad  range  of parasite DNA  in clinical 
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samples, including an internal transcribed spacer (ITS)–based 
Schistosoma-specific  multiplex real-time  polymerase chain 
reaction  (PCR).16,17  In this study,  we further  explored  real- 
time PCR  as a diagnostic  tool for mapping  school-based dis- 
tribution of urogenital schistosomiasis  by comparing  urine 
Schistosoma  DNA  levels  in the  same  cohort  of school  girls 
from South Africa with the findings of multi-sampling micros- 
copy, as well as reported gynecologic symptoms. 
 
 
MATERIALS AND  METHODS 
 
Study population. The study design is a school-based, clus- 
ter,  randomized, cross-sectional  study of girls 10–12 years of 
age in rural primary  schools in KwaZulu-Natal, South Africa. 
Participants  were   recruited  from   18   randomly    selected 
schools,  all  situated in  a  coastal  area  of  5,866 km2   within 
Ugu  district,  south  of Durban.13  The  region  is known  to be 
effects.  Support   of  a  private  psychologist  was  available  to 
assist  with  cases  that  required psychological   support.   The 
project  also had a referral  system with local clinics and hospi- 
tals for those  participants that  required this system. Consent 
forms were returned and signed by 92% of the parents  in the 
first 13 schools, but because of teacher strikes, the turnout was 
only 17% in the remaining  five schools.13 
Sample collection  procedure and microscopy.  A team of 
trained field research  assistants and school nurses visited each 
school for general  study information and urine collection 
between   10:00 AM   and  2:00 PM   on  three  consecutive   days. 
Samples were transported to the laboratory on the same day 
in  dark  cooler  boxes  to  ensure   optimal   processing.   After 
arrival,  two 10-mL urine  samples  (A  and B) were preserved 
with  1 mL  of  2%  tincture of  merthiolate in  5%  formalin 
solution.21  Within  the  same  week,  samples  were  centrifuged 
for 10 minutes  at 4,000 rpm and microscopically  investigated 
endemic  for  S. haematobium and  HIV.18,19  Other  common at a magnification of 10 for S. haematobium eggs. The egg 
helminths   are  Ascaris  lumbricoides   and  Trichuris  trichiura 
but  only occasional  cases of infection  with S. mansoni  have 
been  reported.20  Recruitment of the  study  participants and 
their clinical symptoms have been described in detail else- 
where.13 In brief, data and sample collection were performed 
during September 2009–November  2010. Before  the study, 
information meetings  were organized  at each school and girls 
were invited to participate if their parents  provided  consent. 
Interview.  Research assistants  invited  consenting girls to 
face-to-face   private  interviews   performed in  the  local  lan- 
guage  isiZulu.  In brief,  in this study  we used  four  key vari- 
ables: 1) living with both  parents,  2) reported water  contact, 
3) history  of red  urine,  and  4) history  of genital  symptoms 
because  these variables  potentially reflect social status, expo- 
sure to and clinical outcome of S. haematobium infection. 
Each  girl was questioned about  her  living conditions  and 
relationship with her biological parents  and about  her own 
observations concerning  red  urine.  High-risk  water  contact 
was defined  as reported regular  exposure  to potentially infec- 
tive water bodies covering at least 10% of the body surface or 
being  in  the  risk  water  at  least  60  minutes   per  exposure. 
History  of genital  symptoms  consisted  of reported symptoms 
of bloody discharge,  malodorous discharge,  genital itch or 
burning  sensation  in the genitals,  and some additional symp- 
toms,   which   were   only   occasionally   mentioned.  Further 
details about  the interview are given elsewhere.13 
Ethical  considerations and permissions.  This study project 
drew from a larger project  that was approved by the Biomed- 
ical Research Ethics  Administration, University  of KwaZulu 
Natal  (Ref  BF029/07). The Departments of Health and Edu- 
cation  (Ref  HRKM010-08) of KwaZulu Natal  also approved 
the study. Ethical permission was also granted  from The 
Norwegian  Ethics  Committee, Regional  Etisk  Komité   Øst- 
Norge  (REK-Øst), (Ref  IRB  0000 1870) and  The  European 
Group   on  Ethics  in  Science  and  New  Technologies  (Ref 
IRSES-2010:269245). 
Parents   or  guardians   provided   written  informed   consent 
counts  were  recorded for  each  10 mL  of  urine  separately. 
When more than 1, 000 eggs were seen, counting was stopped. 
Microscopy was performed blinded to previous  results and by 
separate technicians.  Quality  control  was performed by an 
independent senior  microscopy  expert  on 10%  of randomly 
chosen samples. 
Detection of Schistosoma DNA.  Aliquots  of 1 mL of each 
first-day urine sample, before the merthiolate-formalin was 
added,  were  transferred into  cryotubes.   The  aliquots  were 
stored  at  4 °C  for  maximum  of  one  week  in  the  dark  and 
thereafter stored  at −80 °C for several  months,  before  being 
transported to the Netherlands in frozen conditions  for DNA 
isolation  and  detection. For  a subselection of 85 urine  sam- 
ples, 49 of them  that  were microscopy  negative  at all exami- 
nations,   a  second   aliquot   was  tested   by  PCR   at  a  local 
laboratory in South Africa. 
In  the  Netherlands, DNA  isolation  and  the  set-up  of the 
PCR was performed at the Leiden  University  Medical Center 
with a custom-made automated liquid  handling  station 
(Hamilton, Bonaduz,  Switzerland). DNA  was isolated  from a 
200-mL subsample  of each urine sample by using a proteinase 
K heating step and QI Amp spin columns (QIAGEN, Hilden, 
Germany) as  described.16  Phocin  herpes  virus  1 (PhHV-1) 
was added  to  the  lysis buffer  as  an  internal control.22  For 
real-time PCR, Schistosoma-specific primers Ssp48F and 
Ssp124R  were  used  to  amplify  a  77-basepair   fragment   of 
ITS2. The double-labeled probe  Ssp78T was used to detect 
amplification.16  For the internal control,  PhHV-1-specific 
primers   PhHV-267S   and   PhHV-337AS  and   the   specific 
double-labeled probe  PhHV-1-305TQ were included  in each 
reaction   mixture.  The  amplification and  detection of  each 
DNA  sample, with use of the Bio-Rad (Herciules, CA)  CFX 
Manager, was performed as described.16 
Similar  DNA  isolation  and  PCR  procedures were  used  at 
the  laboratory in South  Africa,  with  some  minor  modifica- 
tions.  All  steps  were  done  manually.  The  PhHV-1  internal 
DNA  control  was replaced by Lambda  DNA  (1 mL Lambda 
−6
 
and  consent  was given by each  girl. All girls were  informed DNA;  dilution  of 10 per 400 mL of lysis buffer).  Therefore 
of the right to withdraw  and to abstain  from answering  ques- 
tions without  negative  consequences. To protect  children  from 
stigmatization, the disease  was discussed  in general  terms  as 
urinary   schistosomiasis,   known   as  isichenene   in  isiZulu. 
Lambda-specific primers and the Lambda-specific CAL Fluor 
Orange  560–labeled probe  Lambda-TMp were used in the 
reaction  mixture.  The amplification of each DNA  sample was 
performed in a 25-mL reaction  mixture  containing  PCR buffer 
Treatment of schistosomiasis  with  praziquantel was offered (containing 10 Gold  Buffer,  dNTPs,  and TaqGold), 5 mM 
to all participants, and all were informed  about  possible  side MgCl2,  2.5  mg  bovine  serum  albumin   (Roche   Diagnostics 
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tarting  with a Ct value of 35. Living with both biological parents 163 (23.1) 
Because  the  data  were  not  normally   distributed,  results Living with one biological parent 348 (49.4) 
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Nederland BV, Almere,  The Netherlands), 1.5 pmol of each 
Schistosoma-specific  primer, 1.5 pmol of each Lambda-specific 
primer,  1.25 pmol of each of the Schistosoma-specific  and 
Lambda-specific  probes,   and   5  mL  of  the   DNA   sample. 
The  thermocycler was set  for 15 minutes  at  95 °C, followed 
by  50  cycles,  each  for  15  seconds  at  95 °C,  30  seconds  at 
60 °C, and 30 seconds  at 72 °C. Amplification, detection, and 
data  analysis  were  performed with the  Corbett Rotor  Gene 
3000 (QIAGEN). 
In both  laboratory settings,  the PCR  output consisted  of a 
cycle threshold (Ct) value,  which represented the  amplifica- 
tion cycle in which the level of fluorescent signal exceeded  the 
background fluorescence and thereby  indicating  the presence 
of parasite-specific DNA  in the sample  that  was tested.  The 
Ct values of the internal controls  (PhHV in the Netherlands, 
Lambda   DNA   in  South  Africa)   were  within  the  expected 
range for all samples and will not be further  discussed within 
the results. 
Data analysis and statistical testing. The PCR analysis was 
performed  blinded   from   microscopy   or  other   field  data. 
The  results  of the  real-time  PCR  analysis  were  stored  and 
grouped   in  a  Microsoft  (Redmond, WA)  Access  database 
and imported into IBM (Chicago, IL) SPSS 20.0 for statistical 
analysis together with provided  field data, including results of 
the interviews  and urine microscopy examinations. 
Based on microscopy, the infection was classified as high 
intensity  if the mean  number of eggs of the three  specimens 
was > 50 per 10 mL of urine.23  Based  on PCR,  the infection 
was classified  as high  intensity  (Ct  < 30), medium  intensity 
(30 £ Ct < 35) or low intensity  (35 £ Ct < 50).
15  These catego- 
ries  were  chosen  arbitrarily, based  on  previous  experiences 
with  protozoal and  helminth   infections  where  DNA   loads 
with a Ct value < 30 could generally  be microscopy confirmed 
and DNA  loads with a Ct value > than 35 were always micros- 
copy  negative.  For  better  visualization in the  scatter  plots, 
Ct values were also recalculated into arbitrary units (AU) of 
copy  numbers  of Schistosoma  DNA.  An  arbitrary value  of 
1 AU was assigned to each positive sample with a Ct value ³ 35. 
Assuming  100% efficacy of the  DNA  multiplication process 
up to 35 cycles, a duplication of AU  was calculated  for each 
PCR   cycle,  meaning   for  each   single  Ct   value   reduction 
s 
 
were   described   as  the   total   number,   range,   interquartile 
ranges (IQRs), and median  value of positive subjects. For the 
evaluation  of  S.  haematobium  infection   intensity,   concor- 
dance between  sample egg counts and PCR output (AU) was 
statistically analyzed  by using the non-parametric Spearman’s 
rank  order  correlation coefficient  (r) because  both  variables 
were skewed even after log transformation. The McNemar 
statistical  test was used to analyze  concordance between  the 
 
 
Figure 1.   Flow  chart  of  study  participation and  adherence  by 
708 school girls in KwaZulu Natal,  South Africa.  PCR  = polymerase 
chain reaction. 
 
 
and   not   being   within   the   specified   age   range.   Of   the 
interviewed girls, 708 pupils provided  urine samples for com- 
plete  microscopy  data  and  PCR,  and  13 schools  had  more 
than 20 participants. Discrepancy analysis showed no relevant 
differences  between  the  708 girls tested  and  those  excluded 
because  of incomplete sampling.  At  the  interview,  27.5%  of 
the  708 girls  reported not  living  with  their  parents,  60.4% 
 
 
Table 1 
Epidemiological  and   parasitological  characteristics  of   urine 
Schistosoma  PCR  tested  school girls (n=708) 
Characteristics n (%)  Range 
Number                                                                    708 
Age (years) 
Median  (range)  11 10 –12 
 
Number  of schools                                                   18 
Participants per school 
Median  (range)  33 4 –158 
 
Reported during interview 1) 
Situation  at home 2) : 
 
 
Possible exposure  to infected  water: 
Low risk water contact  180    (25.4) 
High risk water contact  248    (35.0) 
 
Red urine: 
Sometime  before  50 (7.1) 
Last week  60 (8.5) 
Genital  symptoms3): 
History  of bloody discharge  52 (7.2) 
different diagnostic   procedures. Statistical   significance  was 
considered at P < 0.05. 
History  of burning  sensation  in 
the genitals 
101    (14.3) 
 
 
RESULTS 
 
General characteristics of the study population. A summary 
of the  sample  selection  procedure is shown in Figure  1, and 
a  general  description of  the  study  population is shown  in 
Table 1. A total of 1,948 school girls were included  for partic- 
ipation.  However,  some  participants were  excluded  because 
unreturned consent forms, refusal to participate, absenteeism, 
History  of any symptoms  231    (33.1) 
 
Urine  microscopy (S. haematobium eggs) 
60 mL examination                                            225    (31.8) 
Positive in all 6x 10 mL examinations            103    (14.5) 
Showing mean egg count > 50 eggs/10mL         60      (8.5) 
10 mL examination (day 1) 
S. haematobium egg positive cases detected    171    (24.2) 
 
1) Full details are presented in Hegertun et al.(2013) definitions  describes  at material  and 
methods  section. 
2) In 3 cases no answer was given. 
3) In 5 cases no answer was given. 
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reported possible exposure  to infested  water, 15.6% reported 
a  history  of  red  urine,  and  33.1%  reported any  history  of 
genital symptoms (Table  1). These characteristics were within 
the same range  as the answers given by all 1,057 interviewed 
girls, being 27.3%, 62.6%, 17.8% and 35.0%, respectively. 
Schistosoma microscopy.    The   day-to-day    variation    in 
counted  S. haematobium eggs is shown in Figure 2A, which 
depicts egg counts of sample day 1A and sample day 3A. Inten- 
sity of infection  between the  two sample  readings  correlated 
significantly  in those  positive  (n = 195; Spearman’s  r = 0.32, 
P < 0.001). At the same time, discrepancies were seen. Although 
139 girls were  microscopy  positive  for  both  samples,  32 girls 
were positive  in urine  sample  1A and negative  in sample  3A. 
In 24 girls, the opposite result was seen. Less than 50 eggs/10 mL 
of urine were counted  in 43 of the 56 girls; there  was only one 
positive urine  sample. Identical patterns were seen when 
microscopy data for other urine readings were compared. 
The overall prevalence of S. haematobium based on the 
detection of eggs in urine samples collected  on three  con- 
secutive  days was 31.8%, with an average  egg count  of 0.17– 
624 eggs/10 mL  (median  = 20, IQR  = 5–55). One  hundred 
and  three   (45.8%)   of  the  225  microscopy-positive  girls 
showed  eggs in all six urine  examinations, and  average  high 
intensity  infections  were seen in 60 (26.7%)  infected  girls. 
Based on readings from the three consecutive days, the prev- 
alence of each day was 25.8–26.4%, and based on the 
individual  10-mL  urine  examinations, the  prevalence was 
22.5–24.2%. 
Schistosoma PCR.   The  PCR  analysis  of  first  day  urine 
samples  showed  Schistosoma  DNA  in 25.4% of the samples, 
 
 
 
 
 
Figure 2.   Scatter  plots of 708 school girls 10–12 years of age in KwaZulu-Natal, South  Africa.  (A)  Comparison of urine  microscopy  of the 
first 10-mL sample of day 1 (sample  1A) and the first 10-mL sample of day 3 (sample  3A). (B) Comparison of urine microscopy of the first 10-mL 
sample of day 1 (sample  1A) and urine Schistosoma DNA  loads determined in the same day sample (200 mL) by using real-time  polymerase chain 
reaction  (PCR). 
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and 125 of these  180 samples  had high DNA  loads. The AU 
of DNA  copies ranged  from  1 to 154 103  (median  = 448, 
IQR = 12–7 103). The association  between  urine Schistosoma 
DNA  load  quantified in 200-mL samples  and  the  number of 
eggs counted  in a 10-mL sample of the same portion  is shown 
in Figure  2B. A significant correlation was seen between  the 
two  procedures (n  = 199; Spearman’s  r = 0.51, P  < 0.001). 
Discrepancies were  also  observed.   Nineteen samples  were 
PCR  negative  and  microscopy  positive,  all  samples  except 
one had egg counts < 50 eggs/10 mL. In addition,  Schistosoma 
DNA  was detected in 28 urine samples that were microscopy 
negative. In 14 of these samples, eggs were seen in at least one 
of the five other  10-mL urine samples by microscopy,  and the 
remaining  14 had low DNA  levels, which indicated  that  half 
of them  had 1 AU  and the  maximum  seen was 90 AU.  The 
number of detected cases by urine  PCR  did not  statistically 
differ from the number of detected cases by each of the 10-mL 
urine microscopy  examinations, or each of the three  consecu- 
tive day readings, but was significantly less compared with the 
225 cases detected when  all microscopy  readings  were  com- 
bined.  Also,  the  average  egg counts  correlated  significantly 
with the measured urine AU  of DNA  copies (n = 239; 
Spearman’s  r = 0.70, P < 0.001). 
A  comparison  between   PCR   outputs   in  the   two  PCR 
laboratories showed  only  minor  discrepancies. Four  of  the 
36   microscopy-positive   urine    samples   were   missed   in 
South Africa; these samples showed positive results in the 
Netherlands. Conversely,  1 of the 49 microscopy-negative 
samples had a high DNA  level in South Africa, which could 
not be confirmed  when tested  in the Netherlands. 
School level analysis. To fully explore  the diagnostic  value 
of urine PCR to identify high-risk communities, findings were 
further  analyzed  at school level. Data  for 13 schools with at 
least 20 participants per school, representing 666 school girls, 
were  aggregated.  The  prevalence  of  S.  haematobium per 
school  based  on  urine   PCR   ranged   from  3.4%  to  45.9% 
(median  = 27.0%, IQR  = 12.0–37.8%) and showed  a signifi- 
cant correlation with the prevalence range based on complete 
microscopy  (n  = 13; Spearman’s  r = 0.95, P  < 0.001). The 
prevalence of detectable Schistosoma  DNA  showed a signifi- 
cant correlation with reported history of genital symptoms  at 
school level (Figure 3) (n = 13; Spearman’s  r = 0.74, P < 0.01). 
Also, reported history  of high-risk  water  contact  and history 
of  red  urine  showed  a  significant  correlation with  school- 
based Schistosoma prevalence determined by PCR or micros- 
copy  (n  = 13; Spearman’s  r = 0.62–0.73, P  < 0.03). A  total 
of  58.6–83.8%  of  the   girls  reported  living  with  at  least 
one   parent,  and   13.9–34.5%   reported  living   with   both 
parents.  No association  was seen between  household compo- 
sition and prevalence of schistosomiasis  determined by PCR 
or microscopy. 
 
 
 
DISCUSSION 
 
In this study,  we used  a PCR  with 708 urine  samples  col- 
lected  from girls in 18 primary  schools from KwaZulu-Natal, 
South Africa. Microscopy was performed six times on a 10-mL 
urine sample collected  over three  consecutive  days. We found 
substantial dispersion  of counted  eggs in urine; < 15% of the 
girls showed positive results for all six 10-mL urine sample 
examinations. This high day-to-day variability  in Schistosoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Scatter  plot comparing  school-based prevalence of 
Schistosoma  DNA  in urine  samples  and  reported history  of genital 
symptoms  in school  girls in KwaZulu Natal,  South  Africa.  Schools 
(n = 13) with at least  20 participants were included,  which included 
666 school girls of 10−12 years of age. PCR = polymerase chain reaction. 
 
 
eggs shedding is generally  acknowledged, but data have been 
published  only sparsely.24 
Interestingly,  we  found  the  sensitivity  of  the  ITS-based 
PCR  performed with a 200-mL subsample  to be comparable 
to that of each of single 10-mL microscopy examinations. How- 
ever, the sensitivity was lower when compared with repeated 
microscopy   (complete  60-mL  urine   sample   examination). 
DNA  amplification was detected in 98.3% and 88.3% of the 
samples with > 50 eggs/10 mL of urine and £ 50 eggs/10 mL of 
urine,  respectively, and in 28 (5.2%)  of 537 urine  samples  in 
which eggs were not detected at the first 10-mL urine sample 
examination. In one  considers  that  our  population of school 
girls was truly infected  if at least one of the six microscopy 
examination results was positive, or if Schistosoma DNA  was 
detected in urine, this resulted  in a negative  predictive  values 
for  complete   60-mL  microscopy,   10-mL  microscopy,   and 
urine PCR of 98%, 86%, and 88%, respectively. 
In a previous  study, the same ITS-based  real-time  PCR for 
specific detection of Schistosoma DNA  showed excellent 
sensitivities  for 730 urine  samples  collected  from children  in 
five  primary   schools   from   different  communities  in  the 
Greater Accra  region  of Ghana.17 Compared with our study, 
infection  levels  were  low in the  selected  schools  in Ghana; 
the  overall  prevalence was 7.8%  and  only 10 of 57 children 
had > 50 eggs/10 mL of urine. Schistosoma DNA was amplified 
in 100% and 85.2% of urine  samples with > 50 eggs/10 mL of 
urine  and £ 50 eggs/10 mL of urine,  respectively.  In addition, 
Schistosoma  DNA  was detected by PCR  in 102 (15.2%)  of 
673 urine  samples  in which eggs were  not  detected by single 
10-mL urine microscopy. These findings resulted  in higher neg- 
ative  predictive  values  for real-time PCR  (> 94.6%)  than  for 
microscopy (54.3–95.7%).17 
Although Schistosoma DNA  was quantified in both studies 
according  to  the  same  PCR  procedure, microscopy  showed 
better  performance in South Africa. Results  could not be 
explained by the  higher  overall  S. haematobium prevalence 
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in  samples  in  South  Africa  because   concordance between 
PCR   output  and   microscopy   did   not   shift   between   the 
selected schools (e.g., the five schools with a microscopy 
prevalence < 20% showed a similar range in prevalence based 
on urine  Schistosoma  DNA  detection, while the five schools 
tested  in  Ghana showed  substantial higher  infection  levels 
based on PCR).17 
A possible explanation for the comparatively poor PCR per- 
formance  in the current  study could be the procedure of sample 
collection  (i.e., the time lag between  receiving the samples and 
definitive  storage  in a frozen  condition). Because  of logistics, 
freezing  of  samples  could  only  be  performed a  number   of 
days, up to a week, after collection.  When mixed with ethanol, 
fecal  samples  can  be  kept  at  room  temperatures for  weeks 
to months,  even  in tropical  conditions,  before  transported to 
centralized laboratory facilities for DNA  isolation.25 For urine 
samples,  optimal  storage  conditions  without  immediate need 
for a cold chain still need to be further  explored. 
Alternatively, the  ITS-based   PCR  may  not  be  the  most 
optimal  procedure for amplifying Schistosoma DNA  in all 
geographic  settings.  Other  procedures have  been  described 
and some of them seem to show promising  diagnostic  perfor- 
mance.26,27 However,  not all of these  PCRs  have been  trans- 
formed into a multiplex real-time  PCR format. Thus, they are 
substantially more  laborious,   still  observer-dependent, and 
lack the  option  to include  a proper  internal control.27  Also, 
some need  relatively  large serum  volumes.28  Thus, their 
feasibility for large-scale  population based surveys still needs 
to be fully explored. 
Human  errors, including missed observations during 
microscopy  and  mislabeling  and  swapping  of  samples,  can 
never  be completely excluded.  This problem  is illustrated by 
the  single  sample  showing  > 50  eggs/10  mL  of  urine  that 
showed  negative  results  when  tested  by  PCR.  This  person 
showed  S. haematobium eggs at all six microscopy  examina- 
tions, almost all with high egg counts. Thus, it is likely that 
aliquots were swapped during sampling for PCR analysis. The 
potential influence  of human  error  is also illustrated by the 
performance of the real-time  PCR  at the separate laboratory 
facilities. Overall results were highly reproducible, but in case 
of discrepancy, the  output produced by using an automated 
liquid handling station has been more in concordance with the 
microscopy data than the PCR output produced manually. 
The   use  of  an  automated  liquid   handling   station   also 
enables  processing  of large sample numbers  in a short period 
(i.e., we completed DNA  isolation  and detection, including 
automated data handling,  for all 708 samples within 10 work- 
ing days). The small sample  volume  required and the poten- 
tial number of additional DNA  targets that can be quantified, 
in particular when working with fecal samples, makes this 
approach highly attractive for large-scale  population screen- 
ing for the presence  of multiple  urinary  and intestinal  micro- 
organisms.17,29,30  In  this study,  we also  introduced arbitrary 
units  (AU) of copy  numbers  of Schistosoma  DNA  as PCR 
output,  which provides  a more  realistic  view on the  existing 
high linear  range  of intensity  of Schistosoma  infection  than 
Ct values. In addition,  for more in depth  comparison between 
different PCRs,  further  standardization, including converting 
DNA  loads into egg counts, is needed. 
In a previous  study,  the  overall  association  between  urine 
egg excretion  and reported urinary  and gynecologic symptoms 
was described.  In particular, bloody  discharge  and a burning 
sensation  in the genitals were found to be significantly corre- 
lated with repeated urine microscopy findings, even after con- 
trolling  for confounders.13  As expected, we found  the  same 
associations  between  PCR-diagnosed schistosomiasis  and 
reported genital  symptoms.  Because  of the young age of the 
girls  included,  we  were  not  able  to  collect  any  gyneco- 
logic  samples,  which  would  be  of interest  for  quantification 
of  Schistosoma   DNA   levels.31    However,   for  confirma- 
tion,  urinary  and  vaginal  samples  should  be  collected  from 
adult  women. 
Although schools were randomly  selected  from a relatively 
small  rural   area   of  KwaZulu-Natal  that   had  comparable 
ecologic    and    socioeconomic     circumstances,   we    found 
S. haematobium infection  prevalence to  range  from  < 5% 
up to approximately 60% between  the different schools. 
Schistosoma prevalence and the prevalence of reported 
urinary and gynecologic symptoms varied greatly between 
included  schools. Conversely,  we found no association 
between   household  composition, reflecting  social  status  in 
this particular region, and the prevalence of S. haematobium. 
Focal  distribution of schistosomiasis  has been  described  and 
besides behavioral components in relation to exposure  to 
infected water bodies, many other factors may influence prev- 
alence  and  intensity  of infection,  including  micro-level  envi- 
ronmental  circumstances.32  The  consequences are  obvious. 
Although local hot-spots  require  intensive  and repeated mass 
treatment with  appropriate  anti-schistosomal drugs  in com- 
bination    with   intense   control   measures    and   monitoring, 
other  communities will be served sufficiently by targeted 
treatment or even passive case detection. Based on this 
knowledge,  there  is also a clear need for a rapid and field 
applicable   diagnostic   test   to   allocate   these   hot   spots   in 
resource-poor settings  without  the  need  of high  technology 
laboratory equipment.33,34 
In conclusion, our findings illustrate that the diagnostic poten- 
tials of urine  Schistosoma  real-time  PCR  is dependent on the 
quality and intensity  of performed microscopy.  Repeated 
microscopy  may in certain  settings be more sensitive but at the 
same time it is a highly laborious  as well as observer  dependent 
procedure. Although improved  sensitivity is still anticipated, 
parasite-specific  DNA   detection already   seems  an  attractive 
and efficient  automated high-output system for large screening 
programs.  Only  small sample  volumes  are  needed to  identify 
communities  at  risk  for  development  of  genital   morbidity 
caused by S. haematobium infection. 
 
Received  July 11, 2013. Accepted for publication December 17, 2013. 
Published  online  January 27, 2014. 
Acknowledgments: We thank  the study community  district, including 
the KwaZulu Natal Department of Health, the Department of 
Education, and the FGS Project  Team  in South  Africa  for data  col- 
lection;  Roy  Manyaira for  data  management; Colleen  Archer  for 
re-examining microscopic  samples; and Dr. Dennis  York  for provid- 
ing laboratory facilities and training for real-time PCR in South Africa. 
Financial  support:  This study  was supported by Prof.  Dr.  P.C. Flu- 
Foundation, the  University  of Copenhagen (with  the  support  from 
the Bill and Melinda  Gates  Foundation); the South-Eastern Norway 
Regional  Health Authority (Network project  no. 2011073); the Inter- 
national   Research Staff  Exchange   Scheme;  Marie   Curie  Actions, 
Oslo  University  Hospital Ullevaal  (VIRUUS), the  Center  for 
Imported  and   Tropical   Diseases,   Oslo,   Norway;   the   Norwegian 
Research Council (ref 213702/H10); and the National Research Foun- 
dation,  South Africa. 
55 
 
552 PILLAY AND  OTHERS 
 
Authors’  addresses:  Pavitra  Pillay, Department of Biomedical  and 
Clinical  Technology, Durban  University   of  Technology, KwaZulu 
Natal, South Africa, E-mail: pillayp@dut.ac.za. Myra Taylor and 
Siphosenkosi G. Zulu, School of Nursing and Public Health, University 
of KwaZulu  Natal, KwaZulu Natal, South Africa, E-mails: taylormyra@ 
gmail.com and siphogzulu@gmail.com.  Svein G. Gundersen, Research 
Unit, Sorlandet Hospital  HF, Kristiansand, Norway, and University  of 
Agder, Kristiansand, Norway, E-mail: svein.g.gundersen@sshf.no. Jaco 
J. Verweij,  St. Elisabeth Hospital,  Tilburg,  The Netherlands, E-mail: 
j.verweij@elisabeth.nl.  Pytsje  Hoekstra,  Eric  A.  T.  Brienen,  and 
Lisette  van Lieshout,  Department of Parasitology, Leiden  University 
Medical Center,  Leiden,  The Netherlands, E-mails: p.t.hoekstra@ 
amc.uva.nl, e.a.t.brienen@lumc.nl, and e.a.van_lieshout@lumc.nl. 
Elisabeth  Kleppa   and  Eyrun   F.  Kjetland,   Norwegian   Centre   for 
Imported and Tropical  Diseases,  Department of Infectious  Diseases, 
Ulleval,  Oslo  University  Hospital,  Olso,  Norway,  E-mails:  elisabeth 
.kleppa@medisin.uio.no and e.f.kjetland@medisin.uio.no. 
 
 
 
REFERENCES 
 
1. Fenwick  A, 2006. Waterborne infectious  diseases–could  they  be 
consigned to history? Science 313: 1077 –1081. 
2. World  Health Organization, 2006. Preventive  Chemotherapy in 
Human  Helminthiasis: Coordinated Use of Anthelminthic  Drugs 
in Control Interventions: A Manual for Health Professionals and 
Programme Managers. Geneva:  World Health Organization. 
3. Hotez PJ, Fenwick A, 2009. Schistosomiasis in Africa: an emerging 
tragedy  in our new global health  decade.  PLos  Neg Tropl  Dis 
3: e485. 
4. Kjetland EF,  Leutscher PD,  Ndhlovu  PD,  2012. A  review  of 
female genital schistosomiasis.  Trends Parasitol 28: 58. 
5. Leutscher PD,  Ravaoalimalala VE,  Raharisolo C, Ramarokoto 
CE,  Rasendramino M, Raobelison A, Vennervald B, Esterre 
P, Feldmeier H, 1998. Clinical findings in female genital schis- 
tosomiasis in Madagascar. Trop Med Int Health 3: 327 –332. 
6. Poggensee  G, Krantz  I, Kiwelu I, Diedrich T, Feldmeier H, 2001. 
Presence  of Schistosoma  mansoni  eggs in the  cervix  uteri  of 
women in Mwanga District,  Tanzania. Trans R Soc Trop  Med 
Hyg 95: 299 –300. 
7. Wright  ED,  Chipangwi  J, Hutt  MS, 1982. Schistosomiasis  of the 
female  genital  tract.  A  histopathological study  of  176 cases 
from Malawi. Trans R Soc Trop Med Hyg 76: 822 –829. 
8. Ndhlovu  PD, Mduluza  T, Kjetland EF, Midzi N, Nyanga L, 
Gundersen SG, Friis H, Gomo  E, 2007. Prevalence of urinary 
schistosomiasis and HIV in females living in a rural community 
of Zimbabwe: does  age matter? Trans  R Soc Trop  Med Hyg 
101: 433 –438. 
9. Kjetland EF,  Mduluza  T, Ndhlovu  PD,  Gomo  E, Gwanzura L, 
Midzi N, Mason PR, Friis H, Gundersen SG, 2006. Genital 
schistosomiasis in women: a clinical 12-month in vivo study 
following treatment with praziquantel. Trans R Soc Trop Med 
Hyg 100: 740–752. 
10. Mbabazi  PS, Andan  O,  Fitzgerald  DW,  Chitsulo  L, Engels  D, 
Downs JA, 2011. Examining the relationship between urogenital 
schistosomiasis and HIV infection. PLos Neg Tropl Dis 5: e1396. 
11. World  Health Organization, 2010. Statement  – WHO  Working 
Group on Urogenital  Schistosomiasis  and  HIV  Transmission, 
October  12, 2009. Geneva:  World Health Organization. 
12. Gryseels  B, Polman  K, Clerinx J, Kestens  L, 2006. Human  schis- 
tosomiasis. Lancet 368: 1106 –1118. 
13. Hegertun IEA,  Gundersen KMS, Kleppa  E, Zulu SG, Gundersen 
SG, Taylor M, Kvalsvig JD, Kjetland  EF, 2013. S. haematobium 
as a common cause of genital morbidity in girls: a cross-sectional 
study of children in South Africa. PLos Neg Tropl Dis 7: e2401. 
14. Van Lieshout  L, Yazdanbakhsh M, 2013. Landscape of neglected 
tropical diseases: getting it right. Lancet Infect Dis 13: 469 –470. 
15. Cavalcanti  MG, Silva LF, Peralta RH,  Barreto MG, Peralta JM, 
2013. Schistosomiasis  in areas  of low endemicity:  a new era in 
diagnosis. Trends Parasitol 29: 75–82. 
16. Obeng  BB, Aryeetey YA,  de  Dood  CJ, Amoah  AS, Larbi  IA, 
Deelder AM, Yazdanbakhsh M, Hartgers FC, Boakye  DA, 
Verweij  JJ, Van  Dam  G, Van  Lieshout  L, 2008. Application 
of a circulating-cathodic-antigen (CCA)  strip test and real-time 
PCR,   in   comparison  with   microscopy,   for   the   detection 
of  Schistosoma  haematobium in  urine  samples  from  Ghana. 
Ann Trop Med Parasitol  102: 625–633. 
17. Aryeetey YA, Essien-Baidoo S, Larbi IA, Ahmed  K, Amoah  AS, 
Obeng  BB, Van  Lieshout  L, Yazdanbakhsh M, Boakye  DA, 
Verweij  JJ,  2013. Molecular  diagnosis  of Schistosoma  infec- 
tions in urine samples of school children  in Ghana. Am J Trop 
Med Hyg 88: 1028 –1031. 
18. Appleton CC, Kvalsvig JD, 2006. A school-based helminth  con- 
trol  programme successfully implemented in KwaZulu-Natal. 
South Afr J Epidemiol  Infect 21: 55–67. 
19. Department of Health South Africa, 2011. The 2011 National 
Antenatal   Sentinel  HIV  and  Syphilis  Prevalence   Survey  in 
South  Africa.  Johannesburg,  South   Africa:   Department  of 
Health South Africa. 
20. Jinabhai  CC, Taylor  M, Coutsoudis A, Coovadia  HM,  Tomkins 
AM,  Sullivan  KR,  2001. A  health  and  nutritional profile  of 
rural  school  children  in  KwaZulu-Natal, South  Africa.  Ann 
Trop Paediatr  21: 50–58. 
21. Thomassen Morgas DE,  Kvalsvig JD, Gundersen SG, Taylor M, 
Kjetland EF, 2010. Schistosomiasis  and water-related practices 
in school girls in rural KwaZulu-Natal, South Africa. South Afr 
J Epidemiol  Infect 25: 30–33. 
22. Niesters  HG,  2002. Clinical  virology  in real  time.  J Clin  Virol 
25: S3 –S12. 
23. Montresor A,  Crompton D,  Hall  A,  Bundy  D, Savioli L, 1998. 
Guidelines  for the Evaluation of Soil-Transmitted Helminthiasis 
and   Schistosomiasis   at  Community   Level.  Geneva:   World 
Health Organization. 
24. Doehring E, Reider F, Schmidt-Ehry G, Ehrich JH, 1985. Reduc- 
tion of pathological findings in urine and bladder  lesions in 
infection  with Schistosoma  haematobium after  treatment with 
praziquantel. J Infect Dis 152: 807 –810. 
25. Van Lieshout  L, Verweij  JJ, 2010. Newer  diagnostic  approaches 
to intestinal  protozoa. Curr Opin Infect Dis 23: 488 –493. 
26. Cnops  L,  Tannich  E,  Polman  K,  Clerinx  J,  Van  Esbroeck  M, 
2012. Schistosoma  real-time  PCR  as diagnostic  tool for inter- 
national   travellers   and  migrants.   Trop  Med  Int  Health   17: 
1208 –1216. 
27. Ibironke OA,  Phillips AE,  Garba  A, Lamine  SM, Shiff C, 2011. 
Diagnosis of Schistosoma haematobium by detection of specific 
DNA  fragments  from filtered  urine  samples.  Am J Trop  Med 
Hyg 84: 998–1001. 
28. Wichmann D, Poppert S, Von Thien H, Clerinx J, Dieckmann S, 
Jensenius M, Parola P, Richter  J, Schunk M, Stich A, 2013. 
Prospective European-wide multicentre study on a blood based 
real-time   PCR   for  the  diagnosis  of  acute   schistosomiasis. 
BMC Infect Dis 13: 55. 
29. Becker SL, Vogt J, Knopp S, Panning M, Warhurst DC, Polman K, 
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The purposes of writing this paper were to expand on developing early diagnostic tools among 
young women at risk for genital schistosomiasis, to increase the knowledge and awareness of 
FGS among health professionals in endemic areas, and explore the association between 
schistosomiasis and squamous cell atypia in this paper, since this has been under debate through 
several previous studies using different indicators. In this paper possible risk factors for both 
schistosomiasis and squamous atypia were described. Analysis of cervical cytology, urine 
microscopy and Schistosoma PCR in cervico-vaginal lavage and in urine samples were used to 
answer the research questions. The paper was also aimed at raising awareness of these entities 
and to provide laboratory and other health personnel with additional insight into the diagnosis 
and implications of FGS. 
 
Consenting young women aged 16-23 from high schools underwent structured interviews and 
the following samples were collected Pap smears for cytological analysis including 
Schistosoma haematobium ova and cervical squamous cell atypia, vaginal lavage and urine 
samples for real-time PCR for Schistosoma-specific DNA, and urine microscopy for the 
presence of  S. haematobium ova. 
 
 
I was responsible for generating the Cytology results in the research project. Being a 
Cytotechnologist, I used my knowledge and expertise that I have gained over the years in the 
analysis and checking (of problematic) Pap smears. I was assisted by a Cytotechnician with the 
screening and another Cytotechnologist did the quality control. I facilitated the transportation 
of the urine and vaginal lavage samples to the Leiden University Medical Center (LUMC), 
where I did the ITS-based real-time Schistosoma PCR assay together with support and 
assistance from the staff at the LUMC. Performing the Schistosoma PCR on such a large sample 
of urines and vaginal lavage samples and comparing them to the cytology results was novel 
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research among a young population and has furthered our understanding of the early 
development of FGS symptoms in young women. 
 
It was found that the Schistosoma PCR lavage analysis was six times more sensitive than Pap 
smears in detecting schistosomiasis. There was no significant association with genital 
schistosomiasis and squamous cell atypia but this could represent a Type 2 error because of the 
low prevalence of schistosomiasis. Cytology is a useful diagnostic technique that has provided 
insight on cervical cytological atypia detected amongst the sexually active young women who 
are also at risk for schistosomiasis and HIV since screening is not routinely done among young 
women, the cytology findings could contribute to the prevention of cervical cancer. 
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Abstract   
Background: Female genital schistosomiasis (FGS) is a tissue reaction to lodged ova of Schistosoma 
haematobium in the genital mucosa. Lesions can make the mucosa friable and prone to bleeding and 
discharge.Women with FGS may have an increased risk of HIV acquisition, and FGS  may act as a 
cofactor in the development of cervical cancer. Objectives: To explore cytology as a method for 
diagnosing FGS and to discuss the diagnostic challenges in low‑ resource  rural areas.The correlation 
between FGS and squamous cell atypia (SCA) is also explored  and discussed. Cytology results are 
compared to Schistosoma polymerase  chain reaction  (PCR)  in vaginal lavage and urine and in urine 
microscopy. Materials and Methods: In a clinical study, 394 women aged between 16 and 23 years 
from rural high schools in KwaZulu‑ Natal, South Africa, underwent structured interviews and the 
following laboratory tests: Cytology  Papanicolaou  (Pap) smears for S. haematobium ova and cervical 
SCA, real‑ time PCR for Schistosoma‑ specific  DNA in vaginal lavage and urine samples, and 
urine microscopy for the presence of S. haematobium ova. Results:  In Pap smears, S. 
haematobium ova were detected in 8/394 (2.0%). SCA  was found in 107/394 (27.1%), seven of 
these had high‑ grade squamous intraepithelial lesion (HSIL). Schistosoma specific DNA was 
detected in 38/394 (9.6%) of vaginal lavages and in 91/394 (23.0%) of urines. Ova were found 
microscopically  in 78/394 (19.7%) of urines. Conclusion: Schistosoma PCR  on lavage was a better 
way to diagnose FGS compared to cytology.There was a significant association 
between S. haematobium ova in Pap smears and 
the other diagnostic methods. In low‑ resource 
Schistosoma‑ endemic areas, it is important that 
cytology screeners are aware of diagnostic 
challenges in the identification of schistosomiasis 
in addition to the cytological diagnosis of SCA. 
Importantly, in this study, three of eight urines 
were negative but showed Schistosoma ova in 
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their Pap smear, and one of them was also negative for Schistosoma DNA in urine. In this study, 
SCA was not significantly associated with schistosomiasis. HSIL detected in this young population 
might need future consideration. 
Key words: Cervical atypia, cytology, female genital schistosomiasis, gynecology, laboratory 
diagnostics, real‑ time polymerase chain reaction 
 
 
INTRODUCTION 
 
In terms of the public  health  impact,  schistosomiasis 
(bilharzia) is globally  second only  to malaria among 
parasitic diseases. It affects approximately 262 million 
people worldwide.[1] The disease is most commonly found 
in sub‑Saharan Africa. 
 
Schistosoma haematobium infection  is the most common 
schistosome infection in KwaZulu‑Natal, South Africa,[2] 
with  reported focal  prevalences between  40% and 
98%.[3]  A recent study performed in coastal, Southern 
KwaZulu‑Natal showed  a prevalence of S. haematobium 
of 32% among girls aged 10–12 years.[4] 
 
Schistosomal lesions can be seen in the urinary and 
gastrointestinal tracts. It is, however, well known that 
the ova also can be trapped in a variety of sites within 
the human definitive host including the brain, pancreas, 
kidneys, testes, the vagina, and uterine cervix.[5]  This 
partly random distribution of schistosomal  lesions 
makes it difficult to identify a diagnostic gold standard 
for a specific region  where  infections  can occur. It 
has recently been suggested that schistosomal  lesions 
in  the vagina  and  cervix uteri, i.e., female  genital 
schistosomiasis (FGS), may  increase the risk of HIV 
acquisition.[6] FGS has also been suggested a possible 
cofactor in the development of precancerous lesions 
and cervical cancer.[7,8]  FGS lesions are caused by the 
human host’s response  to living  and  dead  parasite 
ova that are lodged  or trapped in the submucosa of 
the uterine cervix and  vagina. Visual inspection  by 
colposcopy  and  targeted biopsies  are considered  a 
more accurate way of diagnosing FGS; however, they are 
expensive, and the latter is not feasible in populations 
at risk for HIV.[9,10] 
 
Papanicolaou (Pap) smears are commonly  used in 
low‑resource areas by doctors and nurses for the diagnosis 
of cervical cancer. The aim  of this study was to explore 
the possibilities  and limits of diagnosing FGS using Pap 
smear cytology. The cytology results were compared  to 
Schistosoma polymerase  chain reaction (PCR) in vaginal 
lavage and urine, and in urine microscopy  in a young, 
female  population who  resided in a rural area. We 
also wanted  to explore a possible  correlation  between 
schistosomiasis and squamous cell atypia (SCA) of the 
cervix. 
MATERIALS AND METHODS 
 
The study area in coastal KwaZulu‑Natal South of Durban 
is endemic for schistosomiasis. This area had a population 
of 710,000 people, 51% below the age of 20 years of which 
55% are female.  In these mostly  rural communities, 
women do their laundry and children play in Schistosoma 
infested rivers. As part of a school‑based,  clinical  study 
of FGS, females from 42 randomly selected high schools 
were included.  Included  in this cross‑sectional study 
were 394 consenting young women aged between 16 and 
23 years (median age 19 years); all were examined in the 
period 2010–2012. Pregnant women, virgins, and those 
who were not ready for gynecological  examination were 
excluded. 
 
The study was initially  discussed with  the relevant 
stakeholders including the KwaZulu‑Natal Department of 
Health, Department  of Education, school staff, parents, 
and pupils. A team of trained field assistants and school 
nurses visited the schools to give general information 
and recruit young women for laboratory investigations, 
treatment, and gynecological  examinations. In the first 
meetings, the focus of the project, its importance, benefits, 
and possible  negative consequences  were explained  to 
the stakeholders. Written informed consent was sought 
at this time. It was explained  that the research samples 
would be investigated in batches and hence, an extended 
waiting  period for results could occur. Participants were 
encouraged to visit local health care facilities should they 
experience any problems in the meantime. Logistical 
arrangements  at suitable times to transport the young 
women to the clinic for their gynecological examinations 
and interviews were discussed with school principals and 
other relevant staff. According to practice in rural clinics, 
a syndromic protocol  was used to diagnose  and treat 
findings at the point  of investigation.  When laboratory 
results became  available,  patients were contacted and 
asked if they had been treated and helped  with further 
management of the disease. 
 
Permission was also obtained from the Biomedical Research 
Ethics Administration, University of KwaZulu‑Natal (Ref 
BF029/07), the Departments  of Health, and Education 
of KwaZulu‑Natal (Ref HRKM010‑08), the Norwegian 
Ethics Committee,  Regional  Committee  for Medical 
and Health Research Ethics (REC), South Eastern 
Norway  (Ref 469‑ 7066a1.2007.535), and the European 
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Group  on  Ethics in Science and  New  Technologies 
(Ref IRSES‑2010:269245). 
 
Consenting participants underwent a private face‑to‑face 
structured interview,  conducted  by research assistants 
in isiZulu, the local language, including their history of 
water contact, observed red urine and genital symptoms. 
In addition, the research assistants asked questions about       a                                              b 
their sexual history and parity as these variables could have 
had a bearing on the risk of cervical atypia. 
 
During  the gynecological  examination, the surfaces of 
the vulva, vagina, and cervix were examined visually and 
colposcopically in accordance with the protocol from  a 
previous FGS study.[11]   Thereafter, cervicovaginal  lavage 
samples were collected by spraying 10 ml saline on the 
vaginal  wall  and cervix 4 times, which  was then drawn 
back into the syringe and divided into six sets of cryotubes 
and  stored in a −80 freezer with  CO
2  
and  generator 
backup  systems. The Pap smears were then collected 
with a wooden spatula or a cytobrush. The Pap smears 
were preserved by using a commercial cytological spray 
fixative. Urine samples  for PCR analysis were stored as 
described for vaginal lavage samples. The urine samples 
for microscopy were stored in dark cooler boxes to ensure 
sample quality. 
 
For cytological analyses, the smears were Pap stained[12] 
and examined by a cytologist using an Olympus B×43 
microscope and viewed at magnification with objectives 
10 and 40. The smears were examined for all cytological 
entities in addition to Schistosoma ova and  SCA. The 
diagnosis of S. haematobium was based on finding intact 
living  or dead ova within oval chitinous  shells with  a 
terminal spine [Figure 1a].[13] 
 
Epithel ia l   dy splasias  [ Figure  1b]  w ere graded 
according  to the Bethesda system.[14]   In  short, the 
SCA was  stratified  into  atypical  squamous cells of 
undetermined signif icance  (ASCUS), low‑grade 
squamous intraepithelial lesion (LSIL), a category that 
encompasses mild dysplasia/cervical intraepithelial 
neoplasia  (CIN)  1 and human papillomavirus (HPV), 
and high‑grade squamous intraepithelial lesion (HSIL). 
High‑grade  lesions  encompass  moderate  dysplasia/ 
CIN 2, severe dysplasia/CIN  3, and carcinoma  in situ. 
To ensure quality  control, 10% of all negative smears 
were re‑screened. 
 
Internal  transcribed spacer (ITS)‑based  real‑time  PCR 
with  quantification  of Schistosoma‑specific DNA  in 
cervicovaginal  lavages and  urines were performed as 
described previously.[4,15,16,] Cycle threshold (Ct) values were 
used as the output of the PCR, reflecting the parasite‑specific 
DNA load in the sample tested. Ct‑values were arbitrarily 
categorized in the following infection  intensity groups: 
Figure  1: (a) Cervical  smear, (Papanicolaou stain, ×40). Schistosoma 
haematobium ovum with an embryo miracidium. Note the diagnostic 
terminal spine (arrow). (b) Cervical smear, (Papanicolaou stain, ×40). 
Cytological  changes consistent with high grade squamous intraepithelial 
lesion including human papillomavirus infection. Long arrow: Human 
papillomavirus cytopathic changes including nuclear and cellular 
enlargement, and koilocytosis. Double arrow: Cells with increased nuclear 
to cytoplasmic ratios, nuclear membrane irregularities and marked 
hyperchromasia consistent with high‑ grade squamous intraepithelial lesion. 
The background contains neutrophil granulocytes denoting inflammation 
 
High‑intensity (Ct <30), medium‑intensity (30≤ Ct <35), 
low‑intensity (35≤ Ct <50), or negative (Ct = 50).[15] 
 
Urine microscopy  samples were preserved with 1 ml of 
2% tincture of merthiolate in 5% formalin solution.[4,15] 
The samples were spun for 10 min  at 4000 rounds/min 
and the sediment  examined microscopically by trained 
fieldworkers.  The samples underwent quality control by 
an independent microscopist on 10% of randomly chosen 
samples, and any discrepancies were discussed with fellow 
field workers. 
 
Data were analyzed using IBM SPSS version 23.0 (Armonk, 
NY, USA) Ct‑values were not normally distributed  and 
therefore described by median and range and compared 
using  a nonparametric statistical method.  Inferential 
statistics was done using the Fisher’s exact test. The odds 
and risks ratios (OR and RR) and the corresponding 95% 
confidence  intervals (CIs)  were determined for 2 ×  2 
cross‑tabulations. All P values were two‑tailed and P < 0.05 
considered significant. 
 
RESULTS 
 
The flowchart  of the study population is presented in 
Figure 2. The population characteristics are presented in 
Table 1 and show that 376/394 (95%) of the participants 
had a prior risk of water contact. 
 
In the Pap smears, S. haematobium ova were detected 
in 8/394 (2.0%). Schistosoma‑specific DNA was found 
in 38/394 (9.6%) of vaginal  lavages including the 8 
Pap smears with  S.  haematobium eggs. Significantly 
lower  Schistosoma DNA loads were seen in the lavages 
of Pap‑smear  negatives (median Ct‑value 32.9, range 
20.4–37.4).  In  78/394  (19.8%), Schistosoma ova 
were detected microscopically in the urines while 
Schistosoma DNA was detected in 91/394 (23.1%) of 
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the urines [Table 2]. There was a significant  association 
between  S.  haematobium eggs in Pap smears and  the 
presence of Schistosoma DNA  in lavage (OR: 12.87, 
P < 0.001; 95% CI 9.13–18.14), Schistosoma DNA in urine 
 
Table 1: Participant characteristics 
Characteristics n (%) Standard 
deviation 
Study population                                  394 
Age (years) 
Mean 19 1.64 
Reported in interview 
History of sexual activity 
Sexually active 392 (99.5) 
Mean age of sexual debut  16.4 1.30 
No sexual partners within the last month  114 (28.9) 
One sexual partner within the last month 271 (68.8) 
(OR: 25.1, P < 0.001; 95% CI 3.1–207.4) as well as eggs 
in urine determined by microscopy  (OR: 7.1, P = 0.009; 
95% CI 1.7–30.6). 
 
Between 95% and 97% of the corresponding Pap smears 
in which Schistosoma ova were identified either in vaginal 
lavage or urines were deemed  suboptimal [Table 3]. 
Smears were deemed  suboptimal or “inadequate”  due 
to technical interpretability or inadequate  cellular 
composition or incorrect sampling. In poorly preserved 
and  bloodstained smears, it was not often  possible 
microscopically to identify  the cellular characteristics 
of epithelial  cells, Schistosoma ova; however,  they were 
identifiable [Figure 3a and b]. 
 
Ova of S.  haematobium typically  range in size from 
80 to 170 µm in length and are 30–70  µm wide  and 
have a diagnostic terminal  spine. Within the ova 
embryo,  miracidia were seen, under‑developed, or 
Two sexual partners within the 
last month 
Three sexual partners within the last 
month 
Number of children alive 
6 (1.5) 
 
1 (0.3) 
well‑developed, or as emergent miracidia with  a finely 
ciliated outline [Figure 4a]. Empty, refractile, folded, and 
crumpled shells with no visible internal structure were also 
seen and read as ova with signs of degeneration [Figure 4b]. 
Partially or completely blackened and opaque, nonviable 
One 163 (41.3) 
Two 12 (3.0) 
Three  1 (0.3) 
Types of risk water body contact 
None 18 (4.6) 
River  284 (72.1) 
Dam 38 (9.6) 
Standing water 7 (1.8) 
Several types 41 (10.4) 
Red urine 
Sometime earlier 83 (21.1) 
Last week 46 (11.7) 
forms were also seen. 
 
The local inflammatory reaction in the cytological smears 
with S. haematobium ova varied from sparse to marked or 
chronic inflammatory changes. The heavily blood‑stained 
smears might  reflect the clinical  finding of abnormal 
mucosal  blood  vessels seen in the FGS lesions prone 
to contact bleeding  [Figure 3b]. All Pap smears where 
Schistosoma ova were identified,  8/8 (100%), included 
blood, as did 25/35 (71.4%) of the Schistosoma positive 
PCR vaginal lavage samples [Table 3]. 
 
On comparing the diagnostic  methods  used in this 
study, Schistosoma PCR lavage analysis was 6 times more 
History of bloody discharge/bleeding  sensitive than Pap smears in detecting schistosomiasis. 
Sometime earlier 58 (14.7)  
Last week 56 (14.2)  
Postcoital bleeding 138 (35.0)  
Spotting 148 (37.6)  
 
Table 2: Schistosoma prevalence  using cytology, 
vaginal lavage, and urine PCR or urine microscopy 
 
Diagnostic test n (%) Median Range 
Pap smear cytology 8/394 (2.0)   
PCRa vaginal lavage 38/394 (9.6) 31.0 Ct 19.5‑ 37.4 Ct 
PCRa urine 91/394 (23.1) 28.6 Ct 19.2‑ 40.2 Ct 
Urine  microscopy  71/394 (17.8) 13 ova/10 mL  1‑ 71 ova/10 mL 
aSchistosoma PCR. Ct refers to cycle threshold output of the PCR. PCR: Polymerase 
chain reaction, Pap: Papanicolaou Figure 2: Flowchart of the study participation 
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Table 3:Summary of cytology results.For definitions 
of suboptimal Pap smears, ASCUS, LSIL, HISL, 
HSIL with possible invasion and SCA 
Cytological entity                                                     n (%) 
Suitability of smears 
Smears containing blood 193/394 (49.0) 
Blood‑ stained smears/Schistosoma Pap smear 
positive 
8/8 (100) 
 
a b 
Blood‑ stained smears/Schistosoma vaginal lavage 
PCR positive 
Suboptimal Pap smears/urine microscopy 
Schistosoma positive 
Suboptimal Pap smears/Schistosoma urine PCR 
positive 
25/35 (71.4) 
 
74/78 (95.0) 
 
87/91 (96.0) 
Figure  3: (a) Cervical  smear, magnification (Papanicolaou stain, ×40). Poorly 
preserved smears with cellular detail obscured by blood and inflammatory 
cells. Small arrow: Non‑ diagnostic, poorly preserved epithelial cells. Double 
arrow:Two Schistosoma haematobium ova, identifiable by 
their refractile shells and characteristic terminal spines. (b) Cervical smear, 
magnification (Papanicolaou stain, ×40). Schistosoma ovum surrounded 
by many neutrophil granulocytes.Terminal spine detected on fine focus, 
Suboptimal Pap smears/vaginal lavage PCR  positive    37/38 (97.3) 
SCA 107/394 (27.1) 
ASCUS 33/394 (8.6) 
LSIL 67/394 (17.0) 
HSIL  6/394 (1.5) 
HSIL possible  invasion  1/394 (0.3) 
Any SCA 107/394 (27.1) 
SCA: Squamous cell atypia, ASCUS: Atypical squamous cells of undetermined 
significance, LSIL: Low‑ grade squamous intraepithelial lesion, HSIL: High‑ grade 
squamous 
however, not seen clearly in this image 
intraepithelial lesion, PCR: Polymerase chain reaction, Pap: Papanicolaou a b 
 
All Schistosoma positive Pap smears were also positive 
for Schistosoma PCR in vaginal  lavage [Table 4]. There 
were, however, three cases with Schistosoma positive Pap 
smears and Schistosoma PCR lavage that had microscopy 
negative urine samples; one of them also negative for 
Schistosoma DNA in the urine. The distribution of SCA is 
shown in Table 3. HSIL was diagnosed  in 6/394 (1.5%). 
One additional case was reported as HSIL with possible 
invasion.  SCA was not significantly  associated with any 
tests for schistosomiasis used in this study. The SCA was 
found  across the whole age range examined [Figure 5]. 
 
DISCUSSION 
 
With emerging  knowledge of possible  serious lifelong 
complications of FGS, there is an increasing demand for 
better diagnostic  tools. It is important to find  ways of 
diagnosing FGS that can be applied  in rural areas with 
low resources. An increased awareness of the symptoms 
and signs of FGS is also needed among gynecologists 
and other health  care workers that encounter women 
from Schistosoma‑endemic areas.[10]  FGS mucosal  lesions 
can clinically mimic sexually transmitted infections  and 
cervical neoplasias.[7‑9,17] 
 
The anti‑schistosomal drug praziquantel is effective in 
killing  adult  worms  responsible  for laying  eggs. The 
effect that the drug has on FGS lesions has not been 
fully explored. Treatment given to adults apparently did 
Figure  4: (a) Cervical  smear, magnification (Papanicolaou stain, ×40). 
Arrows: emergent miracidium with a finely ciliated outline. (b) Cervical 
smear, magnification (Papanicolaou stain, ×40). Numerous calcified, dead 
ova (four calcified ova ‑  short arrows and two non‑ calcified ova ‑  
long arrows) of Schistosoma haematobium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5: Percentage of squamous cell atypia positive in relation to age 
of the 394 examined young women.The number of examined women per 
year of age is indicated 
 
not change their FGS lesions.[18]  Previous studies using 
histopathological reports indicate that the inflammatory 
reactions also around  dead ova, presumably PCR 
negative, continue  to pose a clinical  problem.[19,20] 
This is in contrast to another study among adults with 
urinary schistosomiasis, showing that anti‑schistosomal 
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Table 4: Eight cases positive for Schistosomiasis by cytology compared to Schistosoma PCR in vaginal lavage, 
Schistosoma PCR in urine and urine microscopy 
 
Pap smear Vaginal lavage PCR (Ct) Urine microscopy/ova per 10 mL Urine PCR (Ct) Participant’s age 
Positive Positive (19.5) Positive (75 ova) Positive (23.8) 16 
Positive Positive (28.3) Positive (40 ova) Positive (20.6) 18 
Positive Positive (26.6) Positive (21 ova) Positive (28.6) 23 
Positive Positive (23.0) Positive (15 ova) Positive (32.9) 17 
Positive Positive (21.9) Positive (13 ova) Positive (34.0) 19 
Positive Positive (25.4) Negative Positive (22.3) 18 
Positive Positive (21.9) Negative Positive (31.7) 17 
Positive Positive (27.2) Negative Negative (50.0) 19 
Ct refers to cycle threshold output of the PCR. PCR: Polymerase chain reaction 
 
treatment could contribute to the resolution of bladder 
lesions.[21]   All the young  women in the study were 
offered anti‑schistosomal treatment. The effect of 
treatment on FGS will  be followed and  discussed in 
future publications. 
 
A targeted biopsy  is a method  that has been used to 
diagnose  FGS; however, this procedure is invasive and 
unethical  in a young  population that is also prone  to 
HIV. Alternatively, diagnosis  of FGS can be achieved 
directly by identification of parasite ova or parasite DNA 
in material  from  the vagina. In addition,  the diagnosis 
can be made  or suspected by visual  inspection  at a 
gynecologic  examination through  finding typical FGS 
lesions with the naked eye, by colposcopy, or by a camera 
with a magnification lens.[9] The latter has, however, never 
been tested. FGS should  also be considered  high  on 
the list of differential diagnosis, once sexual abuse and 
sexually‑transmitted infections have been precluded. The 
typical FGS lesions have been described and discussed 
extensively in recent publications and will be addressed 
in a forthcoming WHO FGS pocket Atlas with posters.[10] 
These mucosal lesions include two types of sandy patches, 
abnormal blood vessels, and rubbery papules. 
 
In a recent study, primary  school girls reported similar 
symptoms as adults with genital schistosomiasis There 
was also an association between genital symptoms and 
urinary schistosomiasis.[22] An unresolved question relates 
to diagnosing FGS in pre‑pubertal young girls, who may 
have severe genital symptoms with  bloody  discharge, 
genital pain, and spotting. In our study, we had young 
women with negative urine tests, but positive tests from 
the genital tract [Table 3], in line with  the seemingly 
random submucosal allocation  of the ova‑producing 
parasites to epithelial linings generally in the body, 
including the genital or urinary  tracts. This is in line 
with a recent FGS study from Madagascar where women 
between 15 and 35 years with Schistosoma negative urines 
had Schistosoma DNA in genital samples as well as cases in 
our study.[23]  The important notion of this is that testing 
only urine samples for schistosomiasis may be insufficient 
to diagnose FGS. 
 
In our study, the diagnostic yield of Schistosoma infection 
in Pap smears was low which is consistent with previous 
findings from mainland Africa.[24,25] The number of positive 
results for schistosomiasis in cytology Pap smears in this 
study was small  (8/394); hence, deductions  need to be 
interpreted with caution. The Pap smear yield in our study 
might be low due to the sampling techniques as vaginal 
lavage samples were collected prior to the cervical smears. 
This might  have removed  Schistosoma ova. The lavage 
additionally possibly altered the cervical mucosal surface, 
resulting in suboptimal or unsatisfactory  smears. Poor 
fixation could also contribute to the suboptimal smears. 
Furthermore, it might be that the ova load was low either 
proportional with  a low  parasite load  or proportional 
with a different genotype that did not produce as many 
ova as found in, for example, Madagascan population.[23] 
 
A crucial aspect of the cytology report is the issue of 
adequacy. According to the Bethesda system, adequacy 
is expressed in terms of an adequate number of 
well‑preserved  epithelial  cells including cells from  the 
transformation zone.[14]   Smears which  do not meet 
the criteria but at the same time, enabled  a diagnosis 
are reported as “satisfactory for evaluation  but limited 
by” followed by whichever  criteria was lacking,  for 
example,  inadequate  endocervical  cells, inflammation, 
etc., Smears deemed “unsatisfactory for evaluation” may 
reveal obscuring  blood;  excessive inflammation; thick, 
multicellular areas; poor preservation; air drying artifact; 
or contaminants. In this study, the interpretation  was 
compromised in approximately 75% of the smears. 
 
Furthermore,  in  this study, all cytology Pap smear 
S. haematobium cases identified  were also positive for 
vaginal  lavage Schistosoma PCR. Some  of the smears 
included  nonviable ova. They are; however, significant 
as they indicate lesions where inflammation continues 
to develop.[9] Pitfalls exist, when  contaminants (foreign 
 
              64 
 
 
 
CytoJournal 2016, 13:10 http://www.cytojournal.com/content/13/1/10 
 
bodies)  introduced  into smears either during sampling, 
transportation  or processing, with  similar  oval shapes 
as seen in Figure 6a are encountered.  The depicted 
structure; however, lacks the diagnostic  terminal  spine, 
essential for the cytological diagnosis of S. haematobium. 
It is important to view such cases carefully  since ova 
can be hidden  among the contaminants and  easily 
overlooked  [Figure 6b]. Schistosoma mansoni can be 
differentiated from S. haematobium by its lateral spine. 
 
The diagnostic  yield in our study could  probably  have 
been higher  with  an alternative to conventional Pap 
smears by using liquid‑based cytology (LBC) samples. 
In a population‑based study among Costa Rican women 
who  also have a high prevalence of cervical cancer, LBC 
was compared with conventional Pap smears. The samples 
processed via LBC were significantly  more  sensitive in 
detecting HSIL and other abnormalities.[26]  Specimens 
from  LBC testing could  possibly  also be tested for 
Schistosoma PCR and HPV subtypes. 
 
In our study, the inclusion criteria required that all of 
the participants were or had been sexually active at some 
point in their lifetime to undergo the gynecological 
examination. The mean age of sexual debut was 16 and 
163/394 (41.0%) had at least one child. SCA occurred 
across the age spectrum; the majority was ASCUS and LSIL 
100/107 (94.3%). Seven cases of HSIL occurred between 
ages of 17 and 22 years, including one case of HSIL with 
possible invasion, which occurred at age 19. While studies 
have shown that at least low grade 96% of abnormalities 
in young  women tend to regress within 36 months,[27] 
in contrast to this it has been shown that progression of 
squamous lesions occurs more  rapidly  in HIV‑positive 
women.[28] It is not known if this will occur in individuals 
with schistosomiasis. In South Africa, cervical cancer is the 
second most prevalent cancer affecting women. A screening 
program does exist for women at the ages of 30, 40, and 50. 
Much of the screening is done in family planning clinics 
or antenatal  clinics on symptomatic women.[29]  Many 
 
women are unaware of the routine screening program.[29] 
As a consequence, women usually reach healthcare facilities 
when they have advanced or terminal cervical cancer, which 
could have been prevented by early diagnosis. 
 
The long‑term  outcome  of HSIL in a young population 
who  are at risk for contracting HIV and schistosomiasis 
raises public  health  issues. The young  age of women 
with  HSIL makes  it important for policy  makers  to 
consider increasing  efforts to educate women on the 
dangers of cervical cancer and to screen young women in 
Schistosoma‑endemic areas for SCA. 
 
CONCLUSION 
 
Pap smear cytology is a simple  diagnostic  test, that is, 
relatively cheap and noninvasive. It can be widely used for the 
detection of SCA and may also detect FGS. In our study, the 
“high tech” real‑time PCR detects Schistosoma DNA, reflecting 
FGS, in cervical lavage almost 6 times more often than Pap 
smears. In this limited sample size, there was no significant 
association between cervical atypia and the tests which were 
positive for genital schistosomiasis. It is, however, important 
to note that SCA consistent with at least HPV infection was 
detected in 27% of this young  population who  are not 
conventionally screened for cervical cancer, some of them 
with advanced atypia. A shift in cytology sampling to LBC 
could open for a triage of cytology, HPV DNA testing, and 
Schistosoma PCR; this will be considered in future. 
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Figure  6: (a) Cervical  smear, magnification (Papanicolaou stain, ×40). 
A contaminant easily misdiagnosed for Schistosoma haematobium 
ova. Note the lack of a diagnostic terminal spine. (b) Cervical smear, 
magnification (Papanicolaou stain, ×40).Arrow: Schistosoma ovum with a 
terminal spine found among contaminants 
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6.1 Paper 3 
6.0 CHAPTER SIX 
 
Detection of Schistosoma DNA by real-time PCR in vaginal lavage and urine: a 
comparison between five female African study populations originating from regions with 
distinct S. haematobium and S. mansoni transmission patterns. 
 
Pillay Pavitra, Downs Jennifer, Brienen Eric AT, Taylor Myra , Kjetland Eyrun F and Van 
 
Lieshout Lisette. 
 
 
In manuscript for submission to American Journal of Tropical Medicine and Hygiene 
 
 
The purpose of this paper was to review diagnostic performance among comprehensive recent 
studies using microscopy, PCR urine and cervico-vaginal lavage and cytology (only comparing 
those which were Schistosoma positive) with the aim of showing the potential use of vaginal 
lavage as a diagnostic indicator for FGS in five regions in Africa each with distinct patterns of 
schistosomiasis prevalence. Since some of the regions were endemic for S. mansoni, the role 
of S.  mansoni in FGS was investigated. 
 
This explorative descriptive study compares schistosome real-time PCR analysis of 933 vaginal 
lavages of women from five different study populations among the following three countries in 
Africa; South Africa, Tanzania and Madagascar. In this paper the results of Schistosoma PCR 
in urine, stool, vaginal lavage, urine and stool microscopy and cytology are compared. 
 
 
My role in this research was to participate in the analysis and writing of this manuscript using 
the PCR results in urine and cervico-vaginal lavage, urine microscopy and cytology results that 
were generated from my current research. Professor van Lieshout facilitated the writing of this 
collaborative manuscript since it was at her laboratory where the PCR analysis for the studies 
from Tanzania and Madagascar were conducted. 
 
 
This study confirmed real-time PCR for the detection of Schistosoma DNA in gynecological 
samples to be a valuable diagnostic tool, in comparison to the classical Pap smears, to study the 
distribution of urogenital schistosomiasis at a population level. To elucidate the contribution of 
S. mansoni in the pathogenesis of FGS however there is a need for a species-specific ultra- 
sensitive diagnostic tool. This paper aims to contribute to the body of knowledge on cervico- 
vaginal lavage PCR in the diagnosis of FGS. 
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ABSTRACT 
 
 
Background: Early life genital symptoms such as contact bleeding, homogenous sandy 
patches, grainy sandy patches and rubbery papules are important manifestations of Schistosoma 
haematobium infection in girls and these seem to increase HIV susceptibility when women with 
urogenital schistosomiasis become sexually active. Although lesions, seen during colposcopy, 
facilitate the diagnoses of female genital schistosomiasis (FGS), they are not pathognomonic. 
Additional detection of Schistosoma DNA in gynecological samples can contribute to the 
diagnosis, at least at a population level, but this procedure needs further investigation. This 
explorative descriptive study compares schistosome real-time PCR analysis of 933 vaginal 
lavages of women from five different study populations. Methods: Schistosoma DNA levels 
were determined by real-time PCR in Cervico Vaginal Lavages (CVL) of 422 women from 
Mwanza, Tanzania,  of  which 112 originate from a S. haematobium endemic region (site 1A) 
and 310 from a region where  S. mansoni is  endemic (site 1B). Findings were compared with 
data of CVL collected from 394 women from a S. haematobium region in South Africa (site 2) 
as well as of 79 pre-selected S. haematobium positive women and 39 urine microscopy negative 
women, from two regions with different transmission levels in Madagascar (respectively, site 
3A and site 3B). While urine and stool microscopy and gynecological procedures varied 
between study protocols, standardized DNA isolation and Schistosoma real-time PCR was 
performed in a centralized laboratory. Principle findings: Schistosoma DNA in CVL samples 
generally reflected the distribution and intensity of urine PCR determined S. haematobium 
infection between the selected study groups, with the exception of 2.9% DNA positives in the 
S. mansoni endemic group of Tanzania (1A) who were negative in their urine samples. In 
groups with high S. haematobium infections levels, the PCR demonstrated a substantial number 
of Schistosoma DNA containing stool samples while being microscopy negative. Potentially 
this may be due to leakage of urine during defecation. Conclusion: This study confirmed real- 
time PCR for the detection of Schistosoma DNA in gynecological samples to be a valuable 
diagnostic tool, in comparison to the classical Pap smears and to study the distribution of 
urogenital schistosomiasis at population level. To elucidate the contribution of S. mansoni in 
the pathogenesis of FGS there is a need for a species-specific ultra-sensitive diagnostic tool. 
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INTRODUCTION 
 
 
Female genital schistosomiasis (FGS) is a neglected disease of poverty for which millions of 
women and girls are at risk especially in developing countries (Kjetland,  Leutscher and 
Ndhlovu 2012). The causative agent for FGS is Schistosoma haematobium, however little is 
known about the role of S. mansoni in FGS endemic areas (Kjetland,  Leutscher and Ndhlovu 
2012). FGS has been associated with an increased risk for HIV acquisition which is a 
consideration that is often overlooked in developing countries (Mbabazi et al. 2011) 
 
One of the major challenges however, is to make a direct diagnosis of FGS, given that 
schistosomiasis occurs most frequently among young women and girls who may also be at risk 
for HIV. Taking a direct biopsy from the genital tract is not applicable for this age group. 
Diagnostic tests for schistosomiasis have been described using microscopy in urine and stool 
samples as well as with Schistosoma PCR (Obeng et al. 2008; Meurs et al. 2015; Utzinger et 
al. 2015). However, it is also suggested that urine analysis alone may not be the ideal indicator 
for FGS (Poggensee et al. 1998). The use of Pap smear cytology has also been shown to have 
a low sensitivity, despite the Pap smear being a direct sample from the cervical mucosa causing 
minimal epithelial disruption (Pillay 2015 submitted); (Poggensee and Feldmeier 2001);. 
Results from an earlier study investigating Schistosoma DNA in cervico-vaginal lavage (CVL) 
samples had limitations since the samples examined were frozen for several years and since the 
Schistosoma PCR technique has also evolved (Kjetland et al. 2009).  In more recent studies, 
however Schistosoma DNA has been detected in CVL of women living in S. haematobium 
endemic areas and has shown clear correlation with genital symptoms (Randrianasolo et al. 
2015); (Pillay 2015, submitted). 
 
 
In this paper we review the diagnostic performance among comprehensive recent cross 
sectional FGS surveys using microscopy, Schistosoma PCR in urine and more specifically CVL 
samples from three different countries in Africa namely Tanzania, South Africa and 
Madagascar, each with distinct patterns of schistosomiasis. The main aim of these studies was 
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to determine the prevalence of FGS and contribute to knowledge about FGS diagnostics 
especially from regions with low transmission intensities. The possibility of FGS in an S. 
mansoni endemic area is also considered. Also given that Schistosoma DNA in CVL has been 
found to be an acceptable laboratory indicator of FGS; (Kjetland et al. 2009; Randrianasolo et 
al. 2015); (Pillay 2015, submitted),  we further explore the presence of Schistosoma DNA in 
CVL, including samples collected in a S mansoni endemic region. 
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MATERIALS METHODS 
 
 
Study Population, ethics, recruitment and sampling: Schistosoma DNA levels of 993 CVL 
were evaluated and compared to the Schistosoma DNA levels in urine and where available with 
Schistosoma DNA levels in feces. The flow chart enlisting the study sites is presented in Figure 
1. 
 
 
Site 1. The Tanzania study was nested within a larger cross sectional survey conducted during 
 
2009-2010 at eight rural primary clinics in Mwanza, south of Lake Victoria. Two of the clinics 
were located in a region with predominantly S. haematobium transmission, while the six other 
clinics were located more to the North, closer to Lake Victoria, where mostly S. mansoni 
infections were seen. Ethical permission was received from the Bugando Medical Center, the 
Medical Research Coordinating Committee of the National Institute for Medical Research in 
Tanzania and the Institutional Review Board of Weill-Cornell Medical College. An informed 
consent was part of the inclusion procedure and menstruating women were excluded from 
participation (Downs et al. 2011). Full details of the original study site, the ethical aspects and 
the followed procedures have been described elsewhere (Downs et al. 2011; Downs et al. 
2012). In brief, out of the 550 eligible female visitors to a free cervical cancer screening 
program who were invited to participate in the study, 422 completed the required study 
procedures and could be tested for the presence of Schistosoma DNA in their lavage, urine and 
stool samples (Figure 1). This group consisted of 310 women from the S. mansoni predominant 
northern region, named site 1A, and 112 women from the S. haematobium predominant 
southern region, named site 1B. The median age of group of 1A was 30 years (range 13-60) 
and of 1B was 27 years (range 18-45). Samples were collected and examined as follows. During 
gynecological examination, CVL samples were taken by washing the surface of the cervix three 
times with normal saline and collecting 2 mL aliquots. In addition Pap smears were made using 
a plastic spatula and these were stained with 0.5% Trypan Blue and examined for the presence 
of Schistosoma eggs. Participants were requested to deliver a single urine and stool sample, 
which were examined for Schistosoma eggs by experienced microscopists, using respectively 
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a urine filtration procedure and a Kato-Katz smear examination as described in previous 
publications (Downs et al. 2011) An aliquot of approximately 1.0 -2.0 mL of each urine and 
stool sample was transferred to a cryotube on the day of collection and together with the CVL 
aliquots stored at -800  C. All samples were transported frozen to the Netherlands for 
Schistosoma DNA isolation and detection. PCR outcomes of a small subgroup of 33 S. 
haematobium infected women have been described before in order to specifically study the 
effects of Praziquantel treatment (Downs et al. 2013). 
 
Site 2. For comparison Schistosoma PCR data were included from a cross sectional study 
performed in South Africa during 2010-2012 among young women living in rural KwaZulu- 
Natal, in a region in which the S. haematobium prevalence among girls aged 10-12 years was 
found to be 31.8%, based on microscopic examination of urines collected over three 
consecutive days (Hegertun et al. 2013; Pillay et al. 2014). Ethical approval was obtained from 
the Biomedical Research Ethics Committee, University of KwaZulu-Natal and the Norwegian 
ethics committee as well as the European Group on Ethics in Science and New Technologies. 
The Departments of Health and Education of KwaZulu-Natal gave permission. An informed 
consent was part of the inclusion procedure and pregnant women and virgins were excluded 
from participation. Full details of the study design, ethical aspects, sample collection and major 
outcomes have been described elsewhere (Holmen et al. 2015) (Pillay, 2015 submitted).  In 
brief, 394 out of the 1200 eligible women, ranging in age from 16 to 23 years (median 19 years) 
met the inclusion criteria and completed all required procedures (Pillay, 2015 submitted). CVL 
samples were taken during gynecological examination by spraying 10 mL of saline on the 
vaginal wall and cervix twice, whereupon it was drawn back into a syringe and divided amongst 
2 mL cryotubes. Pap smears were collected by using a wooden spatula and thereafter stained 
via the Papanicolaou technique and examined by a trained cytologist for the presence of 
Schistosoma eggs in addition to other cytological entities. Participants were requested to deliver 
a single urine sample, of which two times 10 mL were examined for Schistosoma eggs by 
experienced  microscopists  as  previously  described  (Pillay  et  al.  2014)  An  aliquot  of 
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approximately 1.0 mL of urine was transferred to a cryotube on the day of collection and 
together with the CVL aliquots stored at -800  C until transportation. In this study no stool 
samples were collected, as S. mansoni was found to be close to absent in the region after 
performing microscopy and real-time PCR analysis on approximately 600 stool samples  of 
young school girls  (unpublished data); (Pillay et al. 2014). 
 
Site 3. Finally, Schistosoma PCR data were used from an FGS-study conducted in 2010 among 
rural farming communities across five villages in the district of Miandrivazo in the western part 
of Madagascar. Four of these villages were situated in a region known to be hyper-endemic for 
S. haematobium, with a prevalence >50% (site 3A), while the fifth village was situated in a 
region with low S. haematobium endemicity, showing a prevalence below 20% (site 3B) 
(Randrianasolo et al. 2015). Eligible women were stratified into different categories based on 
the location of their village and the outcome of a pilot survey on the prevalence of S. 
haematobium performed some months before actual sample collection took place. Within the 
hyper-endemic villages   79 women, age ranging from 15-33 years (median 20 years) were 
selected, based on   the average urinary S. haematobium egg excretion at microscopic 
examination of three consecutive urines, being either highly infected, i.e. > 50 eggs per 10 mL 
of urine (n=40), or infected with a low worm burden, i.e. <20 eggs per 10 mL of urine (n=39). 
In total 38 urine microscopy negative women from the low S. haematobium transmission site 
3B were included, with ages ranging from 15-35 (median 23 years). The Ethics Committee at 
the Ministry of Health in Madagascar granted ethical approval for this cohort. An informed 
consent was part of the inclusion procedure and pregnant women and virgins were excluded. 
Full details on the study design, ethical aspects, sample collection and major outcomes have 
been described elsewhere (Randrianasolo et al. 2015). 
 
In brief, samples at site 3 were collected and examined as follows. CVL samples were taken 
during gynecological examination by spraying 10 mL of saline on the vaginal wall and cervix 
in total five times, whereupon it was drawn back into a syringe and divided amongst 2 mL 
cryotubes. Pap smears were made by using an endocervical brush and after staining with 
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Papanicolaou examined by a trained cytologist for the presence of Schistosoma eggs. 
Participants were requested to deliver a single urine and stool sample on the day of 
gynecological examination. Stool samples were examined for Schistosoma eggs by experienced 
microscopists, using a Kato-Katz smear examination (Randrianasolo et al. 2015). An aliquot 
of approximately 1.0 to 2.0 mL of each urine and stool sample was transferred to a cryotube. 
All collected samples were immediately stored at -800 C and transported frozen to the 
Netherlands for Schistosoma DNA isolation and detection. 
 
DNA isolation and detection. DNA isolation and PCR reaction set-up steps were performed 
using a custom-made high throughput Hamilton robot platform (Hamilton Robotics GmbH, 
Germany) at the Leiden University Medical Centre in the Netherlands. Full details on the used 
DNA isolation procedures and set-up of the multiplex real-time PCR for semi-quantitative 
detection of the Schistosoma genus-specific  internal-transcribed-spacer-2 (ITS2) target are 
given elsewhere (Obeng et al. 2008);(Downs et al. 2013);(Meurs et al. 2015). In brief, DNA 
was isolated using DNeasy 96 Blood & Tissue Kit spin columns and Phocin Herpes Virus-1 
(PhHV-1) was added to the lysis buffer in each sample as an internal control. Negative and 
positive control samples for each parasite species were included in each PCR run. A CFX96 
real-time detection system (Bio-Rad laboratories) was used for DNA amplification and 
detection. Cycle threshold (Ct) value results were analyzed using Bio-Rad CFX software 
(Manager V1.6.541.1028). These Ct-values represent the amplification cycle in which the level 
of fluorescent signal exceeds the background fluorescence, reflecting the parasite-specific DNA 
load in the tested sample. The amplification is considered to be hampered by inhibitory factors 
if the expected Ct value of 33 in the PhHV-specific PCR was increased by more than 3.3 cycles. 
DNA intensities of each species were arbitrarily classified as either high-intensity (Ct<30), 
medium-intensity (30≤Ct<35), low intensity (35≤Ct<50) or negative (Ct=50) (Pillay et al. 
2014). 
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Data Analysis and statistical testing: PCR analysis was performed blinded from microscopy 
or other provided data. The results of the real-time PCR analysis were stored and grouped in a 
Microsoft Access database and imported into IBM SPSS 20.0 (Chicago, Illinois, USA) for 
statistical analysis. Descriptive statistics were used in this exploratory study.  Categorical 
variables were summarized by frequency and percentage and presented using bar charts. 
Continuous variables for the diagnostic tests were summarized by median and interquartile 
range (IQR), (except when less than 10 total range), of all positive cases only using the Mann- 
Whitney rank-sum test. Proportions were compared using Fisher’s exact test and McNemar 
statistical test. Two-sided hypotheses were assumed for all confidence intervals and p-values. 
Statistical significance was set at p value less than 0.05. 
 
 
RESULTS 
 
 
Figure 2 summarizes the prevalence and intensity of Schistosoma infection based on different 
diagnostic procedures performed on urine, stool and lavage. 
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Figure 1. Participation flow and sampling among the 5 Schistosoma endemic regions. 1A and 1B 
represent northern (S. mansoni endemic) and southern (S. haematobium endemic) villages in Mwanza, 
Tanzania respectively, region 2 represents an S. haematobium endemic area in South Africa and Regions 
3A and 3B represent low and high S. haematobium endemic regions of Madagascar. All 5 study areas 
had urine and vaginal lavage analysis and Pap smear analysis. Stool analysis was not included in the 
South African study region. 
 
 
 
 
 
 
Tanzania urine examination. S. haematobium eggs in urine were demonstrated in 4 of the 310 
examined women (1.3%) of the northern study area in Tanzania (site 1A) with counts ranging 
from 2-12 eggs/10mL. At the southern study area (site 1B) 13 of the 112 included women 
(11.6%) were positive in urine microscopy, with counts ranging from 1-54 eggs/10ml (median 
8 eggs/10ml). Based on the urine PCR results, the detection rate was higher at both sites 
compared to microscopy, still showing S. haematobium to be more prevalent in the southern 
region (19.6%) compared to the northern region (8.1%). Accordingly, overall Schistosoma 
DNA loads in urine were significantly higher in the southern region (Mann-Whitney U=15.3, 
n=422, p=0.001). 
 
Tanzania stool examination. S. mansoni eggs were seen at site 1A in 12.3% of the 310 Kato- 
smears examined, with intensity ranging from 12 to 917 epg (median 36 epg) while none of the 
112 women from site 1B showed Schistosoma eggs in stool. PCR on these 112 stool samples 
showed DNA to be present in 10 (8.9%) of them, but with a median Ct of 34 the Schistosoma 
DNA load was generally low (Figure 2). Nine of these 10 women with Schistosoma DNA in 
stool had no detectable Schistosoma DNA in urine. Overall Schistosoma DNA loads in stool 
were significantly higher in the S. mansoni endemic northern region (Mann-Whitney U=21.8, 
n=422, p<0.001). 
 
Tanzania lavage examination. PCR analysis of the lavages showed detectable Schistosoma 
DNA in 9/310 (2.9%) of the women from site 1A compared to 18/112 (16.1%) of the women 
from site 1B. Accordingly, overall Schistosoma DNA loads in lavage were significantly higher 
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in the S. haematobium endemic southern region (Mann-Whitney U = 15.0, n=422, p<0.001). 
(Figure 2) 
 
Tanzania compared to 3 other sites. Either when analyzing microscopy egg counts or 
 
Schistosoma DNA loads in urine or lavage, the findings from the S. haematobium endemic site 
 
1B were comparable to the finding of the South African site 2 (Mann-Whitney, n=506, p>0.05) 
(Figure 2). 
 
On the other hand in all the Schistosoma positive DNA lavages from the S. mansoni endemic 
site, women had negative urine microscopy and were negative for urine Schistosoma DNA, 
only one woman showed Schistosoma eggs in stool microscopy. Schistosoma DNA in stool 
was found among 6 (66.6%) of these 9 women who were positive in their lavage samples. 
 
Relation to cytology outcome. The relation between the outcome of the lavage PCR and 
histopathological examination differed per study site. In Tanzania 5 women of region 1A and 
one women of site 1B were reported with Schistosoma eggs after histopathological 
examination. None of them were positive in the lavage Schistosoma PCR, one showed 
Schistosoma DNA in urine and two of them in feces. On the other hand, in the South Africa 
study Schistosoma DNA was detected in the lavages of all 8 Pap smears with detectable S. 
haematobium eggs and the DNA levels of these 8 were significantly higher than the lavage 
DNA levels of those women negative in the cytology (Mann-Whitney U = 33.5, n=394, 
p<0.001). 
 
In the low endemic region of Madagascar (site 3A) Schistosoma DNA was demonstrated in 
lavage in 1 of the 4 women where eggs were seen in the cytology smear, while in the selected 
S. haematobium infected women from site 3B, Schistosoma DNA was demonstrated in 28 of 
the 41 women where eggs were seen with cytology. Again lavage DNA levels of these women 
where eggs were seen in the Pap smears were significantly higher than the lavage DNA levels 
of those women negative in the cytology (Mann-Whitney U = 990.0, n=117, p<0.001). 
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Figure 2. Summary of Schistosoma diagnostics according to DNA loads and egg intensities among the 
5 study populations. Intensity in urine samples was defined as follows; high intensity >50 ova per 
10mL, moderate intensity as 10-50 ova per 10mL and low intensity as <10 ova per 10mL. High 
intensity of eggs in stool samples was defined as >400 eggs per gram (epg), moderate intensity as 100- 
400epg and low intensity as <100epg. The Schistosoma DNA loads were defined as high-intensity 
(Ct<30), medium-intensity (30≤Ct<35) or low intensity (35≤Ct<50). Region 1A and 1B represent the 
S. mansoni and S. haematobium endemic areas in Tanzania respectively, region 2 represents the S. 
haematobium endemic area in South Africa and Regions 3A and 3B represent the low and high S. 
haematobium endemic regions of Madagascar respectively. Details of the populations are given in the 
text. 
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DISCUSSION 
 
The quest for more sensitive and specific diagnostic tools in the diagnosis of FGS continues as 
more information on this neglected entity unfolds. It is clear that non-invasive FGS diagnosis 
among women who are also at risk for HIV needs to complement colposcopy in the rural 
settings. 
 
PCR in urine and stool. While traditional microscopy is cheaper and more readily available, 
it also poses challenges like observer variation and decreased sensitivity in detecting low 
intensity infections. The Schistosoma PCR as detected amongst the study areas in urine and 
stool samples showed higher detection rates generally, in comparison to urine and stool 
microscopy respectively, as has been noted previously (Obeng et al. 2008; Cavalcanti et al. 
2013). While PCR has better specificity and sensitivity, the major disadvantage is the cost, and 
field applicability (Cavalcanti et al. 2013). Another limitation of the PCR assay used in this 
study is that it is not able to distinguish between S. haematobium and S. mansoni. 
 
US vs FGS. Urinary tract involvement in FGS has been studied and it has been reported that 
women could have urinary schistosomiasis with or without genital schistosomiasis (Poggensee 
et al. 1998); (Swai et al. 2006). While urine microscopy and urine PCR might show improved 
sensitivity and specificity for the detection of schistosomiasis, it might not be the best tool to 
assess genital schistosomiasis. In the South African study, despite the correlation of urine PCR 
and CVL PCR, some cases were positive in CVL only, supporting the notion that 
schistosomiasis could occur in the genital tract only, this raises a question about whether urine 
PCR is the best indicator of FGS (Pillay submitted 2015). However, in rural areas where 
resources are lacking, and gynaecological analysis is not always feasible, urine may be a more 
practical sample to obtain although not ideal. 
 
Comparison of CVL results among 5 regions. Schistosoma DNA in CVL was detected in all 
 
5 study sites, although providing variable results among the regions. In this comparative study 
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the CVL results correlated to the Pap results (despite the prevalence in Pap smears being 
generally much lower, except in Madagascar- Region 3B) and should be considered as an 
additional diagnostic tool for FGS at a population level. CVL results were much more sensitive 
than the Pap smear results in all of the regions except one (Region 1A). 
 
S mansoni and FGS. While there is evidence that S. haematobium is the causative agent for 
FGS, little is known about the effect of S. mansoni. The S. haematobium worm is known to 
prefer residence in the pelvic venous plexuses therefore the ova tend to become lodged in 
urogenital tissues, while S. mansoni prefers the portal venous system and is usually found in 
the intestinal tract (Colley et al. 2014). It has been suggested that while S. mansoni ova are 
usually lodged in the liver or intestines, this parasite can also be found in the genital tract 
(Feldmeier et al. 1998). 
 
In regions in Africa, it has been found that there is overlap between the geographical areas in 
which both species are endemic and at risk for co-infections (Gryseels et al. 2006). There has 
however been limited information about mixed infections. In a cross-sectional study conducted 
among two communities in Senegal it was found that 53% had mixed infections (Meurs et al. 
2012). In an FGS study conducted in Tanzania S. mansoni was reported to be found in 13% of 
the women (Poggensee,  Feldmeier and Krantz 1999).  In the few recent case reports from 
Brazil, detection of S. mansoni in the fallopian tubes and ovaries has been described (Arruda et 
al. 2007; Cavalcanti et al. 2011; Gonçalves Amorim et al. 2014). In the present study, two 
thirds of the women from the S. mansoni endemic region who had positive Schistosoma CVL, 
also had positive Schistosoma DNA in their stool samples. This could support the finding that 
S. mansoni might be responsible for FGS especially in endemic regions as indicated by the case 
reports (Poggensee,  Feldmeier and Krantz 1999; Cavalcanti et al. 2011). 
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CONCLUSION 
 
 
In conclusion, Schistosoma PCR in urine and stool samples may be better diagnostic tools 
especially for mapping disease at population level, in light of the costs and logistics. CVL PCR 
is also a valuable tool for diagnosing genital schistosomiasis since it is more sensitive than 
conventional Pap smears. The potential for S. mansoni being implicated in FGS should not be 
underestimated especially in populations at risk for HIV as there are implications, from the 
association that has been reported in several studies. Further research towards developing a 
species specific point of care diagnostic tool that can be applied to urine, stool and cervical 
mucus is recommended for field applicable diagnosis of schistosomiasis to enable appropriate 
patient management. 
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7.0 CHAPTER SEVEN 
 
7.1 Paper 4 
 
 
Liquid-based cytology as a tool for a more precise diagnosis and risk- assessment of 
cervical squamous cell atypia among young women from Schistosoma and HIV endemic 
populations in South Africa. 
 
Pavitra Pillay, Myra Taylor, Hashini N Galappaththi-Arachchige, Siphosenkosi G Zulu, Irene 
 
K Christiansen, Ole-Herman Ambur, Borghild Roald and Eyrun F Kjetland 
 
In manuscript. 
 
 
The purpose of writing this paper was to investigate further the value of laboratory tools for 
FGS. In this study we compared traditional Pap smears to liquid-based cytology (LBC) samples 
and found that there was a better cellular quality using LBC sampling. In this research it was 
found that more than two thirds 567(68.1%) of the population of young women had cervical 
squamous atypia. The atypia was also significantly associated with urogenital schistosomiasis. 
Possible risk factors for cervical atypia and schistosomiasis are also reported. 
 
Young women aged 16-23 years from rural high schools in the north coast of KwaZulu-Natal 
were invited to participate in a study. Risk factors were identified through a questionnaire. 
Cytology Pap smears and Liquid based cytology (LBC) samples were investigated for 
Schistosoma ova and squamous cell atypia among 833 young women at baseline. Urine 
microscopy was done for the identification of Schistosoma ova. HPV genotyping was 
conducted in the LBC supernatant in a selection of 10 cases that were cytologically diagnosed 
with high grade squamous intraepithelial lesion (HSIL). 
 
My role in this research was to conduct the cytology, and based on the results from the initial 
study among young women, I facilitated the change from traditional Pap smears to LBC 
sampling. This change in sampling improved the diagnostic quality of the results. LBC 
sampling is not only advantageous for cytology but DNA analysis is possible in the LBC 
residual. From a public health perspective, we consider including a risk analysis of the cervical 
atypia using HPV subtyping since this information could inform the future management of 
young women with cervical atypia. We have also proposed a sampling triage which consists of 
LBC cytology and HPV and possibly Schistosoma DNA analysis using the residual LBC 
sediment. This triage for women at risk for schistosomiasis and cervical atypia is novel and to 
our knowledge it has not been done among Schistosoma endemic populations. 
89  
Paper 4 
 
 
Liquid-based cytology as a tool for a more precise diagnosis and risk-assessment 
of cervical squamous cell atypia among young women from Schistosoma and 
HIV endemic populations in South Africa. 
 
 
 
 
 
Pillay P1,2*, Taylor M2, Galappaththi-Arachchige HN3, Zulu SG2, Christiansen IK4, Ambur 
 
OH4, Roald B3,5, Kjetland EF2,6. 
 
 
 
 
 
 
1 Department of Biomedical and Clinical Technology, Durban University of Technology, 
KwaZulu-Natal, South Africa 
 
2 Discipline of Public Health Medicine University of KwaZulu-Natal, Durban, South Africa 
 
3Faculty of Medicine, University of Oslo, Oslo, Norway 
 
4Norwegian HPV Reference Laboratory, Dept. Microbiology and Infection Control, Akershus 
University Hospital, Lørenskog, Norway 
 
5 Department of Pathology, Oslo University Hospital, Oslo, Norway 
 
6Norwegian Centre for Imported and Tropical Diseases, Department of Infectious Diseases, 
Oslo University Hospital, Oslo, Norway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Corresponding Author 
90  
Key words: Female Genital Schistosomiasis, cervical squamous cell atypia, liquid-based 
cytology, HPV genotyping, risk assessment. 
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ASCUS atypical squamous cells of undetermined significance 
DNA deoxy ribonuclease 
CIN cervical intraepithelial lesion 
FGS female genital schistosomiasis 
HPV human papillomavirus 
HIV human immune deficiency virus 
PCR polymerized chain reaction 
LBC liquid-based cytology 
SIL squamous intraepithelial lesion 
LSIL                 low grade squamous intraepithelial lesion. 
HSIL                 high grade squamous intraepithelial lesion 
SCA                  squamous cell atypia 
S haematobium Schistosoma haematobium 
STIs sexually transmitted infections 
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ABSTRACT 
 
 
Background: Globally, Africa has the highest prevalence of HIV, schistosomiasis and cervical 
cancer. Female genital schistosomiasis (FGS) is hypothesized to be associated with both HIV 
and cervical cell atypia. We wanted to explore the correlation between schistosomiasis and 
cervical squamous cell atypia in a hot and humid rural area. We additionally wanted to compare 
two diagnostic methods for cytological evaluations [Pap smears and Liquid-based cytology 
(LBC)] and to explore DNA analysis in the residual LBC sample as a tool for risk assessment 
for high-risk HPV types. The residual LBC sample also has the potential to be used to test for 
Schistosoma DNA 
 
Methods: In this cross sectional study, young women aged 16-23 years from rural high schools 
in KwaZulu-Natal were invited to participate in the study. Risk factors were identified through 
a questionnaire. Cytology Pap smears and LBC samples were investigated for Schistosoma ova 
and squamous cell atypia in 833 women at baseline. Urine microscopy was done for the 
identification of Schistosoma ova. In a small sub-population, HPV genotyping was conducted 
using residual LBC samples in a selection of 10 cases that were cytologically diagnosed with 
high grade squamous intraepithelial lesion (HSIL). 
 
Results: The participants were sexually active from the mean age of 18 (SD 9.97), and more 
than half of them had at least one child. The majority (92.4%) relied on rivers as their primary 
water source. The Schistosoma prevalence detected cytologically and via urine microscopy was 
12 (1.4%) and 178 (21.4%), respectively. Squamous cell atypia was detected in 567 (68%) 
young women of which 19 (2.3%) were diagnosed with HSIL. There were significant 
associations between the participants who were positive for any squamous cell atypia and those 
who had S. haematobium ova in Pap smears (OR= 5.6, p=0.005; 95% CI 1.6-21.0) and S. 
haematobium eggs in urine OR= 2.9, 95% CI 1.72 - 4.99, p=0.005). Majority (85.4%) 
(p=0.000) of the LBC samples were suitable for assessment as compared to 97.6% (p=0.000) 
of Pap smears which were sub-optimal. HPV genotyping done on the 10 HSIL cases using the 
residual LBC revealed a spectrum of HPV types, some of them high-risk. The samples were 
adequate for DNA analysis despite being stored at ambient temperatures for 12-18 months. 
 
Conclusion: A significant association exists between urogenital schistosomiasis and squamous 
atypia in this young population. More than half of the women in this study population had 
cervical atypia and a small proportion also had high grade cervical lesions. Better diagnostic 
specimens were obtained using LBC sampling compared to Pap smears. Importantly, HPV 
genotyping in the residual LBC samples worked well in the 10 cases diagnosed as HSIL, many 
revealing high-risk HPV infections. In a single LBC sample, cervical cytology with 
identification of sexually transmitted infections, cervical atypia and HPV DNA-genotyping can 
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thus be used for risk assessment in the identification of which patients should have follow-up. 
In the wake of decreasing costs of LBC this might be a cost effective and sustainable solution 
for targeted intervention in rural Africa.  Further research is needed to see if the LBC residual 
sample also could be used for testing Schistosoma DNA. 
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INTRODUCTION 
 
 
Genital lesions in women caused by schistosomiasis have been identified for many years 
 
(Madden 1899; Youssef,   Fayad and Shafeek 1970; Berry 1976; Poggensee and Feldmeier 
 
2001; Kjetland et al. 2005). When ova of the parasite Schistosoma haematobium become 
lodged in the genital mucosa, they cause immunological and tissue changes. Female Genital 
Schistosomiasis (FGS) causes sandy patches, mucosal vascular abnormalities and contact 
bleeding that may render women more prone to acquiring HIV (Kleppa et al. 2014; Norseth et 
al. 2014). 
 
Human papillomavirus (HPV) has a high prevalence in young women and is one of the major 
causes of cervical cancer (Schiffman et al. 2007).  In Schistosoma endemic areas, it has been 
suggested that schistosomiasis could be a risk factor for acquisition and maintenance of HPV, 
thus being a co-factor for the development of cervical cancer, a major health burden in 
developing countries (Prabhakaran and Brown 2004; Kjetland et al. 2009). Africa has the 
highest global distribution of HIV, schistosomiasis and cervical cancer as is shown in Figure 1; 
(Organisation 2014; WHO 2015; World Health Organisation 2015). 
 
It is suggested that schistosomiasis is mostly acquired in childhood. Associated changes in the 
cervical mucosa have been hypothesized to facilitate the development of cancer through early 
transmission of HPV (Poggensee and Feldmeier 2001). Diagnosing FGS among young women 
is challenging since the direct diagnosis with tissue biopsies are not applicable in young women 
who are also at risk for HIV in rural endemic areas. 
 
The aim of this study was to explore the relationship between squamous cell atypia (SCA) and 
schistosomiasis in a young HIV endemic population, highlight the risk factors and investigate 
diagnostic tools that can be used in low resource areas. As part of that, we also wanted to 
compare traditional Pap smears and liquid-based cytology (LBC) and explore the possibilities 
of using HPV genotyping in residual LBC samples for risk analysis. 
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Figure1.   Three   maps   showing   global   distributions   of   the   following   entities:   (A) 
Schistosomiasis –showing mostly a moderate prevalence in most of Africa, (B) HIV- adults- 
15-49 years and (C) Cervical cancer incidence. Africa has the largest overlap and distribution 
of all three disease entities. (Organisation 2014; WHO 2015; World Health Organisation 2015). 
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MATERIALS AND METHODS 
 
 
In a Schistosoma endemic area on the north coast of KwaZulu-Natal, high school females were 
invited to participate in a cross-sectional study as described previously (Kleppa et al. 2015; 
Randjelovic et al. 2015). The detailed description of the sampling and ethical considerations 
are described elsewhere (Holmen et al. 2015). Consenting participants underwent a semi- 
structured face-to-face interview in the local language isiZulu and urine samples for 
microscopy were collected and processed locally as described previously, prior to 
gynaecological examination (Pillay et al. 2014); (Pillay 2015- submitted). Traditional Pap 
smears were collected by scraping a wooden spatula in the cervix and the fornices, then spray- 
fixed using a commercial cytological fixative for preservation in the first period in 510/833 
participants. Based on the initial limited quality of cytology results, Liquid-based cytology 
(LBC) using the SurePathTM (Franklin Lakes, NJ, USA) was used for the remaining 323/833 
samples. 
 
The cytology screening was done blinded to any of the other laboratory results or clinical 
findings.  Smears were examined microscopically in a systematic manner for all cytological 
entities that are expected to be found in cervical smears (Solomon et al. 2002). The diagnosis 
of Schistosoma haematobium was based on finding intact ova within shells, empty shells with 
terminal spines and calcified or dead ova (Berry 1966). Epithelial dysplasias were graded 
according to the Bethesda System (Solomon and Nayar 2004) and reported as described 
elsewhere (Pillay 2015- submitted). Ten HSIL samples were selected for HPV genotyping 
using the residual LBC sample that had been stored at ambient temperature for 12-18 months. 
The HPV genotyping was conducted at the Norwegian HPV Reference Laboratory in Akershus 
University Hospital using the WHO-validated hybridization based Luminex protocol (Schmitt 
et al. 2006; Söderlund-Strand,  Carlson and Dillner 2009) which is used in the surveillance of 
the effectiveness of the HPV vaccine in Norway. The method detects the following 37 HPV 
types: 6, 11, 16, 18, 26, 30, 31, 33, 35, 39, 40, 42, 43, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 67, 
68, 69, 70, 73, 74, 81, 82 ,83, 86, 87, 89, 90, 91. In addition two genetically distinct versions 
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of HPV35, 58 and 68 are detected, respectively. A separate β-globin PCR was used for the 
detection of human DNA to check the sample adequacy. 
 
 
 
 
Statistical analyses: 
 
IBM SPSS 20.0 (Chicago, Illinois, USA) was used for statistical analysis. Descriptive statistics 
were used in the explorative study.  Categorical variables were summarized by frequency and 
percentage and presented using bar charts.    For the diagnostic tests the continuous variable 
output was given for the positive cases only. Inferential statistics were done using the Fisher’s 
Exact Test. The odds and risk ratios and the corresponding 95% confidence intervals were 
determined for 2 × 2 cross-tabulations. All p-values were two-tailed values and p-values less 
than 0.05 were considered as significant. 
97  
 
 
RESULTS 
 
 
Study Population: The flow of participation in which 833 young women gave urine samples, 
underwent gynaecological examinations and had cytology performed (Figure2). Traditional 
Pap smears were done in 510/833 participants; the remaining 323/833 had LBC samples 
collected. Table 1 shows the risk factors reported in the questionnaire and that 742 (89%) of 
these young women reported water contact with rivers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2. Flow chart detailing study participation and adherence among the participants 
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Table1: Participant characteristics 
 
 
 
Characteristics Number (%) 
Study population 833 
Age (years) 
Standard 
Deviation 
Mean 19 1.78 
 
 
Reported in interview 
Mean age of sexual debut 18 9.97 
 
 
 
Number of children alive 
None 288 (34.6) 
One 528 (63.0) 
Two 7 (1.0) 
 
Types of risk water body contact: 
None 
 
 
30 
 
 
(3.6) 
River 770 (92.4) 
Dam 38 (4.6) 
Standing water 6 (0.7) 
Several types 17 (2.0) 
 
Treated for Bilharzia Previously Baseline   
No 317 (38.1) 
Yes 151 (18.1) 
Unsure 365 (43.8) 
 
 
Cytology: Of the Pap smears, 97.6% (498/510) (p=0.000) were sub-optimal and for the LBC 
samples 85.4% (267/323) (p=0.000) were satisfactory for evaluation. The most common 
reasons why Pap smears were sub-optimal for cytological assessment included the following: 
thick smears, poor preservation and cells obscured by blood. The squamous cell atypia detected 
via traditional Pap smears was 271/833 (32.5%) as compared to that detected using LBC 
sampling which was 296/833 (35.3%).  Schistosoma ova were detected in 12 (1.4%) cases via 
cervical cytology (Table 3). Five of the 12 cases were seen in Pap smears and 7 in LBC 
preparations. In the total population of 833, S. haematobium ova were detected in only 5/510 
(0.01%) cases using Pap smears compared to 7/ 323 (2.2%) LBC samples. Of the 12 cases that 
were Schistosoma positive on cytology, 5 (41.7%) were negative on urine microscopy. Ten of 
the 12 (83.3%) young women with cytologically detected Schistosoma ova reported rivers as 
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their main source of water contact. Only 3 (25%) of them reported having received treatment 
for schistosomiasis before. Squamous cell atypia was diagnosed in 10/12 (83.3%) young 
women with Schistosoma ova in their Pap smears. 
 
 
 
 
 
Table 3 Twelve Cases positive for Schistosomiasis by cytology compared to urine Microscopy, 
squamous cell atypia, participant age and cytology sampling type 
 
 
 
 
n Urine microscopy 
Ova per40x field 
Cytology 
Schistosoma 
Positive 
Baseline 
Specimen 
type 
SCA 
baseline 
Follow 
up 
Specimen 
type 
Cytology 
Schistosoma 
Positive 
Follow-up 
SCA 
follow 
up 
Age 
1 Negative Positive Pap NEG NO n/a n/a n/a 18 
 
2 
 
Negative 
 
Positive 
 
Pap 
 
ASCUS 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
18 
 
3 
 
Negative 
 
Positive 
 
LBC 
 
LSIL 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
17 
 
4 
 
Negative 
 
Positive 
 
LBC 
 
ASCUS 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
22 
 
5 
 
Negative 
 
Positive 
 
LBC 
 
LSIL 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
21 
 
6 
 
Positive 
(4.00 Ova) 
 
Positive 
 
Pap 
 
NEG 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
20 
7 Positive (3.00 Ova) Positive Pap ASCUS NO n/a n/a n/a 20 
 
8 
 
Positive (2.50 Ova) 
 
Positive 
 
LBC 
 
ASCUS 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
23 
 
9 
 
Positive (5.50 Ova) 
 
Positive 
 
LBC 
 
LSIL 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
17 
 
10 
 
Positive  (140.5 Ova) 
 
Positive 
 
LBC 
 
ASCUS 
 
NO 
 
n/a 
 
n/a 
 
n/a 
 
16 
 
11 
 
Positive  (27.5 Ova) 
 
Positive 
 
LBC 
 
LSIL 
 
YES 
 
LBC 
 
POS 
 
LSIL 
 
19 
 
12 
 
Positive  (20.00 Ova) 
 
Positive 
 
Pap 
 
ASCUS 
 
YES 
 
LBC 
 
POS 
 
HSIL 
 
19 
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Figure 3. Distribution of squamous cell atypia (SCA) overall and as per specified categories high grade 
squamous intraepithelial lesion (HSIL), low grade squamous intraepithelial lesion (LSIL) and atypical 
cells of unknown significance (ASCUS)] in young women aged 16-23. 
 
There  was  a  significant  association  between  the  participants  who  were  positive  for  any 
squamous atypia and those who had S. haematobium eggs in Pap smears (OR= 5.8, 95% CI 
1.61-21.00, p=0.005) or S. haematobium eggs in urine (OR= 2.9, 95% CI 1.72 - 4.99, p=0.005) 
at baseline. Most of the squamous atypia was in the low grade squamous intraepithelial lesion 
(LSIL) category which refers to active HPV infection or CIN1 was found at baseline (Figure 
3). Nineteen (1.4%) of the young women were diagnosed cytologically with HSIL. HPV 
 
genotyping results from 10 LBC samples with cytologically detected HSIL are shown in Table 
 
4. Among the 10 HSIL cases Schistosoma ova were not detected via cytology, but 4/10 (40%) 
 
were however positive for urinary schistosomiasis. 
 
 
 
 
 
Table 4. HPV Genotyping, age and urine microscopy results among 10 cases of HSIL 
 
 
 
Age Urinary Schistosomiasis HPV Genotype 
22 Positive 51, 53 
16 Positive 6, 18, 66 
16 Negative 6, 16 
17 Positive 33, 35 
18 Negative 16, 40, 59 
19 Positive 18, 31 
19 Negative 82 
20 Negative 35, 68, 82 
20 Negative 18, 31, 58, 66 
23 Negative 16,82 
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Urine microscopy: The urinary schistosomiasis prevalence was 178/833 (21.4%), with a mean 
egg count of 7.2 eggs/10mL and the range was 0.01-680.50 eggs per 10mL. More than 50 
eggs/10mL were found in 23/178 (13.0%) and less than 50 eggs/10mL were found in the 
remaining 155/178 (87.0%). There was a significant association between the two testing 
methods used: Schistosma detection in cytology and urinary schistosomiasis (OR = 5.3, p = 
0.005; 95% CI 1.66 – 16.97). 
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DISCUSSION 
 
 
FGS, cervical cancer and HIV affect women and girls in developing countries. Evidence 
suggesting the link between HIV and schistosomiasis are discussed in several studies (Mbabazi 
et al. 2011; Jourdan 2013; Kleppa et al. 2014).The link between schistosomiasis and cervical 
cancer has been more challenging to establish. 
 
Population characteristics and risk factors: In South Africa the highest mortality from cervical 
cancer occurs among Black women (De Abreu, Horsfall and Learmonth 2013). Based on their 
general characteristics of environment, age, poverty, lack of knowledge of risk factors and lack 
of knowledge on appropriate health care, our study population appeared no different from other 
South African rural women who experienced several barriers towards cervical cancer 
screening. This results in women mainly being diagnosed in advanced stages of cervical cancer 
highlighted earlier (Learmonth, van Vuuren and De Abreu 2015). 
 
Sexually transmitted HPV infection has been implicated in almost 100% of invasive cervical 
cancers (Walboomers et al. 1999). Other established risk factors include early onset of sexual 
activity, high number of lifetime sexual partners, parity, young age at full term pregnancy, use 
of oral contraceptives, immunosuppression and smoking (Berrington and Green 2007). More 
than half of our study population had at least one child which indicates that there were engaging 
in unprotected sex. The majority of atypia was found in the LSIL category which comprises 
active HPV (koilocytosis) and histologically CIN1. It is known that HPV infections with or 
without cytological dysplasia can resolve spontaneously (Stanley 2006). 
 
In developed countries, screening of young women is therefore a controversial topic since there 
may be a tendency to over-treat (Szarewski and Sasieni 2004). Infections with the high 
risk/carcinogenic genotypes of HPV more often lead to cervical cancers, including types 16, 
18, 31, 39, 45, 52 and 58 (Walboomers et al. 1999). 
 
 
The International Agency for Research on Cancer (IARC) has defined the following 12 types 
as carcinogenic (meaning that they have sufficient evidence for carcinogenicity) 16, 18, 31, 33, 
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35, 39, 45, 51, 52, 56, 58, 59 and types 26, 53, 66, 67, 68, 70, 73, and 82 have been identified 
as the group that has limited evidence for carcinogenicity (International Agency for Research 
on Cancer 2007). In the present study a challenge was to decide on the course of further 
management of cervical atypia in 68% of young women who are also at risk for HIV and 
schistosomiasis. It was therefore decided from a public health perspective to evaluate the 
carcinogenicity of HPV through using HPV genotyping among a subsample of 10 HSIL cases 
using the residual LBC samples. 
 
 
 
Conventional Pap smears versus LBC: LBC is an advanced method since cells are collected 
and placed into a liquid preservative medium. The sample is further processed in the laboratory 
using an automated technique whereby the cells are concentrated into a 1cm circular area on 
the slide (Maharaj and Munthree 2007). This process is advantageous compared to conventional 
cytology since excess background material like blood and mucus are removed. When the 
cytology preparation has been made, further testing on the residual LBC sample is possible 
(Hutchinson et al. 1999). A previous study in which HPV DNA was analyzed using 21 day old 
residual LBC samples showed successful results (Dixon et al. 2010). Our samples were stored 
12 to 18 months. In the present study, there was concern about the viability of the LBC samples 
since they were stored for an extended period in ambient temperatures. Despite this, the samples 
proved adequate for HPV DNA analysis. It was also of concern that of the 19/833 (1.4%) young 
women having HSIL, all 10 who were typed for HPV had one or more of the carcinogenic 
types. 
 
Cytology detection of schistosomiasis: The detection of schistosomiasis using cytology was 
low as found previously in similar studies (Feldmeier, Helling-Giese and Poggensee 2001; 
Poggensee and Feldmeier 2001); (Pillay submitted 2015). The diagnostic yield using LBC 
however was higher than conventional Pap smears. Inclusion of LBC sampling improved the 
diagnostic quality of the cytology results in comparison to traditional Pap smears. This could 
contribute to the higher detection rate of cervical cell atypia. While an association of squamous 
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atypia with genital schistosomiasis in Pap smears and with urinary schistosomiasis was found, 
this should be viewed in context. The relationship between schistosomiasis and cervical cancer 
is complex, and while there could be a strong association among these entities, in this study it 
was not possible to prove causality or eliminate the confounders. Previous studies have shown 
that women with HIV have an increased risk for HPV infection and invasive cervical cancer 
compared to HIV negative women (Manzini 2001; Sasco et al. 2010). 
 
 
 
 
CONCLUSIONS AND PUBLIC HEALTH PERSPECTIVE 
 
LBC had several advantages over conventional Pap smears in this study. LBC sampling 
improved cytology diagnostic quality and yield and rendered the opportunity for additional 
molecular testing, shown by the HPV genotyping in a small subset. It is of interest to explore 
if Schistosoma DNA testing could be additionally done in the residual LBC stored at ambient 
conditions. If that can be done, such a diagnostic triage would greatly benefit health care 
possibilities in low resource areas. The disadvantage of LBC sampling is that it costs 
considerably more than conventional Pap smears and requires some automation for further 
processing. Despite the disadvantages, collecting LBC samples especially among studies 
conducted in rural settings, where opportunities for repeat Pap smears and follow up are 
challenging, might be more effective and of value in enhancing the diagnosis and identification 
of high-risk HPV DNA for further management. 
 
 
 
Cytology was useful in revealing the extent of squamous atypia among this young population 
who is not routinely screened; a limitation is that it was not feasible to confirm these results 
using histology. While the solution to institute screening among a younger age group may not 
be practical considering that the current national South African cervical screening programme 
is finding it a challenge to implement among older women (Denny,   Quinn and 
Sankaranarayanan 2006). HPV vaccination is also an option for consideration especially if 
targeting primary school aged girls (Anorlu 2008; Moodley et al. 2013). More research is 
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required on the prospect of screening women younger than the age of 30 especially if they have 
multiple risk factors such and have early onset of sexual activity in developing countries. 
 
HPV genotyping is potentially beneficial as a complementary diagnostic indicator in 
identifying carcinogenic types and this can inform the further management of young women 
with HSIL. The long term benefit for endemic populations is to be educated about 
schistosomiasis and cervical cancer risks and given options for appropriate health care in order 
to reduce the prevalence of these preventable diseases. 
 
In this study, we have shown that residual LBC material can be used for HPV genotyping in a 
non-frozen state, and we postulate that the same material could be used as a triage for 
Schistosoma PCR together with cytological analysis. In rural areas it would be beneficial to 
investigate cervical atypia and sexually transmitted infections together with HPV and 
Schistosoma DNA analysis, for risk assessment and management of cervical atypia and 
antischistosomal treatment. 
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8.0 CHAPTER EIGHT 
 
 
8.1 Paper 5-Short Communication 
 
 
Preliminary findings of the effect of prior treatment with Praziquantel on squamous atypia are 
described     in     young     women     at     risk     for     female     genital     schistosomiasis. 
Pavitra Pillay, Myra Taylor, Hashini N Galappaththi-Arachchige, Borghild Roald and Eyrun F 
Kjetland. 
 
In manuscript. 
 
 
The purpose of writing this short communication is to consider the study objective on the effect 
of anti-schistosomal treatment with Praziquantel on squamous cell atypia (SCA). At the onset 
of the research it was postulated that the mass drug administration (MDA) would be rolled out 
in the study communities and that we could measure the effect of cervical atypia in relation to 
mass treatment at baseline and post treatment. The MDA did not occur as planned since there 
were many logistical and community issues that were beyond the control of this study. Instead 
MDA was done in a few schools at the time of writing and it was not possible to determine who 
had received treatment. 
 
My role in addressing this aspect of the research was to conduct the analysis of the cytology 
results at baseline. In order to attempt to address the research question, it was decided to use 
information pertaining to prior anti-schistosomal treatment received from the questionnaire 
data. 
 
The findings allude to a possible benefit of prior treatment with less atypia found in the group 
that reported prior treatment, however the results are preliminary and were insufficient to 
completely address this objective. Further research on the effect of anti-schistosomal treatment 
is required. 
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HIV human immunodeficiency virus 
FGS female genital schistosomiasis 
SCA squamous cell atypia 
LBC liquid-based cytology 
 
LSIL                 low grade squamous intraepithelial lesion 
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WHO                World Health Organization 
MDA mass drug administration 
 
HPV human papillomavirus 
DNA deoxyribonucleic acid 
PCR polymerase chain reaction 
SADOH South African Department of Health 
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ABSTRACT 
 
 
 
 
Background:   Efforts   to   eradicate   schistosomiasis   using   the   anti-schistosomal   drug 
 
Praziquantel have been undertaken over many decades, yet we are still faced with an estimated 
 
260 million people at risk in Africa. Female genital schistosomiasis (FGS) is hypothesized to 
increase the risk of HIV and cervical cell atypia. Anti-schistosomal treatment could potentially 
reduce morbidity and prevalence of other diseases such as HIV infection, and perhaps, cervical 
lesions. Preliminary findings on self-reported anti-schistosomal treatment are described in 
relation to schistosomiasis and squamous cell atypia (SCA). 
 
Methods: Young women aged 16-23 years from rural high schools in KwaZulu-Natal were 
included. Urine microscopy was undertaken and a questionnaire was administered. Cytology 
Pap smears and Liquid based cytology (LBC) samples were investigated for schistosomiasis 
and SCA from 833 young women. 
 
Results: The participants were sexually active from a mean age of 18 years, more than half had 
at least one child 528 (63%) and the majority 770/833 (92.4%) relied on rivers as their primary 
water source. Only 151 (18.1%) of the young women reported having taken anti-schistosomal 
treatment previously. The Schistosoma haematobium ova detected cytologically and in urine 
microscopy was 12 (1.4%) and 178 (21.4%) respectively. SCA was detected among 567 (68%) 
of which, 19 (2.3%) were diagnosed with high grade squamous intraepithelial lesion (HSIL). 
Of those with S. haematobium in cytology and urines, 9/12 (75%) and 104/178 (58%) reported 
no previous treatment (or unsure) for schistosomiasis. The findings were non-significant. None 
of the participants who had HSIL had been treated for schistosomiasis previously. 
 
Conclusion: Of the group that recalled having received Praziquantel treatment there was a 
lower prevalence of SCA and schistosomiasis than among those who were unsure of prior 
treatment or not previously treated, the sample size was however small and further research is 
required. 
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INTRODUCTION 
 
 
Urogenital schistosomiasis, affects approximately 260 million people from Africa (World 
Health Organisation 2015).The anti-schistosomal drug Praziquantel has been in use for decades 
yet schistosomiasis remains a public health burden (King 2015). Female genital schistosomiasis 
(FGS) is caused by damage to mucosal surfaces by the parasite Schistosoma haematobium. It 
is hypothesized that alterations to the genital mucosa could make women more susceptible to 
acquiring HIV infection as well as cervical atypia (Jourdan 2013); (Kjetland,  Leutscher and 
Ndhlovu 2012) One report indicates that genital lesions are prevented or resolve if anti- 
schistosomal treatment is taken in the early years as opposed to in adulthood (Kjetland et al. 
2008). 
 
 
 
 
The World Health Organization (WHO) set goals to treat 75% of school age children in 
endemic countries by 2010 (World Health Organisation 2015). In response, a mass drug 
administration (MDA) pilot programme was implemented in KwaZulu-Natal, South Africa in 
the period 1997 to 2001 by the South African Department of Health (SADOH) (Johnson and 
Appleton 2005).This programme resulted in a (95.3%) reduction in ova excretion and heavy 
infections were also reduced (Johnson and Appleton 2005). The national policy of annual MDA 
has however not been implemented although occasional initiatives such as  Ugu District 
Department of Health in 2012 sometimes provide local, limited MDAs. 
 
 
 
The SADOH has yet to implement its policy from 2008 and the Integrated School Health 
Programme from 2012 for treatment of helminth infections (Department of Health and Basic 
Education 2012); (Department OF Health 2008). One of the reasons for the lack of MDA 
programme implementation in South Africa is the high cost of brand Praziquantel, which has 
been calculated as 50 times higher than the costs of generic anti-schistosomal treatment that is 
offered for free to all in other countries in Africa (Berge et al. 2011). Introduction of generic 
drugs in South Africa require that the donor embarks on a costly, bureaucratic process for 
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approval from the South African Medicines Control Council who will not accept medication 
accredited in foreign institutions (Berge et al. 2011). 
 
 
 
Praziquantel is effective in killing adult schistosomal worms and administered as a single dose 
of 40mg/kg. Previous studies have found that in Schistosoma infections that are untreated or 
treated too late could have serious implications for health and the social well-being (King, 
2015). Viable or dead ova trapped in tissues of the genito-urinary tracts can cause pathology in 
both males and females (Gryseels et al. 2006; Leutscher et al. 2008; Stecher et al. 2015). 
 
 
 
FGS has been associated with secondary infertility, menstrual disorders and ectopic 
pregnancies but the effect of treatment has not been explored (Leutscher et al. 1998; Poggensee 
and Feldmeier 2001; Kjetland et al. 2006). In a non-blinded case control study among adults 
(Magak et al. 2015). In the present study among young females we sought to explore the effect 
of self-reported prior anti-schistosomal treatment on young women with squamous cell atypia. 
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MATERIALS AND METHODS 
 
 
This was a cross sectional study with a nested prospective study in an area where high schools 
had been offered treatment by the Department of Health. Females aged 16-23 years were invited 
for gynaecological investigations, the ethics, methodology for sample collection and processing 
have been described previously (Holmen et al. 2015; Kleppa et al. 2015); (Pillay et al submitted 
2015). Figure 1 shows that 833 underwent gynaecological examinations and Pap smears, gave 
urine samples and answered an interview administered questionnaire. This included a question 
in isiZulu (the local language), “Have you ever been treated for Bilharzia (using the local word 
“isichiene” the local word for Bilharzia), response: (yes/no). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow of participation showing baseline and follow up 
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RESULTS: 
 
 
All participants were recruited from schools where Praziquantel drug administration had been 
offered previously, but only 151/833 (18.1%) reported ever having received treatment (Table 
1). The participants reported being sexually active from a mean age of 18 years (SD 9.97), and 
more than half 528 (63%) had at least one child and the majority 770 (92.4%) relied on rivers 
as their primary water source. The Schistosoma prevalence detected cytologically and via urine 
microscopy was 12 (1.4%) and 178 (21.4%) respectively. Squamous cell atypia was detected 
among 567 (68%) of which, 19 (2.3%) were diagnosed with high grade squamous 
intraepithelial lesion (HSIL). Of the participants who were positive for schistosomiasis in Pap 
smears, only 3/12 (25%) young woman had reported receiving prior anti-schistosomal 
treatment. Of those who had Schistosoma ova detected in urine only 74/178 (41.5%) had been 
treated previously.  Squamous atypia was found among 104/567 (19.0%) of the women who 
reported prior anti-schistosomal treatment (Figure 2) 
 
 
 
 
Table 1: Number of participants who reported prior anti-schistosomal treatment 
 
 
Treated for Bilharzia  n= 833 
Number (%) 
No                                                                                317             (38.1) 
Yes                                                                               151             (18.1) 
Unsure                                                                          365             (43.8) 
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Figure 2. Comparing the occurrence of SCA and Schistosomiasis as detected in Pap smear 
cytology and urine microscopy among participants who reported prior antischistosomal 
treatment, no treatment or were unsure of prior treatment. 
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DISCUSSION 
 
The prevalence of squamous cell atypia and schistosomiasis among the young women who had 
reported that they received prior anti-schistosomal treatment was significantly lower than 
amongst those who did not report prior treatment. The women in our study population had high 
levels of both schistosomiasis and SCA. Known contributing factors are the age of sexual debut 
which was not unusual in this population. More than two thirds of these young school going 
women had at least one child, indicating unprotected sex. In young women who had received 
prior treatment, none had HSIL, and it may be possible that prior treatment in these young 
women could have influenced this. 
 
 
 
The exact timing of the anti-schistosomal treatment was not known. Furthermore the diagnostic 
tools were inadequate. HPV DNA genotyping would have provided information on this co- 
infection as an ultimate cause of the atypia. Furthermore Schistosoma PCR would have 
supported the diagnosis. A further limitation to this study was the low uptake of mass treatment, 
at 43% as reported previously (Randjelovic et al. 2015). 
 
 
 
Furthermore, not all women seen at baseline came for a follow-up visit. In some instances 
contact details provided by participants had changed or were incorrect, or participants had 
moved to another area. The findings may represent a Type 2 error due to the small number of 
women who reported having received prior treatment. 
 
 
 
These are preliminary findings and the confounders have not been fully explored. The MDA 
did not occur at the planned time due to rejection of donated generic Praziquantel from the 
WHO. It was therefore not possible to measure the effect of Praziquantel on genital lesions at 
the time of writing. Further, the information on prior Praziquantel treatment was only the self- 
reported information 
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CONCLUSION 
 
In order to implement MDA programmes, it is necessary to first complete mapping which 
entails identifying the prevalence of schistosomiasis, once this is done then targeted mass drug 
administration can occur  and should reach the 75% coverage envisioned by the WHO. 
Diagnostic are required during the different phases of MDA (Utzinger et al. 2015). Political 
will must be there to ensure that participants are not only given a once off dose of anti- 
schistosomal drugs but repeated treatment options need to be considered to prevent reinfection, 
and to ensure sustained elimination of this parasitic infection (King 2015). 
 
 
 
Further investigation on the effects of adequate anti-schistosomal treatment on genital lesions 
is warranted and several rounds of treatment may be necessary (Kjetland et al. 2008). 
Furthermore, the role of genital schistosomiasis on the infection and persistence by human 
papillomavirus (SCA) should be explored. The extremely high prevalence of young women 
with squamous cell atypia requires both further research and public health interventions, in the 
risk assessment and for further management of squamous cell atypia. 
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9.0 CHAPTER NINE 
 
9.1 Unpublished Cytology Results 
 
 
 
Other micro-organisms identified cytologically, but not included in the written manuscripts are 
listed in Table 1.4. Trichomonas vaginalis, Bacterial vaginosis and Herpes simplex virus are 
sexually transmitted infections in addition to HPV that was found among the young women. 
 
 
Table1.4  Cytologically detected micro-organisms among the young women from the 
south and north coast regions 
 
 
Characteristics Number (%) 
Study population south coast region 394 
Standard 
Deviation 
 
Schistosoma haematobium 8 (0.2) 0.14 
Trichomonas vaginalis 47 (11.9) 0.32 
Bacterial vaginosis 133 (33.8) 0.47 
Candida albicans 53 (13.5) 0.34 
Lactobacillus 108 (27.4) 0.45 
Herpes simplex virus 1 (0.2) 0.50 
Study population north coast region 833 
 
Schistosoma haematobium 
 
12 
 
(1.4) 
 
0.48 
Trichomonas vaginalis 59 (7.1) 0.26 
Bacterial vaginosis 250 (30) 0.46 
Candida albicans 99 (11.9) 0.32 
Lactobacillus 403 (48.4) 0.50 
Herpes simplex virus 7 (0.8) 0.91 
Ascaris lumbricoides 6 (0.7) 0.85 
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10.1 Synthesis 
10.0 CHAPTER TEN 
 
The hypothesis that young women from Schistosoma endemic populations in our study are at 
risk for HPV and squamous cell atypia of the cervix is confirmed. We found there was an 
association between the squamous cell atypia and schistosomiasis. Diagnostic tools for FGS 
namely, Pap smear and LBC cytology; Schistosoma PCR in urine and cervico-vaginal lavage; 
and urine microscopy were used and compared to investigate this. The full effect of mass 
treatment was not possible to investigate since the roll-out of mass treatment had not occurred 
at the time of writing, however preliminary results of reported prior treatment and the effect on 
cervical squamous atypia are considered. In each investigation conducted in this study, the 
public health effects have been discussed and recommendations have been made with respect 
to reducing the burden of FGS and SCA. 
 
 
Prevalence of SCA and other cytopathology in the presence of FGS among young women: 
Among the young women in our study population SCA was detected using cytology samples 
with 27% of SCA found in the south coast (Paper 2) and 68% using two different methods of 
detection in the north coast (Paper 4). The prevalence of schistosomiasis in both regions was 
focal using microscopy it was 21.4% in the north coast and 19.7% in the south coast. Paper 2 
shows that squamous atypia was not associated with schistosomiasis but this could represent a 
Type 2 error, since the prevalence of schistosomiasis, as found by Pap smear cytology and 
Schistosoma PCR was quite low. Paper 4 shows that there was a significant association between 
squamous atypia and schistosomiasis, determined by Pap smear and LBC cytology. It was not 
possible to establish in young women with both genital schistosomiasis and cervical squamous 
cell atypia which disease acted as a catalyst for the other. Previous studies are contradictory, 
some studies indicate that there is an association but there are also studies which have found no 
association between schistosomiasis and cervical atypia. It has been hypothesized that   the 
damage to mucosal linings in genital schistosomiasis could make young women more prone to 
HPV infection (Kjetland et al. 2009a). 
 
 
In South Africa it was reported that women have a 1 in 35 lifetime risk of acquiring cervical 
cancer (Ferlay et al. 2010). Cervical cancer is one of the few cancers that can be prevented if 
detected and treated early. Regular screening for cervical cancer using Pap smears, has resulted 
in a decline in cervical cancer among many developed countries, however this cancer is 
reported to be the second most common cancer among South African women (Moodley et al. 
2006). Most of the squamous cell atypia in our study was in the LSIL category; it was also 
concerning that a few cases of HSIL (7/394 in the south coast and 19/833 in the north coast) 
were found among these young women. Among a subsample of 10 HSIL cases from the north 
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coast region, HPV genotyping revealed one or more of the identified high-risk or carcinogenic 
types of HPV (Paper 4). HPV infections have the highest prevalence among young women at 
the onset of sexual activity, in their teens, 20s, or 30s and cervical cancer is estimated to take 
about 20 years after the initial HPV infection to develop (Cuzick et al. 2008). HPV infections 
are also known to regress spontaneously even amongst those who have SIL (Walboomers et al. 
1999). In our study population, young women may face an additional health burden of HIV 
(Directorate Epidemiology 2013). Studies in women with pre-cancerous cervical lesions and 
HIV infections have shown that lesions tend to persist and progress to invasive cancer at a much 
faster rate (Moodley et al. 2006; Adam et al. 2008). An additional exacerbating fact is that most 
women are unaware of cervical cancer or the importance of screening and usually present when 
in the advanced stages of cancer. It has been reported that women in Sub-Saharan Africa lose 
the most  years of life to cervical cancer compared to than other cancers (Anorlu 2008). 
 
 
In an FGS study conducted among Tanzanian women, additional STI’s that were found to be 
associated with gynaecological damage pre and post antischistosomal treatment, included 
Chlamydia, syphilis, gonorrhoea, trichomoniasis and cervical warts (Downs et al. 2013). In the 
present study, it was found that the young women in both the north and south coast had the 
following infective agents in their cytology samples, Trichomonas vaginalis, Bacterial 
vaginosis, Candida albicans, Lactobacillus and Herpes simplex virus in addition to HPV. STI’s 
and schistosomiasis within the lower genital tract have been suggested as agents which favour 
the acquisition of HIV, and although many studies in Africa usually consider the effects of most 
STI’s in HIV acquisition, the effects of schistosomiasis seems to be a neglected entity (Kjetland 
et al. 2014). 
 
 
It is not known how early FGS occurs and in this study among 10-12 years old girls the aim 
was to explore this (Paper1). It was also not possible to directly identify squamous atypia 
among the young girls as gynaecological examinations are not ethical. Information pertaining 
to genital symptoms was acquired using self-reported questionnaire data (Hegertun 2013). The 
inclusion of the following genital symptoms, were regarded as an indirect marker for atypia in 
the genitals: discharge, bleeding, ulcers, tumours and pain. It was found that 35% of the girls 
had genital symptoms even before the onset of sexual activity (Hegertun et al. 2013). On 
comparing these genital symptoms with the Schistosoma PCR results a significant association 
between the two entities was found at the school level (Paper1). This was the first study among 
pre-pubertal girls where an association between schistosomiasis and genital symptoms was 
found at the school level and these findings support previous studies in which there has been 
the suggestion that genital Schistosoma infections occur in early childhood (Poggensee and 
Feldmeier 2001; Prabhakaran and Brown 2004; Kjetland et al. 2009a). 
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In (Papers 2 and 4) we report on the risk factors identified in both our study areas, where it 
was found that the mean age of sexual debut among the young women was 16 and 18 years 
respectively. Of the young women in the study sample, in the South coast 41% had one child 
while 63% had one child in the north coast. The young women came from rural areas where 
poverty and unemployment is rife, and in both study areas, rivers were the most common water 
source reported by 71% in the south coast and 94% in the north coast respectively. When 
comparing the overall prevalence of squamous atypia and schistosomiasis, it was found that the 
north coast region had a higher prevalence of these two entities as compared to the south. The 
following are thus potential risk factors; having at least one child, water contact with rivers 
infested with schistosomiasis, and young age at sexual debut. 
 
 
Our findings could be the result of other social and cultural challenges that young women in 
South Africa face. It has been reported that teenage pregnancy is a common occurrence and 
that sexual activity commences in the mid-teenage years, where boys particularly have multiple 
sexual partners (Jewkes et al. 2001). Young women in South Africa have little power over their 
sexual encounters, which are sometimes forced or coerced (Maharaj and Munthree 2007). Other 
factors such as poverty and lack of education are factors which contribute to the 
disempowerment of young women in negotiating their sexual encounters (Manzini. Ntsiki 
2001). The finding of atypia with the potential to become invasive cancer among a young non- 
routinely screened population should not be underestimated. 
 
 
 
 
Early diagnostic tools for FGS 
 
Since it is known that invasive sampling techniques to detect FGS in the lower genital tract of 
young women who may be also at risk for HIV and other sexually transmitted infections is not 
a possibility, this study investigated the role of Schistosoma PCR in urine and cervico-vaginal 
lavage samples. Urine microscopy was used to compare the PCR results. Schistosoma ova were 
also detected using Pap smears and LBC samples. 
 
 
Schistosoma PCR testing among 708 girls revealed that this test was significantly associated 
with single urine microscopy, and since there was a considerably large sample from which the 
Schistosoma PCR analysis was run, these findings are in support of Schistosoma PCR in 
cervico-vaginal lavage being used as a standardized diagnostic technique to identify 
populations at risk for FGS. The additional association with genital symptoms indicates that 
FGS exists among the girls in the study population. (Paper1). 
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Among the participants from the south coast, Schistosoma PCR in urine and cervico-vaginal 
lavage samples were done and these results compared to urine microscopy (Paper 2). All three 
testing methods for Schistosoma identification were significantly associated. There was a 
higher prevalence of schistosomiasis among cervico-vaginal lavage samples 107/394 (27.1%) 
than in the Pap smears 8/394 (2.0%) and the low sensitivity of Pap smears was consistent with 
a previous study (Feldmeier,  Helling-Giese and Poggensee 2001).  In this study in 3/8 
(37.5%)young women there was evidence of schistosomiasis in the genital tract being seen in 
Pap smears and in cervico-vaginal lavage without being found in the urinary tract. This is an 
important finding since it suggests that urine microscopy alone may not be the best indicator 
for FGS. 
 
In the light of the low detection rate of schistosomiasis using traditional Pap smears it was 
decided to use an alternative method of collecting cytological material from the cervix, namely 
LBC sampling (Papers 2 and 4). Using LBC cytology resulted in an improvement in the 
preservation and diagnostic quality of the sample and the detection of schistosomiasis was 
slightly improved using LBC sampling. This was a novel method of cytological analysis in an 
FGS study, since all previous studies have used the conventional Pap smears (Feldmeier, 
Helling-Giese and Poggensee 2001; Randrianasolo et al. 2015). Using the LBC sampling also 
brought in the possibility of adding a novel triage of testing for FGS populations using 
diagnostic cytology and molecular testing for HPV DNA and Schistosoma PCR (Paper 4). The 
use of complementary HPV genotyping in identifying the following 37 HPV types: 6, 11, 16, 
18, 26, 30, 31, 33, 35, 39, 40, 42, 43, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 67, 68, 69, 70, 73, 
 
74, 81, 82 ,83, 86, 87, 89, 90, 91 will be considered in a follow-up study to inform further 
management among the young women with cervical atypia. 
 
In a South African study that was conducted by the National Health Laboratory Services, 
investigating the cost effectiveness of LBC against conventional cytology it was found that the 
LBC results were comparable to conventional cytology based on the detection of CIN2 or 
higher lesions detected. Additionally it was reported that within the public sector the cost per 
slide for a conventional Pap smear was R64 compared to R85 for an LBC slide (de Jager et al. 
2013). The findings of comparable sensitivities in detecting cytological atypia, are in contrast 
to the findings of the present study and they do not take into consideration the benefits of 
additional testing for HPV. In research settings, where there are limited opportunities for repeat 
smears and in order to ensure that many of the diagnostic tests are done with minimal sampling 
would thus favour LBC sampling, despite the cost difference when compared to conventional 
Pap smears. 
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In Paper 3, we compare the diagnostic performance of non-invasive laboratory tests across five 
regions from three countries in Africa which are endemic for schistosomiasis (S. haematobium 
or S. mansoni). In this study 903 cervico-vaginal lavage Schistosoma PCR assays were 
completed collectively, and the results from this analysis confirmed that the PCR assay has a 
higher sensitivity in detecting genital schistosomiasis than other techniques like cytology. 
There was also generally a higher Schistosoma detection rate among the urine and stool PCR 
assays compared to urine and stool microscopy. Since the PCR assay was able to detect 
schistosomiasis in the young women who had low DNA loads, such an assay could be useful 
in low endemic areas. The drawback of the PCR assay is that it was unable to differentiate 
between the S. haematobium and S. mansoni and the assay that we used is not field applicable. 
Samples for PCR analysis also have to be stored in frozen conditions to ensure optimal results. 
 
 
 
Effect of treatment on early stages of genital disease 
 
The precise effect of the antischistosomal drug Praziquantel on genital tract lesions is still under 
investigation, although prior studies have inferred that early treatment may help in the 
resolution of lesions and that lesions among women remain unchanged with treatment (Richter 
2000; Kjetland et al. 2008) The genital lesions identified in FGS include sandy patches, 
abnormal blood vessels, contact bleeding and rubbery papules (Norseth et al. 2014; 
Randrianasolo et al. 2015). In a study among Tanzanian women it was concluded that early and 
frequent doses of Praziquantel should be administered to populations at risk, to help prevent 
the possible long term effects of genital schistosomiasis (Downs et al. 2013). 
 
 
In this study, there were delays in the acquisition of the anti-schistosomal drug Praziquantel as 
well as delays in the anticipated rollout of the MDA programme among schools in the study 
area. These challenges were beyond the control of the research team. Due to this it was not 
possible at the time of writing to fully explore the effects of treatment on genital lesions. This 
objective is considered in Paper 5 -Short Communication, where questionnaire data 
pertaining to whether participants had received prior treatment were compared to squamous 
atypia. The findings revealed that women who had received prior treatment had overall less 
squamous cell atypia, and that of the 12 cases with HSIL that were detected cytologically, none 
of these women had received prior treatment. The other results were variable and it was not 
possible to draw any solid conclusions about the effect of treatment. 
 
 
While there are other risk factors like early sexual debut, number of sexual partners, pregnancy 
at an early age, it is established that HPV types 16 and 18 are associated with almost 100% of 
invasive cervical cancers (International Agency for Research on Cancer 2007). 
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9.2 Limitations 
 
Mostly we report cross-sectional studies that cannot inform about the direction of the 
associations between for example FGS and SCA. 
 
 
For Schistosoma PCR assays to be performed ensuring optimal DNA preservation samples 
must be stored at -800C once collected. In our study, when the initial PCR analysis was done 
on urine samples and cervico-vaginal lavage samples they were stored a week at 40C and 
thereafter stored for several months at -800C before being transported under frozen conditions 
to the Netherlands. It was not possible to store them directly at -800C since there were logistical 
challenges with the freezers. Despite this, significant associations between the Schistosoma 
PCR tests and microscopy were found. It is possible that the performance of the PCR tests could 
have been slightly compromised due the initial challenges with storage. 
 
 
When Pap smears were collected in the south coast study area the preservation of the smears 
was not optimal for most of the samples. The clinicians and research assistants who were 
collecting the samples were made aware of the importance of proper fixation of smears and 
they made efforts to improve on the collection procedure, but with limited success. It is possible 
that the smear preservation was altered due to the sequence in which sampling was done since 
the cervico-vaginal lavage samples were collected prior to the Pap smears. In collecting lavage 
samples it is possible that the saline used could have altered the mucosal surface of the cervix, 
thereby causing the Pap smears to be poorly preserved. Despite Pap smears being sub-optimal 
a diagnosis was made where possible, and later LBC sampling was introduced. The LBC 
samples showed improved diagnostic quality and also offered the possibility of using further 
DNA testing to enhance the diagnostic techniques in FGS. 
 
 
The slow MDA among the study participants was a limitation. At the onset of the main research 
project it was planned that research would occur simultaneously with the roll-out of 
antischistosomal treatment which was co-ordinated by the Department of Health. This process, 
however had faced many setbacks, among the most important was the late release of funds for 
the MDA, there was also insufficient collaboration between all sectors, like health, education, 
water and sanitation. One of the major reasons for poor or limited implementation of MDA in 
South Africa is the high cost of Praziquantel tablets, and the challenges with getting cheaper 
generic drugs registered with the Medicines Control Council in South Africa. Using the self- 
reported questionnaire data on prior receipt of Praziquantel treatment to assess the effect of 
treatment is a form of recall bias. This is a limitation since some of the participants could have 
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answered this question incorrectly because the response is dependent on memory. The accuracy 
of the recall was not possible to measure and therefore these results must be treated with 
reserve.  If MDA had occurred as planned, assessing the effect of treatment on genital lesions 
would have been more accurate if young women were followed over time, using biomarkers 
instead. 
 
 
Despite these limitations, it is promising to note that at a recent meeting held on the 9th  of 
November 2015 with the following stakeholders, the research project team, District Health 
Managers and School Health Nurses, a representative from the WHO and gynaecologists, 
doctors and nurses from local district clinics and hospitals, a resolution toward the 
implementation of MDA was pledged and agreed to by all stakeholders. The research project 
members had also presented some of the health concerns around the impact of FGS to raise 
awareness and to promote the importance of providing anti-schistosomal treatment to those at 
risk. 
 
 
Further difficulties occurred with the tracking of the young rural women after the baseline 
analysis since often original details provided by participants had changed or were sometimes 
incorrect, or participants had moved to another area and it was difficult to trace them. Some 
participants also refused follow up and treatment. 
 
 
This study focussed only on girls and young women who are at risk for schistosomiasis. Male 
genital schistosomiasis (MGS) is also an important neglected entitythat was not considered. It 
has been reported that among males, urogenital schistosomiasis peaks around the second 
decade, additionally, young men are also prone to STIs around this time of their lives as well 
(Leutscher et al. 2008). It has been reported that diagnosing MGS is also challenging, since like 
genital schistosomiasis, the effects of MGS may be undetected or misdiagnosed (Leutscher et 
al. 2008). Further research is required on MGS and the possible effects with HIV transmission 
as well as other STI’s, since the information on MGS is limited (Stecher et al. 2015). 
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11.0 CHAPTER ELEVEN 
 
 
 
11.1 Conclusions and Recommendations 
 
In conclusion, this research has revealed that girls and young women in Schistosoma endemic 
areas are at risk for cervical squamous cell atypia. Contributing risk factors for young women 
from rural areas include poverty since in both study areas the majority relied on rivers as their 
main water source as well as age at sexual debut and having at least once child. As a result, the 
neglect in the identification and management of schistosomiasis and cervical squamous cell 
atypia may in part contribute to the high prevalence rates for invasive cervical cancer and HIV 
in KwaZulu-Natal. While this study was unable to prove a causal relationship between 
schistosomiasis and cervical cell atypia, it must be noted that both these entities are prevalent 
amongst our young female population and it is important for policy makers to ensure that this 
is addressed. Bearing in mind the fact that women in Sub-Saharan Africa lose most life years 
to cervical cancer than any other cancer, health promotion should be targeted at girls and young 
women to ensure that they are at least aware of the consequences of risky sexual behaviour. 
 
 
Schistosomiasis continues to be a problem affecting many girls and young women in KwaZulu- 
Natal. The focus of this study was on the female sex and did not include males, and those using 
contaminated water sources who are also at risk of schistosomiasis infections. 
 
 
An essential step in addressing this health problem is to get support and involvement from 
communities, but for this to occur, people need to be made aware of these diseases. A 
programme in which young girls and boys in high schools are identified and trained to help 
impart knowledge to others in their communities may be an option to consider, since in this 
way, youth are not only educated, but they are empowered by being given some responsibility 
in communities to help improve health status. In KwaZulu-Natal the school health teams visit 
schools and can inform both educators and learners (Randjelovic et al. 2015).  It is also 
recommended that while health education can be spread though schools, it would also be 
appropriate for youth health clinics to be set up so that youth can seek appropriate health care 
that includes testing for infections more easily. 
 
 
Schistosomiasis is a focal disease which depends on the distribution of the snail species Bilinus. 
The use of real-time PCR as a method to determine the prevalence of schistosomiasis in a large 
volume of samples to improve the targeting of the MDA using Praziquantel to treat the infection 
and reduce or prevent the morbidity caused by schistosomiasis, is promising. 
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While it was not possible to directly diagnose FGS among young 10-12 year old girls, their 
reported symptoms suggest early FGS infections. There is the possibility of using “non- 
invasive” sampling devices like the use of a sleeve that is placed into a girl’s underwear to 
collect vaginal discharge for PCR analysis. This analysis should include both Schistosomiasis 
and HPV and further research into devising and implementing such a device needs to be 
considered. Regular MDA with Praziquantel must be implemented depending on the 
prevalence. In light of the high prevalence of invasive cervical cancer among South African 
women, policy makers need to ensure the regular implementation of HPV vaccination among 
young girls. 
 
 
 
 
Among the older cohort, it was also found that non-invasive diagnostic tools like LBC cytology 
and Schistosoma PCR in cervico-vaginal lavage samples together with HPV DNA testing could 
improve the detection of genital schistosomiasis. While traditional cytology was found to be 
limited, LBC sampling showed an improved detection rate and there is room for further 
research investigating the use of Schistosoma PCR testing in residual LBC samples. Further 
research comparing the clinical data including the colposcopy findings is recommended. 
 
 
It was not possible to fully investigate the effect of antischistosomal treatment on genital lesions 
among the participants however, cervical atypia among young women who are at risk also for 
HIV is of major concern. It might be argued that finding cervical atypia among a young 
population could not be too concerning since most cervical atypia caused by HPV infections 
tend to clear within 24-36 months. However the findings of one or more high risk HPV in the 
sub-sample of young women with HSIL is of concern. Prior studies have concluded that 
cervical atypia can persist and progress to invasive cancer much quicker among women with 
HIV. KwaZulu-Natal has a high prevalence of HIV amongst this age group (Directorate 
Epidemiology 2013). 
 
 
Cervical cancer is the second most common cancer in South Africa, and while invasive cancer 
is known to occur in women over the age of 30, the precise impact of HIV and schistosomiasis 
on cervical atypia is not fully understood. The reported genital symptoms among girls and 
presence of cervical atypia among the young women from our Schistosoma endemic 
populations, warrants immediate and repeated mass drug administration. , Especially among 
young children, girls and young women as a priority to help reduce the negative consequences 
of FGS. While it not be feasible to implement cervical screening among young women below 
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the age of 30, it is important for policy makers to be aware of the possible impact FGS and HIV 
 
on cervical atypia, and to design health literacy with these disease dynamics included. 
 
 
 
In KwaZulu-Natal, the number of school health teams has been increased and these teams will 
be informed about the results of this study. With emphasis on an increase in awareness of the 
problem of schistosomiasis the association with cervical atypia and the importance of anti- 
schistosomal treatment and early diagnosis and monitoring of atypia. In a province with 
endemic schistosomiasis, and high prevalence of HIV and high SCA, health literacy concerning 
these diseases is essential and the Department of Health has a critical role in increasing 
awareness. 
 
 
In terms of South Africa’s Constitution and Bill of Rights everyone has the right to health and 
clean water and adequate sanitation is an essential component. This has yet to be achieved and 
advocacy is required to ensure that these basic requirements are met and that sources of water 
are not contaminated. An intersectoral campaign by government departments is urgently 
required to achieve this. 
 
 
This study was undertaken in KwaZulu-Natal, but five of South Africa’s provinces are endemic 
for schistosomiasis and it is a disease prevalence in many Sub-Saharan countries. The results 
of this study indicating the association of schistosomiasis and SCA emphasise the relevance of 
early and regular MDA. 
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APPENDIX 3 
 
 
Female genital schistosomiasis (FGS) as an epidemiological risk factor for squamous cell 
atypia and genital disease in a longitudinal cohort of young women in KwaZulu Natal 
 
 
 
Information and request for participation in the research project 
 
 
 
 
We, the Universities of Oslo in Norway and KwaZulu-Natal, are doing research on Bilharzia 
 
To find out if and how Bilharzia affects young women. 
To investigate if treatment works better in the young. 
 
 
 
Why you are being asked to participate 
 
We know that treatment kills the Bilharzia worms and works for urinary disease. Previous 
research has shown that treatment did not work properly for genital damage in older adult 
women.  Now we wish to test it in young adults. We ask you 
 
 because you may have had contact with the parasite in the water 
 because you are still young 
 because we hope to protect you from genital damage from Bilharzia. 
 
 
Your decision 
 
Participation in the study is entirely voluntary and you may withdraw at any time. You may ask 
any questions and we will try to answer. You do not have to give a reason if you do not wish 
to participate. Your treatment now or in the future will not be affected by your decision. You 
may also interrupt any investigation as you wish. Approximately 2000 young women may 
participate. 
 
If you are pregnant you cannot join the study, but you are welcome to participate in the study 
two months after giving birth. 
 
Some of the investigations we do can be done at a hospital, but others are not yet available in 
South Africa and some samples may therefore be sent overseas but at no cost to you. 
 
 
 
 
Consequences for you 
 
151 
 
Participating in this study will mean that 
 
 you will give urine, stool and have blood tests, and an interview will be done 
 you  will  have  gynaecological  investigations  for  diseases.  The  gynaecological 
examination will last about 20 minutes. If there is reason to do more tests during the 
examination you will be asked for permission 
 you will be taken to the VIBE youth clinic by a female driver 
 samples will be tested for cancer, infections and HIV, and you decide if you want the 
results or not 
 you  will  receive  treatment  for  Bilharzia  as  recommended  by  the  World  Health 
Organisation 
 you might be asked to participate for a period up to 2 years 
 if we discover special problems during the interview or the investigation we will either 
refer you or treat you 
 you will lose half a day from school to participate in the study 
 
 
 
 
 
Gynecological examination 
 
You will have an ordinary gynaecological investigation to look for genital Bilharzia and other 
genital problems by experts. The procedure is uncomfortable and it is better if you relax. The 
examination will be done by a female doctor with a female nurse/assistant present in the room. 
The doctor will explain the procedure to you before the examination. 
 
 
 
 
Risks 
 
The tablets for Bilharzia may have side effects; some will feel sick for a couple of days. Some 
may get a rash, diarrhoea, or vomit. People with many worms feel worse as the worms die.’ 
 
Benefits 
 
You will receive treatment for any disease we discover at no charge and be referred if 
necessary. Your Bilharzia worms will die and you will feel healthier. 
 
 
 
 
How your samples and personal data are taken care of 
 
The information that we collect in research will provide new information about Bilharzia in 
women and we will share this information with health workers who need this. However no 
one will ever know about your personal information. Samples and the interview will be 
analysed and stored without your name on it. Anything with your name is stored separately. 
This will be done both before and after treatment so that the investigators can see if the 
disease is better. The specimens will be investigated in the best laboratories without your 
name. Samples might be sent to other countries for analysis by experts. If you agree to 
participate in the study, you also give permission for this. All information will be stored 
securely. The samples and information will only be used to study Bilharzia together with 
women’s diseases, risks for cancer and HIV for up to 20 years. It will not be used for other 
purposes. The Principal Investigators and the doctors of the study are formally responsible for 
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the security. These have access to the address file. If important information is discovered 
during the study we will make sure that you are informed, if you wish. 
 
 
 
 
Who approved the project 
 
The project has been reviewed and approved by the KwaZulu-Natal Department of Health 
and ethical committees in both South Africa and Norway. 
 
 
 
 
Economy 
 
The study is financed by research grants from abroad. There are no plans for collaborations 
with industry, nor plans for commercialization. The researchers involved in the study have no 
personal financial gain in connection with this study. 
 
 
 
 
Project Management/More information 
 
If you have any questions regarding the study, please feel free to contact the Principal 
Investigator and project manager: Dr M Taylor 031 2604499 or 2661592. 
 
 
 
 
Contact details in case you have problems. We will also contact the person below in case of 
adverse events: Biomedical Research Ethical Committee 
 
tel.: (031) 260 4769; fax: (031) 260 4609; e-mail: BREC@ukzn.ac.za 
 
The participants of the study:  Dr M Taylor, Dr J Kvalsvig 031 260-4499 (w) 2661592 (h) 
 
The Department of Public Health Medicine at the University of KwaZulu-Natal 031- 2604463 
 
Dr. Eyrun Kjetland, Department of Infectious diseases, University of Oslo, Norway 
+47 9700 8579, SOUTH AFRICA: +27 76 4920 800 (Cell) 
+27 31 205 6808 (Durban Office), +27 39 314 9612 (Field station) 
 
Dr Elisabeth Kleppa 079 194-2652 
 
 
 
 
Your rights 
 
If you agree to participate in the study, you have the right to access all personal information we 
have registered about you. You have the right to correct any faulty information. You may at 
any time withdraw from the study without having to explain your reasons. This will not affect 
your normal access to healthcare and treatment in any way. If consent is withdrawn, you may 
request material/ information to be destroyed/ deleted. 
 
Consent to participate in the research project 
 
 
 
 
 
 
You have been informed about the study by    
 
 
 
Participation in the study is based on voluntary, informed consent. You are free to ask for any 
additional information. If you, after having received all the information you deem necessary, 
wish to participate in the study, you must sign this consent form 
 
 
 
I,                                                                                (name in capital letters), confirm that I 
have received written information about the study and have had the opportunity to ask for 
additional information, and that I will participate in the project. 
 
 
 
 
 
 
Signature  Date   
 
(Signed by the project participant) (Dated by the project participant) 
 
 
 
 
Participation in other project, which, what happens there?    
 
 
 
  Year: 
 
 
 
 
If you would like information about the study as we go along, how do you wish to be 
contacted? 
 
 
 
 
 
 
 
 
 
 
 
 
If you were invited in the weekend or during school holidays would you be allowed to come? 
Where should we pick you up? (home/ school/ clinic/ other) 
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APPENDIX 4 
 
TEEN QUESTIONNAIRE  
 
Teen-15 id | | | | | 
Interviewer 
Interview date dd/ mm/ yy   /  /   
 
Please use a circle or tick where there are pre-entered responses QC 
BY  (sign, red pen) 
 
Isiqalo: Igama lami......ngisebenzela iVIBE project njengoba kwakushiwo ngaphambilini. 
Ngiphinde ngikubonge ngokunginikeza imvume yokuthi ngisebenze nawe. Ngithanda 
ukugcizelela amanye amaphuzu ngaphambi kokuthi siqale. 
Yonke lembuzongxoxo imayelana nesichenene sesibeletho sabesifazane kanti futhi yonke 
into esizoyixoxa izohlala phakathi kwethu..Ayikho imibuzo elungile nengalungile. 
Unelungelo lokuyimisa impendulo ngxoxo noma isiphi isikhathi. Ukusebenzisana kuyoba 
intokozo / Introduction: I am .........................and I am working for the VIBE project as 
mentioned during the informed consent procedure. Thank you again for giving me permission 
to work with you. I would like to emphasize some points before we start. 
All the questions below are related to Female Genital Bilharzia and everything discussed 
here will be confidential. There are no wrong or right answers. You are free to stop the 
interview at any time. Your cooperation will be appreciated. 
1)   Isikole / school:    
2)   Igama lesikole sebanga eliphansi ophuma kuso / Name of the primary school you came 
from   
3)   Uyasebenza na? njenge?/Are you working? As?    
4)   Iminyaka / Age |  |  | 
5)   Wazalelwaphi? / Where were you born ?   
6)   Inkolo / Religious affiliation [Christian] [Muslim] [Shembe] [Leganyana] [Methodist] 
[other   
 
 Yebo 
/ Yes 
Cha 
/ No 
NA Uma kungu yebo hlobo luni 
lwezinkomba? /  If yes 
what kind of symptoms? 
a) Unaso isifo sesifuba somoya? / 
Do you have asthma? 
    
b) Kukhohona imithi othi uma 
uyiphuza ube nokungaphatheki 
kahle? / Do you have any allergies to 
medication? (Penicillin, 
Cotrimoxazole or Bactrim) 
    
c) Kukhona ukudla othi uma 
ukudlile  kungakuphathi  kahle?  / 
Do you have any allergies to food? 
(fruit/seafood/nut) 
    
7)   Ulimi lwasekhaya / Home Language [Zulu] [Xhosa] [English] [Other   
ALLERGY 
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MENSTRUATION 
9) Ugcine nini ukuya esikhathini? / LMP (First day of last menstural period): 
  /  /  dd/mm/yy or NA 
 
10) Waqala uneminyaka emingaki ukuya esikhathini? / Age of your first menstruation? 
|  |  | 
11) Ubanaso isilumo kangangokuba kumele uhlale ekhaya? / Do you normally have 
painful periods so that you have to stay home from school? [yebo] [cha] 
12)  Ubanaso isilumo esikwenza ufise ukuthatha amaphilisi ezinhlungu? / Do you 
normally have painful periods so that you wish to take painkillers? [yebo] [cha] 
13)  Indlela yokuhlela / Contraceptive method: 
a)   Uyajova? / Are you on contraceptive injection? [yebo] [cha] 
b)   Amaphilisi okuhlela / contraceptive pills [yebo] [cha] 
14)  Uya ngendlela efanayo nyanga zonke / Are your periods regular [yebo] [cha] [NA= Post 
Partum / if injectable contraceptive / pills] 
15)  Uya izinsuku ezingaki esikhathini? / How many days does your period normally last? 
|  |  | [NA= Post Partum / if injectable contraceptive / pills] 
16) Kuye kwenzeke wophe ungalindele? / Do you have times of unexpected bleeding or 
spotting in between your normal periods? [yebo] [cha] [NA= Post Partum / if injectable 
contraceptive / pills] 
17)  Ujwayele ukopha kakhulu kuze kube namahluli? / Do you normally have periods with 
heavy bleeding and clots? [yebo] [cha] [NA= Post Partum / if injectable contraceptive / 
pills] 
 
 
PREGNANCY 
18)  Usukhulelwe kangaki sekukonke? / How many times have you been pregnant? |    |     | 
19) Bangaki abantwana abaphilayo? / How many children are alive? |    |    |  [NA=99] 
 
 
Month 
Year 
Abortion = 1. 
Miscarriage =2. 
Birth =3 
Trimester: 1= 1st (before 3 
mnths) . 2= 2nd (between 3 to 
6 mnths). 3=3rd (6 to 9 
months) 
Complications, 
please describe 
    
    
    
URINE AND BILHARZIA 
 
20)  Wake walashelwa isichenene nini?/ Have you ever been treated for Bilharzia, when? 
 
Never |     | OR [age] |__|     |1st time |    |    |2nd ime |    |    |3rd time 
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21)   Urinary symptoms: 
 
 Wake waba nayo inkinga noma yiphi ngokuchama 
njenge: / Have you ever had any problems with urination 
like: 
Esontwe 
ni 
eledlule / 
This last 
week 
Kudala 
phambilin 
i / 
Sometime 
before 
Akukaz 
e / 
Never 
a. Zinhlungu uchama / Pain when you urinate    
b Ukuzwa sengathi ufuna ukuchama esikhaleni noma uhlezi 
unganyakazi uze ucishe uzichamele / Sudden urge to urinate 
causing a leak, even when sitting still [urge incontinence] 
   
c. Ukuzwa sengathi ufuna ukuchama esikhaleni noma 
unganyakazi ngaphandle kokuthi ucishe uzichamela / 
Sudden urge to urinate, even when sitting still [urge] (no 
leakage) 
   
d. Iconsi lomchamo uma ugxuma, ukhwehlela noma uhleka 
/ Drop of urine if you jump, cough or laugh [stress 
incontinence] 
   
d. Umchamo obomvu / Red urine    
 
 
 
 
WATER CONTACT 
22) Manje ngizokubuza ngezinhlobo zezinto ozenzayo noma owake wazenza ngamanzi, uzenza 
noma wazenza kangakanani, uhlala isikhathi esingakanani emanzini nokuthi umzimba 
uthintana kangakanani namanzi. /Now I will ask you what kind of water activity you have or 
have had, how often you do them, for how long you stay in the water and how much of your 
body that is in contact with the water: 
a.   Umfula/river Amadamu/dam Amanzi amile/standing water. Amanzi avela 
kulezizisuka/ water from these sources. None 
b.   Igama lomfula noma idamu olisebenzisayo njengamanje? / What is the name of 
your current waterbody? Name of river / dam etc: 
 
 
c. Ingabe abanye esikoleni sakho basebenzisa lamanzi? Bangaphezu kwe 10   
noma bangaphansi kwe 10  Abekho  _/ Do others in your high school use this 
waterbody? More than 10 people ------less than 10  ----- None 
d.   Kwakunjalo nisebancane? Yebo Chaza uma kuhlukile/ Is that the same as in 
 
childhood ? If different:    
 
 
23) Kukhona isikhathi empilweni yakho owake wahlangana nalamanzi? [yebo] [cha] 
Is there a period in your life when you had water contact? (make crosses for each period) 
 
|  |  |  |  |  |  |  |  |  |  |  |  |    _|  |  |  |  |  |  |  |  |  | 
 
1 2 3 4 5 6 7 8 9  10   11   12  13   14 15 16   17  18  19  20   21  22 yrs 
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24) Usuke wathintana namanzi omfula noma idamu ngonyaka odlule (2013) noma 
kulonyaka (2014)? / Did you have contact with the river or dam in 2013 or 2014? [yebo] 
[cha]. Uma kungu Yebo sicela uchaze: / If yes, please explain: 
 
 Kangaki/ How 
often? Nsukuzonke 
/Daily (4) 
Kujwayele /Often 
(3) Kwesinye 
isikhathi 
/Sometimes (2) 
Kuthukela/ 
qabukela / Rarely 
(1) Ngeke / Never 
(0) 
Uke uhlale kangakanani / 
Uhlala kangakanani 
emanzini? / For how long did/ 
do you stay in the water? 
Ngaphezulu kuka 5 h / More 
than 5 h (4). 3-5 Amahora / 3- 
5 hours (3). Ngaphansi 
kwamahora amathathu / Less 
than 3 hours (2). Kuze kube 
yimizuzu ewu-60 / Up to 60 
minutes (1) 
 
 
 
Umzimba wake 
wawathinta / 
uwathinta 
kangakanani amanzi 
ngesikhathi wenza 
lezizinto /How much of 
your body was/is in 
contact with water 
during this activity? 
Uke noma wake 
wadlala/ 
ukubhukuda?/ Did or 
do you play / swim? 
   
Uke noma wake 
wawasha / 
wageza?/Did or do 
you wash / bathe? 
   
Uke noma wake 
wazihlanza izingubo? 
/ Did or do you do 
laundry? 
   
Uke noma 
wazihlanza izingubo 
zokulala? /Did or do 
you wash blankets? 
  
 
 
Uke noma wake 
wawakha 
amanzi?/Did or do 
you collect water? 
  
 
Uke noma wake 
wadoba? /Did or do 
you fish? 
  
 
Uke uwele umfula 
zize izinyawo zakho 
zithintwe 
amanzi?/Did or do 
you ever cross the 
water , so your feet 
become wet? 
  
 
 
 
 
 
            157
 
 
SYMPTOMS AND EVENTS 
25) Kubukeka kunjani ukuphuma ngaphansi kuwena? / How is your current discharge? 
a)   Kumbala muni/ Colour 1 2 3 4 5 6 7 8 [NA=99] (please circle) 
b)   Okusagazana / Trace of blood 0 1 2 3 4 5 6 [NA=99] 
26) 
 
Wake wezwa ukungaphatheki kahle esithweni sakho 
sangasese njengo: / Have you previously felt any 
discomfort in your private parts like: 
Esontweni 
eledlule / 
This last 
week 
Kudala 
phambilini 
Sometime 
NA / 
Never 
a. Ukuluma / Itch    
b. Ukushisa / Ukushoshozela / Burn / Sting    
d. Isilonda / Sore / ulcer    
e. Isimila / isigaxa / Lump / tumour    
f. Okuphumayo okusagazana / Bloody discharge    
g. Okushubile/ Okusasigaxana okuphumayo Thick/ 
lumpy discharge 
   
h. Okusamanzi okuphumayo / Watery discharge    
i. Iphunga elingajwayelekile / Abnormal smell    
j. Okuphumayo okunombala ongajwayelekile / Abnormal 
coloured discharge 
   
k. Kukhona osuke wakushutheka esithweni sakho 
sangasese njenge nsipho? / Did you put substances inside 
your vagina? Such as soap ? 
   
l. Wake wagcatshwa esithweni sangasese noma 
waxilongwa ngezinsimbi ezicijile / Ever had genital 
cutting or used a sharp instrument in the genital area (not 
episiotomyand not previous Pap smear ) 
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27) Usuke wabanazo izinhlungu esinyeni? [yebo] [cha] Uma kungu Yebo sicela uchaze: / 
Have you ever experienced abdominal pain? If YES, please explain: 
 
 
 
WHERE (abdominal location, see figure)? 
WHEN (activity)? 
HOW OFTEN? (This last week or sometime) 
 
RA: Plese write the code(s) directly in the correct quadrant(s) in the figure 
 
 
Activity 
 
This last week 
(last 7 days) 
 
Sometime 
 
Menses 
 
M2 
 
M1 
 
During sex 
 
DS2 
 
DS1 
 
After sex 
 
AS2 
 
AS1 
 
Urination 
 
U2 
 
U1 
 
Other 
 
X2 
 
X1 
 
Anytime 
 
A2 
 
A1 
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CONTRACEPTION & STDs 
28)  Uke wakusebenzisa okulandelayo kuleli sonto eledlule / Have you used the following the last 
week( the last 7 days): Ikhondomu yabesilisa / male condom [yebo] [cha] 
29)  Uyazi ukuthi ziyini izifo zocansi STI? / Do you know what an STI is? [yebo] [cha] [angazi] 
STD izifo ezithelelana ngokocansi, zibonakala kube khona okuphumayo 
okungajwayelekile, ukuluma, kube bomvu, amaqhubana noma isilonda esithweni sangasese 
/STI’s are diseases that you get through sexual contact, and symptoms include an abnormal 
vaginal discharge, itchiness, redness, lumps or sores in your private parts. 
 
30)  Wake walashelwa izifo zocansi ngenyanga edlule? / Have you been treated for an STI the last 4 
weeks? [yebo] [cha] [angazi] 
31)  Ucabanga ukuthi unaso isifo socansi njengamanje? / Do you think you have an STI now? 
 
Kungani Why?    
 
32)  Usulashelwe kangaki izifo zocansi? / How many times treated for an STI? |   |  | 
33)  Usuke wathola ukulashelwa noma isiphi isifo socansi komunye umtholampilo emuva 
kokuba ulana? / Have you received any STI treatment since you were at this clinic last time? 
[yebo] [cha] [angazi]. If yes, when?   /  /  _dd / mm / yy 
 
 
INTERCOURSE 
 
34)  Waqala uneminyaka emingaki ukwenza ucansi? / What was your age when you had sex for the 
first time? |  |  | 
35)  Uma ubanezinhlungu wenza ucansi chaza ukungaphatheki kahle kwakho: / If you have pain 
during sex, please describe the discomfort: 
 
a. Ubuhlungu obujulile / Deep / thrusting pain [yebo] [cha] [NA if no sex the last 6 
months] 
b.   Ubuhlungu uma kungena / Superficial / upon entering [yebo] [cha] [NA if no sex the 
last 6 months] 
36) Hloboluni locansi owake walwenza? / What kind of sex have you had? 
c. Ukuphathaphatha isitho sangasese kuphela / Petting [yebo] [cha] 
d.   Ukusoma / Thigh sex [yebo] [cha] 
e. Olokukhotha isitho sangasese / Oral [yebo] [cha] 
f. Olwasesithweni sowesifazane / Vaginal [yebo] [cha] 
g.   Olwasembotsheni yokuzikhulula / Anal [yebo] [cha] 
h.   Ugcine nini ukwenza ucansi? / When was the last time you had sex? 
  /  /  dd / mm / yy 
i. Uyisebenzisile Icondom ugcina ukwenza ucansi? / Did you use a condom the last time 
you had sex? [yebo] [cha] 
37)  Ucabanga ukuthi kujwayelekile ukopha kancane emva kokwenza ucansi / Do you  think it is 
normal to have a little bleeding after sex? [yebo] [cha] [angazi] 
38)  Uke wabona wopha emva kocansi? / Have you ever seen bleeding after sex? 
[yebo] [sometimes / ngesinye isikhathi] [cha] 
39)  Uyalwenza ucansi ngesinye iskhathi uma usesikhathini / Do you sometimes have intercourse 
during your menstrual period [yebo] [cha] 
40) Uke uzizwe ucindezelekile ukwenza ucansi nomuntu ngenxa yezipho/imali akunike yona?  / 
Have you ever felt pressured to have sex, because of the gifts or money you have been given ? 
[yebo] [cha] 
41)  Wake wahlukunyezwa ngokocansi noma waphoqwa ukwenza ucansi / Have you ever been 
sexually abused or forced to have intercourse? [yebo] [cha] IF YES: 
 
42) Sekuke kwenzeka kulezinsuku ezintathu ezidlule? / Has it happened the last 3 days? [yebo] 
[cha] [NA] 
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Ngiyadabuka ukuzwa lokho, ngiyazi kunzima kuwena ukukhuluma ngalokhu. Kuwumthwalo 
onzima kakhulu ukuwuthwala ngokwakho. I am so sorry to hear that, that must have been very 
hard. I know it is very difficult for you to talk about this. It’s a very heavy load to have to carry on 
your own. Ukhona osuke wakhuluma naye ngalokhu. Have you talked to anyone about it? [yebo] 
[cha] 
Ungathanda ukukhuluma nomaluleki ngaloludaba? / Would you like to talk to a mentor  about it? 
[yebo] [cha] 
 
 
RELATIONSHIP AND HIV STATUS 
Ngaphambi kokuba uphendule imibuzo elandelayo sifuna ukukuqinisekisa ukuthi lolulwazi 
luyimfihlo futhi angeke lwatshelwa noma ubani. Imibuzo elandelayo imayelana nobudlelwane 
kanye nesimo sakho sesandulela ngculazi. Ngiyazi eminye yalemibuzo inzima ukuyiphendula 
kodwa ngicela usize wenze okusemandleni akho. Lemibuzo siyibuza wonke umuntu./ Before you 
answer the next questions, we want to assure you that the information you give will not be told to 
anyone. The next questions are about relationships and HIV status I know some of these questions are 
hard to answer but please do your best. We are asking the same questions to everybody. 
 
43)  a) Wayeneminyaka emingaki umaqondana wakho omdala kunabo bonke? / How  old was 
your oldest partner? |   |    | 
b) Uke waba nomaqondana osokiwe? / Have any of your partners been circumcised?  (Loku 
kuchaza ukuthi inyama yesitho sowesilisa sangasese isusiwe futhi ikhanda laso liyabonakala 
ngaso sonke isikhathi / This means that the foreskin has been removed and the penis head is visible at 
all times) 
 
44)  Uma ucabanga wake waba nomaqondana onesandulela ngculazi / Do you think you have had 
an HIV positive partner ? [yebo] [cha] [angazi] 
 
 
Umaqondana / 
Partner 
Current former 
(1) 
former 
(2) 
former 
(3) 
former 
(4) 
former 
(5) 
former 
(6) 
former 
(7) 
Yebo         
Cha         
Angazi         
Not applicable         
45) Uke waba nnmaqondana odla imishanguzo / Have you ever had a partner who is taking ARV’s? 
[yebo] [cha] [angazi] 
46)  Unaye umaqondana njengamanje? / Do you have a steady partner at the moment? [yebo] [cha] 
47)  Usuwenze ucansi nabantu abangaki empilweni yakho? / Lifetime sexual partners? |    |    | 
48) Ulale nabantu abangaki ngenyanga edlule? / Number of sexual partners you have had the last 
month( The last 30 days?) |   |    | 
49)  Ezinyangeni ezintathu ezedlule ugcina ukwenza ucansi waphuza utshwala noma 
izidakamizwa ? / In the past 3 months; have you had sexual intercourse under the influence of 
alcohol or drugs? [yebo] [cha] 
50)  Wake wahlolelwa isandulela ngculazi / Have you been tested for HIV? [yebo] [cha] 
51)  Ungakhululeka ukungitshela ngesimo sengculazi, ingabe unaso isandulela ngculazi? Would 
you feel comfortable telling me your status, do you have HIV? [yebo] [cha] [angazi] [Patient 
declined information] 
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UMA KUNGU YEBO: Ngiyaxolisa ukuzwa lokho, kufanele ukuthi kunzima. / IF YES: I am sorry 
to hear that, it must be hard for you. 
 
52)  Waze nini ngesimo sakho? / When did you get to know / / mm / yy 
 
53)  Ukhona osuke wamutshela ngalokhu? / Have you told anyone about it? [yebo] [cha 
54)  Ngabe CD4 count uyayihlola? / Is your CD4 count monitored? [yebo] [cha] 
a)  Uma kuwuyeboibingakanani CD4 count? / If yes, last CD4 count? |   |     |__| 
 
b)  Nini? / When?   _/  /   mm / yy 
 
55)  Uyayithatha imishanguzo? / Are you taking ARV’s? [yebo] [cha] 
56)  Ungathanda ukuthi sinihlelele iqembu lokululekana nabanye abafundi abanesimo esifana 
nesakho?/Would you like us to organise a support group for HIV positive learners and would 
you join? [yebo] [cha] [angazi] 
 
Wahlolwa watholwa unegciwane lengculazi futhi neCD4-count ayibhekwa. Ingabe lokhu 
kuyiko? / You have been tested positive for HIV and your CD4-count is not monitored. Is this 
correct? 
Uma kungu YEBO: Sibona ukuthi uhlolisiswe ngokushesha. Ngakho ke, uzothola incwadi evela 
kuthina ezokusiza ukuthi uxhumane nomtholampilo./ If yes: We recommend that you have a 
thorough investigation as soon as possible. Therefore, you will receive a letter from us that will help 
you to contact your clinic. 
 
 
 
ALCOHOL / IZIDAKAMIZWA / DRUGS 
Imibuzo elandelayo ingophuzo oludakayo. Izimpendulo onginika zona angeke zatshelwa muntu. 
/ The following questions are about drugs. The answers you give will not be told to anybody. 
57) Ingabe abangani bakho bayazisebenzisa izidakamizwa? / Do your friends use drugs? [yebo] 
[cha] [angazi] 
58) Uyazisebenzisa izidakamizwa? / Do you use drugs ? [yebo] [cha] 
59) Wake wasebenzisa okunye noma okungaphezulu kwalokhu okulandelayo? / Have you ever 
used one or more of the following 
a) Insangu / dagga [yebo] [cha] f) Yiglue / glue [yebo] [cha] 
b) Yibensin / bensin [yebo] [cha] g) Umgwinyo / ecstacy [yebo] [cha] 
c) Okunye 1 / Other 1[specify]    
d) Okunye 2 / Other 2 [specify]    
e) Izidakamiswa ezijovwayo / Injectable drugs? [yebo] [cha] 
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FAMILY AND LIVING 
60) Qala ngomdala kunabobonke endlini: / Start with the oldest in the household: 
 
 
Relation: M = mother. F= father. G= Legal guardian. B = brother. S = sister. Gm = 
grandmother. Gf = grandfather. U = uncle. A = aunt. C = cousin. Sf = Stepfather. Sm = 
Stepmother. Ss = Stepsister. Sb =Stepbrother. FR- friend, H=housekeeper. Ch= Child 
(son/daughter of study subject). Y= Husband / boyfriend of study subject. O = other. Ni = 
Niece. Ne=Nephew. X=study subject 
Ubani ohlala 
kulendlu 
yakini? Who 
lives in your 
house? 
Isilinganis 
o 
seminyaka 
App. age 
Umsebe 
nzi Work 
Umfundi 
Student 
Izinga lemfundo eliphezulu [Ayikho / 
Ephansi / Ephezulu / Ephakeme] Top 
education (0=None) (1=Primary) 
(2=High school) (3=Tertiary) (10=don’t 
know) 
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
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INFORMATION ABOUT CLINICAL FINDINGS 
Uma ucwaningo luthola lezizifo ezilandelayo ungafuna ukwazi?/ If the study discovers 
the following diseases, do you want to know: 
 
1.   Izifo ezithathelana ngokocansi zingadala ukulimala kwenqondo, ukungabatholi 
abantwana noma umdlavuza olaphekayo. Ungafuna ukwazi uma unalezozifo / 
Some sexually transmitted diseases may cause brain damage, infertility and treatable 
cancer. You want to know if you have such a disease [yebo] [cha] [angazi] 
 
2.   Igciwane lengculazi liyathibeka futhi ungaphila isikhathi esideuze uguge uma 
wazi ngesimo sakho. Uyafuna ukwazi? / HIV is treatable and you can live until you 
get old if you have your result. You want to know [yebo] [cha] [angazi] 
 
3.   Ezinye izifo ezingatholakala ocwaningweni.Uyafuna ukwazi? / Other diseases that 
maybe discovered. You want to know [yebo] [cha] [angazi] 
 
 
 
Do you have any questions for me? 
 
 
 
Is there anything you want to talk about? 
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LONG TERM TRACKING DATA PAGE 
Person 1 
 
1. Isibongo / Surname[s]    
2. Amagama / First name[s]    
3. Isidlaliso / Isithakazelo / Noma elinye igama / Other names    
4. Isikole / school:   Grade: |  |  | Section:|   
5. Ubani uthishawakho manje? / Who is your current teacher ?   
6. Usuku lokuzalwa / D.o.b.   /  /  dd/ mm/ yy Wazalelwaphi? / Where   
7. Uhlala kuphi isikhathi esiningi? [Ikheli lala uhlala khona] / Where do you live most 
of the time? Physical address    
8. Ujwayele ukulala kangakanani lapha? [sonke isikhathi] [ingxenye yesikhathi] / 
How often do you sleep here? [All the time] [Most of the time] 
9. Ikheli leposi / Postal address    
10.  Inombolo kamakhalekhukhwini / Cell |  |  |  | - |  |  |  |  |  |  |  | 
11.  Inombolo yocingo lwasekhaya / Landline |  |  |  |-|  |  |  |  |  |_    |  | 
12.   Email:    
13.  Kungani ubelapha isikhathi esiningi? / Why are you here most of the time? 
 
 
14.  Ubani okunakekelayo lapha? [igama] / Who is looking after you here? [name] 
 
 
15.  Igama lombheki / Name of a guardian_  sex [M][F] 
 
16.   Ubuhlobo / Relation (see below)   
17.   Ngubani ongumninimuzi? / Who owns the house?   
18.   Ngubani oyinhloko yekhaya? / Head of the household?   
19.   Uyasebenza na? njenge?/Are you working? As? Where ?   
 
 
 Person 2 
 
20.  Ingabe ikhona enye indawo ohlala kuyo ngezimpelasonto, amaholide noma ezinye 
izinsuku? Another place where you stay (eg weekends,holidays,other)? [yebo] [cha] 
21.  Ujwayele ukulala kangakanani lapho? ngezinye zezinsuku zesikole ngezimpelasonto 
amaholide okunye [chaza] / / How often do you sleep there? [some school days] 
[weekends] [holidays] [other   
22.   Ikheli lapho ovakashela khona / Physical address    
 
 
 
23.   Ikhelileposi / Postal address   
 
24.  Inombolo kamakhalekhukhwini / Cell | | | |-| | | | | | | | 
25.  Inombolo yocingo lwasekhaya / Landline |  |  |  |-|  |  |  |  |  |_    |  | 
 
26.   Kungani uhlala lapha ngesinye isikhathi? / Why do you stay here sometimes?    
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27.  Ubani okunakekelayo lapha? [igama] / Who is looking after you here? (name) sex [M] [F] 
28.   Ubuhlobo umama / umalume / umngani etc. / Relation (see below)    
29.   Ngubani ongumninimuzi? / Who owns the house?   
30.  Ngubani oyinhloko yekhaya?(ubuhlobo) / Head of the household? (Relationship) 
 
 
 
Asisoze sanikeza omunye umuntu imininingwane yakho kodwa kungenzeka sifune 
ukukuthola. Singabuza bani? / We will never give information about you to 
anyone, however we may want to find you. Who should we ask? 
 
 
Person 3 
31.  Sicela usinike igama lomunye umuntu osondelene naye esingamthinta uma singakwazi 
ukukuthola ocingweni lakho. / Please give the name of another close person we can contact 
if we can`t get hold of you 
32. Igama? / Name   sex 
[M] [F] 
33.   Ubuhlobo / Relation (see below)   
34.  Kungabe uhlala endaweni efanayo njengeyakho / Does he / she live in your area? [yebo] 
[cha] 
35.   Ikheli lapho ehlala khona / Physical address (may be skipped)   
 
36.  Inombolo kamakhalekhukhwini / Cell | | | |-| | | | | | | | 
37.  Inombolo yocingo lwasekhaya / Landline |  |  |  |-|  |  |  |  |  |_    |  | 
 
 
 
Person 4 
38.  Uma ungase ube nohambo noma usuke kulendawo, ubani ongaba nemininingwane 
yakho yokukuthinta [ngaphandle kwalena engenhla]? / If you were to travel or move 
away, who in your class or in school would have your contact details [other than the above]? 
39.  Igama / Name  sex [M] [F] 
40.   Ubuhlobo umama / umalume etc / Relation (see below)    
41.   Ikheli lapho ahlala khona / Physical address (may be skipped)   
 
 
 
42.  Inombolo kamakhalekhukhwini / Cell | | | |-| | | | | | | | 
43.  Inombolo yocingo lwasekhaya / Landline |  |  |  |-|  |  |  |  |  |_    |  | 
 
 
---------------------------------------------------------------------------------------------------------------------- 
Relation: M = mother. F= father. G= Legal guardian. B = brother. S = sister. Gm = 
grandmother. Gf = grandfather. U = uncle. A = aunt. C = cousin. Sf = Stepfather. Sm = 
Stepmother. Ss = Stepsister. Sb =Stepbrother. FR- friend, H=housekeeper. Ch= Child 
(son/daughter of study subject). Y= Husband / boyfriend of study subject. O = other. Ni = 
Niece. Ne=Nephew. X=study subject 
           166
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REDUCING BILHARZIA PROJECT 
 
 
APPENDIX 5 
 
NB: Please use a tick where there are pre-coded responses 
Name of Interviewer:   
 
A. Personal data page 
1. Isibongo / Surname(s ) 
 
Date: |  |  |  | 
day   month  year 
 
Amagama / First name(s) 
 
Nickname/praise names/other 
names   
2. Uneminyaka emingaki?/ How old are you? Age (years) |  |  | 
3. Wazalwa nini? /When were you born? |  |  |  | 
day  month year 
4. Wazalelwaphi? /Where were you born? 
 
 
School:   Area: 
  _ 
Grade: |  |  | Section: |  | 
5. Ubani igama likathisha wakho kulonyaka?/ What is the name of your class teacher this 
year? 
 
 
6. Uhlala kuphi isikhathi esiningi? (Ikheli lala uhlala khona) /Where do you live most of the 
time? (Physical 
address)   
 
 
 
7. Ujwayele ukulala kangakanani lapha? sonke isikhathi ingxenye yesikhathi / 
How often do you sleep here? (All the time / Most of the time) 
8. Ikheli leposi / Postal address 
 
 
a. Inombolo kamakhalekhukhwini/Cell phone number 
|  |  |  | -|  |  |  |  |  |  |  | 
b. Inombolo yocingo lwasekhaya/Landline number |  |  |  | - 
|  |  |  |  |  |  |  | 
9. Kungani ubelapha isikhathi esiningi? / Why are you here most of the time? 
 
 
a. Ubani okunakekelayo lapha? (igama)/ Who is looking after you here? (name) 
 
 
b. Igama lombheki /Name of a guardian  sex M/F 
c. Ubuhlobo umama /umalume /umngani omunye (chaza). / Relation (mother 
/uncle /friend /other 
(specify)_   
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d. Ngubani oyinhloko yekhaya?/ Who is the head of the 
household?   
e. Ngubani ongumninimuzi? /Who owns the house? 
 
 
10. Ingabe ikhona enye indawo ohlala kuyo ngezimpelasonto, amaholide noma 
ezinye izinsuku? yebo       cha        Uma kungu CHA → 11/_/Is there another place where 
you stay on weekends, holidays or other days? (Yes, no) (IF NO →11) 
a. Ujwayele ukulala kangakanani lapho? ngezinye zezinsuku zesikole 
ngezimpelasonto amaholide okunye (chaza) //How often do you sleep 
there?(some school days,weekends,  holidays, other –explain)) 
 
b. Ikheli lapho uhlala khona / Physical address 
 
 
 
 
 
c. Ikhelileposi / Postal 
address   
 
 
d. Inombolo kamakhalekhukhwini/Cell phone number 
|  |  |  ||  |  |  |  |  |  |  | 
e. Inombolo yocingo lwasekhaya /Landline number |  |  |  ||  |  |  |  |  |  |  | 
f. Kungani uhlala lapha ngesinye isikhathi? / Why do you stay here sometimes? 
 
 
g. Ubani okunakekelayo lapha? (igama)/ Who is looking after you here? (name) 
   sex F/M 
h. Ubuhlobo umama /umalume /umngani etc. / Relation (mother /uncle 
/friend etc.other (specify) 
 
i. Ngubani oyinhloko yekhaya?(ubuhlobo) / Who is the head of the household?( 
Relationship) 
 
 
j. Ngubani ongumninimuzi? / Who owns the house? 
 
 
11. Unaso esinye isihlobo esisondele kuwe esihlala kwenye indlu? yebo 
cha            uma kung CHA → 12 / Do you have any other close relative living in another 
household? (Yes, no) (If no go to 12) 
a. Ubani igama? /What is the name                                                                                              - 
 
b. Ubuhlobo umama /umalume etc / Relation (mother/uncle etc) 
 
 
c. Ingabe uhlala endaweni efanayo njengeyakho yebo cha /Does he/she live 
in the same area as you? (Yes, no) 
d. Ikheli lapho uhlala khona / Physical address 
168 
Id. no: |  |  |  |  | 
Bilharzia Project 
Girls Questionnaire Reducing  
 
, , 
 
e. Ikhelileposi / Postal address 
 
 
 
f. Inombolo kamakhalekhukhwini /Cell phone number 
|  |  |  |-|  |  |  |  |  |  |  | 
g. Inombolo yocingo lwasekhaya / Landline number 
|  |  |  | -|  |  |  |  |  |  |  | 
 
 
12. Uma ungase ube nohambo noma usuke kulendawo, ubani ongaba 
nemininingwane yakho  yokukuthinta (ngaphandle kwalena engenhla)?/If you 
were to travel or move away, who would have your contact details (other than the above)? 
a. Igama/Name 
 
b. Ubuhlobo umama /umalume etc / Relation mother/uncle etc 
 
 
c. Ikheli lapho ahlala khona / Physical 
address   
 
 
d. Ikhelileposi / Postal address 
 
 
 
e. Inombolo kamakhalekhukhwini/Cell phone number 
|  |  |  |-|  |  |  |  |  |  |  | 
f. Inombolo yocingo lwasekhaya / Landline number |  |  |  | - 
|  |  |  |  |  |  |  | 
13a. Ubani osayine ifomu lakho lemvume? (ubuhlobo, igama) / Who signed your 
consent form? (relation, name) 
 
b. Kungani kunguyena? / Why this person? 
 
 
14. Awukakamusho/yiphathi u/ekamama wakho noma ubaba wakho okuzalayo. 
/You haven’t yet mentioned your biological mother and/or biological father. 
a. Ingabe umama wakho usaphila? Yebo cha angazi /Is your mother still 
alive? (Yes, no, DK) 
b. Ingabe ubaba wakho usaphila? Yebo cha angazi /Is your father still alive? 
(Yes, no, DK) 
Uma kungu CHA: Ngiyadabuka ukuzwa ukuthi umama noma ubaba wakho 
usashona. Ngizokubuza ngomzali osaphilayo./ I’m sorry to hear that your mother or father 
has passed away. I am going to ask you about the parent who is alive. 
c. Uma kungu CHA kubo bobabili abazali yiya ku15./ If No for both parents go to 15. 
 
14d. Igama likamama okuzalayo / 
Biological mother 
Igama likababa okuzalayo / 
Biological father 
i) Unako ukuthintana 
nomama/ubaba wakho? 
Do you have contact with 
your mother/father? 
 
yebo cha akwenzeki 
yes no NA 
 
yebo cha akwenzeki 
yes no NA 
ii) Ingabe umama/ubaba 
wakho uhlala eduze 
kwala uhlala khona? 
 
yebo cha akwenzeki 
yes no NA 
 
yebo cha akwenzeki 
yes no NA 
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Does your mother/father live 
near you? 
  
iii) Ingabe yiliphi izinga 
lemfundo eliphezulu 
likamama/baba wakho? 
/What is your mother/father’s 
top education? 
Ayikho imfundo esemthethweni 
No formal education 
Imfundo ephansi 
Primary school 
Imfundo ephezulu 
High school 
Imfundo ephakeme 
Tertiary 
Angazi 
Don’t know 
Ayikho imfundo esemthethweni 
No formal education 
Imfundo ephansi 
Primary school 
Imfundo ephezulu 
High school 
Imfundo ephakeme 
Tertiary 
Angazi 
Don’t know 
iv) Ubani igama 
likamama/baba wakho? 
/What is your mother/father’s 
name? 
  
v) Lithini ikheli 
likamama/baba wakho? 
/What is your mother/father’s 
address? 
  
 
e. Ingabe ubaba wakho uhlala nawe ekhaya? Yebo cha Uma kungu CHA → 
15a)/Does your father live with you at home? (Yes, no) (If no → 15a) 
f. Ingabe ubaba wakho uyakusiza ngomsebenzi wakho wesikole uma udinga 
usizo? Yebo cha /Does your father help you with schoolwork if you need help? (Yes, no) 
g. Ingabe ubaba wakho uke akujezise ngokwenza okungalungile? Yebo cha 
/Does your father ever punish you for doing wrong? (Yes, no) 
h. Ingabe lokho kuyakuvimba/gwema ukuthi ungakwenzi futhi? Yebo cha 
/Does that stop you from doing it again? (Yes, no) 
i. Ungasho uthi ubaba wakho unomthetho oqinile? Yebo cha 
/Would you say that your father is too strict? (Yes, no) 
j. Ingabe unomthetho oqinile kunobaba womngane wakho? Yebo cha 
angazi 
/Is he stricter that your friends’ fathers? (Yes, no, D/K) 
15a. Ingabe umama wakho uhlala nawe ekhaya? Yebo cha Uma kungu 
CHA →   /Does your mother live with you at home? (Yes, no) (If no → 16a) 
b. Ingabe umama wakho uyakusiza ngomsebenzi wakho wesikole uma udinga 
usizo? Yebo cha /Does your mother help you with schoolwork if you need help? (Yes, no) 
c. Ingabe umama wakho uke akujezise ngokwenza okungalungile? Yebo cha 
/Does your mother ever punish you for doing wrong? (Yes, no) 
d. Ingabe lokho kuyakuvimba/gwema ukuthi ungakwenzi futhi? Yebo cha 
/Does that stop you from doing it again? (Yes, no) 
e. Ungasho uthi umama wakho unomthetho oqinile? Yebo cha /Would you 
say that your mother is too strict? (Yes, no) 
f. Ingabe unomthetho oqinile kunomama womngane wakho? Yebo cha 
angazi /Is she stricter that your friends’ mothers? (Yes, no, D/K) 
 
16a. Ngubani omandla ekukunakekeleni? 
Who is your main caregiver? 
M = mother  F = father  B = brother  S = sister  
Gm = grandmother  Gf = grandfather  U = uncle  A = aunt  
C = cousin  Sf = step-father  Sm = step-mother  Sb= step-brother  
Ss= step-sister  N = none  O = other (please list) 
 
16b. Ingabe uyakusiza ngomsebenzi wakho wesikole uma udinga usizo? Yebo 
cha /Does she/he help you with schoolwork if you need help? (Yes, no) 
16c. Ingabe uke akujezise ngokwenza okungalungile? Yebo cha /Does 
she/he ever punish you for doing wrong? (Yes, no) 
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nga 
 
 
 
 
 
 
‘ 
 
 
 
 
Isilinganiso 
seminyaka 
Approximate 
age 
 
 
 
 
Umsebenzi 
Yebo, cha, 
Work 
(Yes/No) 
 
 
 
Umfundi 
(Yebo, cha,) 
Student 
(Yes/No) 
Izinga lemfundo 
eliphezulu 
(Ayikho/Ephansi/ 
Ephezulu/Ephakeme) 
Top education 
(0=None/1=Primary/ 
2=High/3=Tertiary) 
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
  Yes No Yes No  
 
 
16d. Ingabe lokho kuyakuvimba/gwema ukuthi ungakwenzi futhi? Yebo cha 
/Does that stop you from doing it again? (Yes, no) 
16e. Ungasho ukuthi unomthetho oqinile? Yebo cha /Would you say she/he is 
too strict? (Yes, no) 
16f. Ingabe unomthetho oqinile kunombheki womngane wakho? Yebo cha 
angazi /Is he stricter that your friends’ caregiver? (Yes, no, D/K) 
 
 
 
B. Family and living 
1. Usuhlale isikhathi esingakanani lapha? |_   |  |/How long have you lived here? (years) 
2. Wake wahlala edolobheni? Yebo cha angazi /Have you ever lived in a city? 
(Yes, no, D/K) 
Uma kungu CHA yiya ku Q5: If no :go to Q5 
Uma kungu YEBO:/If yes: 
3. Wawuneminyaka emingaki ngesikhathi uhlala edolobheni? / How old were you 
when you lived in the city? (D/K)  |_     |_     |/ a zi 
4. Wahlala isikhathi esingakanani lapho? Isikhathi esingaphansi konyaka 1-5 
iminyaka ngaphezulu kuka 5 weminyaka /For how long did you live there?(Less than 1 
year, 1-5 years, more than 5 years) 
 
5. Qala ngomdala kunabobonke endlini:/Start with the oldest in the 
household: 
 
 
M = mother 
F= father 
B = brother 
S = sister 
Gm = grandmother 
Gf = grandfather 
U = uncle 
A = aunt 
C = cousin 
Sf = Step-father 
Sm = Step-mother 
Ss = Step-sister 
Sb =Step-brother 
O = other (friend, 
housekeeper etc) 
OC = Our Child 
Ne = nephew 
Ni = niece 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Ngubani omandla ekunihlinzekeni/pheni ekhaya? (igama 
nobuhlobo) /Who is the main provider in the household? (name and relation) 
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C. Ukuthinta amanzi / Water contact 
Manje ngizokubuza imibuzo ngokuthinta amanzi. 
Now I will ask you some questions about water contact. 
1. Uwatholaphi amanzi okuphuza? emfuleni empompini/womphakathi 
esiphethwini esivikelekile esiphethwini esingavikelekile kuxubene 
empompini ongaphakathi /Where do you get drinking water? (river, stand pipe/communal 
stand pipe, protected spring, unprotected spring, mixed, indoor tap) 
2. Ingabe amantombazane ekilasini lakho ayabhukuda emfuleni noma edamini 
ezinsukwini ezishisayo? yebo cha angazi / Do girls in your class swim in the 
river or dam on hot days?(Yes, no, D/K) 
3. Ingabe umngane wakho omkhulu uyakwenza lokho? yebo cha angazi 
/ Does your best friend do this?(Yes, no, D/K) 
4. Uyakwenza wena? yebo cha / Do you do this? (Yes, no) 
 
 
 
 
 
5. Manje ngizokubuza ngezinhlobo zezinto ozenzayo ngamanzi, nizenza kangakanani, 
isikhathi eside kangakanani osihlala emanzini nokuthi uthintana kangakanani umzimba 
wakho namanzi? /Now I will ask you what kind of water activity you do, how often you do them, for 
how long you stay in the water and how much of your body that is in contact with the water. 
 
 
 
 
 
Umfula/river 
Amadamu/dam 
Amanzi 
amile/standing 
water 
Amanzi avela 
kulezisuka/water 
from these sources 
Kangaki/ How often? 
Daily (4)/Daily (4) 
Kujwayele (3)/Often(3) 
Kwesinye isikhathi (2) 
/Sometimes (2) 
Kuthukela/qabukela (1) 
/ Rarely (1) 
Ngeke (0) / Never (0) 
Uhlala kangakanani 
emanzini? / For how long do 
you stay in the water? 
Ngaphezulu kuka 5 h (4) 
More than 5 h (4) 
3-5 Amahora (3)/ 3-5 hours 
(3) 
Ngaphansi kwamahora 
amathathu (2) 
Less than 3 hours (2) 
Kuze kube yimizuzu ewu- 
60 (1) 
Up to 60 minutes (1) 
Umzimba 
uwathinta 
kangakanani 
amanzi 
ngesikhathi 
wenza 
lezizinto /How 
much of your 
body is in 
contact with 
water during 
this activity? 
Uyadlala / 
Uyabhukuda?/Do 
you play / swim? 
  
 
 
Uyawasha / 
uyageza 
Do you wash / 
bathe? 
   
Uyazihlanza 
izingubo?/Do you 
do laundry? 
   
Uyazihlanza 
izingubo 
zokulala? 
/Do you wash 
blankets? 
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Uyawakha 
amanzi? 
/Do you collect 
water? 
   
 
 
Uyadoba?/Do you 
fish? 
   
 
 
Uke uwele 
emanzini?/Do you 
ever cross the 
water? 
  
 
 
 
 
D. Wena nomndeni wakho / You and your family 
1. Imibuzo elandelayo ingobudlelwane nomndeni wakho kanye nontanga bakho. 
Ngizokufundela isitatimende kumele ucabange ngesitatimende ungitshele uma 
kungekona, ingxenye ingekona, ingxenye iyiqiniso noma iqiniso/ The next questions are 
about your relationships with your family and peers. I will read out a statement, and you must think 
about the statement and tell me if it’s false, partly false, partly true or true. 
 
1. Isitatimende / Statement Akukona/ 
False 
Ingxenye 
Ayikona/ 
Partly false 
Ingxenye 
yiqiniso/ 
Partly True 
Iqiniso/ 
True 
1a. Kukhona abantu obaziyo 
emndenini wakho abenza zinto 
ukukujabulisa/ 
There are people you know amongst 
your family who do things to make you 
happy 
    
1b. Kukhona abantu obaziyo 
emndenini wakho abakwenza 
uzizwe uthandeka/ 
There are people you know amongst 
your family who make you feel loved 
    
1c. Kukhona abantu obaziyo 
emndenini wakho ongathembela 
kubo noma kwenzekani/There are 
people you know amongst your family 
who can be relied on no matter what 
happens 
    
1d. Kukhona abantu obaziyo 
emndenini wakho abangabona 
ukuthi uyanakekelwa uma udinga 
lokho / There are people you know 
amongst your family who would see that 
you are taken care of if you needed to 
be 
    
1e. Kukhona abantu obaziyo 
emndenini wakho abakumukela 
njengoba unjalo 
/There are people you know amongst 
your family who accept you just as you 
are 
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4 Ingabe umbheki/mzali wakho 
uyathanda ukwazi / Does your 
caregiver want to know 
Ngeke 
Never 
Ngesinye 
isikhathi 
Sometimes 
Izinsuku 
eziningi 
Most 
days 
Nsukuzonke 
Every day 
4a. Ukuthi kuqhubeka kanjani 
esikoleni?/How you are getting on at 
school? 
    
4b. Ukuthi uyaphi uma nizikhipha 
nabangani bakho?/Where you are 
going when you go out with friends? 
    
4c. Ukuthi ubani ozikhipha naye?/Who 
you go out with? 
    
 
 
1f Kukhona abantu obaziyo 
emndenini wakho abakwenza 
uzizwe uyingxenye ebalulekile 
emindenini yabo./There are people 
you know amongst your family who 
make you feel an important part of their 
lives 
    
1g. Kukhona abantu obaziyo 
emndenini wakho abakuxhasayo 
nabakuqguqguzelayo./There are 
people you know amongst your family 
who give you support and 
encouragement 
    
 
NB: Siza ufunde isitatimende 2 kuzozonke izitatimende ezingezansi./NB: Please read this 
for all statements below: 
2. Uma umbheki/mzali wakho ekucela ukuba uhlale ekhaya uwashe ngesikhathi 
engekho bese: /If your caregiver asked you to stay at home and do the washing while she/he was 
out, and then: 
 
 Isitatimende / Statement Yebo / Yes Cha / No 
2a. Abangani bakho bakucele ukuthi uphumele 
emnyango uyodlala nabo ungahamba?/Your 
friends asked you to come out and play with them, 
would you go? 
  
2b. Abangani bakho bakucele niyobhukuda 
emfuleni nabo ungahamba?/Your friends asked 
you to go swimming in the river with them, would you 
go? 
  
2c. Umhambi akucele ukuthi uye naye esitolo 
niyothola amaswidi ungahamba?/ A stranger 
asked you to go to the shop with him to get sweets, 
would you go? 
  
 
NB: Siza ufunde isitatimende 3 kuyoyonke imibuzo yesitatimende ngasinye/NB: Please 
read statement  3 for questions below each statement 
3 Ingabe umbheki/mzali 
wakho usuke esekhaya 
uma usekhaya /Is your 
caregiver at home when you 
are home: 
Ngeke 
Never 
Ngesinye 
isikhathi 
Sometimes 
Izinsuku 
eziningi 
Most days 
Nsukuzonke 
Every day 
3a. Emini / In the daytime?     
3b. Ebusuku / At night?     
3c. Ngempelasonto /On the 
weekend? 
    
 
 
NB: Siza ufunde isitatimende 4 kuyoyonke imibuzo yesitatimende ngasinye/NB: Please 
read statement 4 for questions below each statement 
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E. Ezempilo / Health 
Imibuzo elandelayo ingezempilo yakho./The next questions are about your health. 
1. Ingabe uyazi siyini isichenene? yebo cha anginasiqiniseko /Do you 
know what Bilharzia is? (Yes, no, unsure) 
Isichenene yisifo ongasithola ngokuthinta amanzi angcolile./Bilharzia is an infection 
you can get through contact with infected water. 
2. Ingabe kukhona emndenini onaso noma owake wabanesichenene yebo 
cha Angazi / Has anyone in your family ever had Bilharzia? 
3. Wake waba naso isichenene? yebo cha angazi / Have you ever had 
Bilharzia? (Yes, no, D/K) 
Uma kunguyebo:/If yes: 
4a. Wake walashelwa isichenene phambilini? yebo cha /Have you ever been 
treated for Bilharzia before?Yes, no) 
Uma kungu CHA yiya ku Q5/If No go to Q5 
Uma kungu YEBo yiya ku4b/ If Yes go to 4b. 
4.b Walashelwa nini isichenene (iminyaka) |   |   _| |___|  |  |  |___| /When were 
you treated for Bilharzia (age) 1st time 2nd time  3rd time 
 
Ngaphambi kokuba uphendule imibuzo elandelayo sifuna ukukuqinisekisa ukuthi 
lolulwazi luyimfihlo futhi angeke lwatshelwa noma ubani. / Before you answer the next 
questions, we want to assure you that the information you give will not be told to anybody. 
 
5. Unako ukukhwehlela, inkinga yokuphefumula, isifo esiqhubekayo noma 
ukukhubazeka? Siza chaza/Do you have a cough, breathing problems, a chronic disease or a 
disability? Please 
describe._   
 
 
 
6. Ingabe uyaye uye kohlolwa emtholampilo noma kudokotela? yebo cha 
akwenzeki / Do you regulary go to a clinic or a doctor? (Yes, no, NA) 
Ingculazi yisifo esithathelana ngegazi noma ngokuhlangana ngokocansi nasobisini 
lwebele. /HIV is a disease that is transmitted through blood, sexual contact and breast milk. 
7. Wake wezwa ngengculazi? yebo cha /Have you heard about HIV before? (Yes, no) 
8. Usuke wahlolelwa ingculazi? yebo cha angazi /Have you ever been tested 
for HIV? (Yes, no, DK) 
9. Ingabe uyazi ukuthi unayo ingculazi? yebo cha angazi /Do you know if you have 
HIV?(Yes, no, DK) 
Uma kungu CHA yiya ku Section F?If No go to Section F 
Uma kunguYEBO: Ngiyadabuka ukuzwa ukuthi unengculazi kodwa kukhona 
imishanguzo emihle yazo zonke lezizifo eziqhubekayo. /(If yes:) I am so sorry to hear that you 
have HIV, but nowadays there is good treatment for all of these chronic diseases. 
10. Kukhona obheka izinga lakho leCD4-count emtholampilo? yebo cha angazi 
I is there someone at the clinic monitoring your CD4-count? (Yes, no, DK) 
 
 
 
 
 
F. Okuphathelene nezitho zokuzala nomchamo / Genitalia and urine 
Mhlawumbe uyazi ukuthi abesifazane bayopha zinyanga zonke. Lokhu kubizwa 
ngokuthi ukuya esikhathini. Ungaya esikhathini kusukela eminyakeni 
eyisikhombisa (7) kuya kwengamashumi amabili (20) ubudala / Maybe you know that 
women bleed every month. This is called menstruation. You can start your menstruation from 7 up to 20 
years of age. 
 
1. Usuqalile ukuya esikhathini? Yebo cha /Have you started menstruating? 
(Yes/no) 
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Uma kungu YEBO yiya kuQ2/If No go to Q2 Uma kungu CHA yiya kuQ4/If No go to Q4 
2. Waqala nini ukuya esikhathini |    |    |(iminyaka)/ When did you first get 
menstruation(age) 
3. Uma kunguyebo, ingabe uya esikhathini njalo nje?/ Yebo cha /If yes, do 
you  get your menstruation regularly?Yes, no 
 
 
 
 
SEBENZISA ICHART YEMIBALA BESE UFAKA INAMBA YOMBALA kuColour 2a No 2b 
USE COLOUR CHART AND INSERT ONE COLOUR NUMBER FOR 2a AND ONE COLOUR NUMBER 
FOR 2b. 
4 Wake waba nakho 
okuphumayo noma 
okusagazana ungekho 
esikhathini ungasiza 
ukhombe ukuthi 
kumbala muni / Have 
you ever had discharge or 
trace of blood when it’s not 
your menstruation and can 
you please point out the 
colour. 
Njalo 
ngesonto 
Every week 
Njalo 
ngenyanga 
Every month 
Kanye 
Once 
Akukaze 
Never 
(0) 
Njalo (3) 
kwesinye 
isikhathi (2) 
akukaze (0) 
/Always(3) 
sometimes (2) 
never (0) 
4a. Okuphumayo /Discahrge 
(Grade 1-8) 
     
4b. Okusagazana/Trace of 
blood (Grade 1-6) 
     
4c. Ingabe kunephunga 
(njalo, kwesinye 
isikhathi, akukaze) 
Does it smell (always, 
sometimes, never) 
     
 
 
Emantombazaneni isitho sangasese sinezimbobo/gudu ezintathu. Imibuzo 
elandelayo igxile ikakhulu embotsheni yesibili ebizwa ngokuthi yinkomo (Isitho 
sangasese sowesifazane)/In girls the private parts consist of three openings. The next questions 
focus mostly on the second opening, called the vagina. 
 
5 Wake wezwa ukungaphatheki kahle 
esithweni sakho sangasese njengo: 
/Have you ever felt any discomfort in your 
private parts like: 
Esontweni 
eledlule 
This last 
week 
Kudala 
phambilini 
Sometime 
before 
 
Akwenzeki 
/Never 
5a Ukulunywa / Itch    
5b Ukushisa/Ukushoshozela / Burn/Sting    
5c Uzozo/isilonda / Sore (ulcer)    
5d Isimila/isigaxa / Lump (tumour)    
6 Wake waba nayo inkinga noma yiphi 
ngokuchama njenge:/Have you ever had 
any problems with urination like: 
Esontweni 
eledlule 
/This last 
week 
Kudala 
phambilini 
/Sometime 
before 
Akwenzeki 
/Never 
6a Zinhlungu uchama / Pain when you urinate    
6b Ukuzwa sengathi ufuna ukuchama 
esithubeni /Sudden urge to urinate 
   
6c Iconsi lomchamo uma ugxuma, 
ukhohlela noma uhleka / Drop of urine if 
you jump, cough or laugh 
   
6d Umchamo obomvu / Red urine    
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G. Wena nabangani bakho - Ubuhlobo / You and your friends – Relations Manje 
ngizokubuza imibuzo ngabangane bakho nokuhlobana kwenu. Lezi yizitatimende, 
ngizokufundela izitatimende kufuneka ungitshele ukuthi akukona, ingxenye ayikona, 
ingxenye iyiqiniso, iqiniso. /Now I will ask you some questions about your friends and 
relationship. These are statements, and I will read the statement for you, and you must tell me if it is 
false, partly false, partly true or true. 
 
1 Isitatimende /Statement Akukona 
False 
Ingxenye 
Ayikona 
Partly 
false 
Ingxenye 
yiqiniso 
Partly True 
Iqiniso 
True 
1a. Kukhona abantu obaziyo 
kubangane bakho abenza izinto 
ukukujabulisa/There are people you 
know amongst your friends who do things 
to make you happy 
    
1b. Kukhona abantu obaziyo 
kubangani bakho abakwenza 
uzizwe uthandeka. /There are people 
you know amongst your friends who make 
you feel liked. 
    
1c. Kukhona abantu obaziyo 
kubangani bakho abangathenjwa 
noma kwenzakalani. /There are people 
you know amongst your friends who can 
be relied on no matter what happens. 
    
1d. Kukhona abantu obaziyo 
kubangane bakho abangabona 
ukuthi unakekelekile uma udinga 
lokho/There are people you know 
amongst your friends who would see that 
you are  taken care of if you needed to be 
    
1e. Kukhona abantu obaziyo 
kubangane bakho abakwenza 
uzizwe uyingxenye ebalulekile 
ezimpilweni zabo /There are people 
you know amongst your friends who make 
you feel that you are an important part of 
their lives 
    
1f. Kukhona abantu obaziyo 
kubangani bakho abakumukela 
njengoba unjalo. / 
There are people you know amongst your 
friends who accept you just as you are. 
    
1g. Kukhona abantu obaziyo 
kubangani bakho abakuxhasayo 
nabakugqugquzelayo. /There are 
people you know amongst your friends 
who give you support and encouragement. 
    
 
 
 
H. Okudakayo / Alcohol 
Imibuzo elandelayo ingophuzo oludakayo. Izimpendulo onginika zona angeke 
zatshelwa yinoma ubani./The following questions are about alcohol. The answers you give will 
not be told to anybody. 
1. Umbono kabani owazisa kakhulu mayelana nezophuza (ukusebenzisa 
utshwala) (abazali noma ogogo /ababheki abafowenu /odadewenu 
abangani abanye abadala /Whose opinion do you value most about the use of 
alcohol? (parents, grandparent, guardian, brother, sister, friend, other person, who (relation). 
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2. Wake wabuphuza utshwala? Yebo cha akukhompendulo /Have you 
ever drunk alcohol? Yes, no, NR 
Uma kungu YEBO yiya ku Q3/If Yes go to Q3 
Uma kungu CHA → izitatimende ngotshwala emva kukaQ5/If NO → statements about 
alcohol after Q5 
3. Yisiphi isikhathi sokuqala uzwa utshwala? (iminyaka) /When was the first time you 
tasted alcohol? (age) .  |    |    | 
4. Ubuphuza utshwala ezinyangeni ezintathu ezedlule? yebo cha 
akwenzeki /Have you been drinking alcohol the past 3 months? (Yes, no, NA) 
 
Manje ngizokufundela izitatimende ngotshwala, kumele ungitshele uma 
isitatimende singekona, ingxenye ingekona, ingxenye iyiqiniso noma iqiniso / 
Now I will read you some statements about alcohol, and you have to tell me if the statement is false, 
partly false, partly true or true. 
5 Isitatimende /Statement Akukona 
False 
Ingxenye 
Ayikona 
Partly 
false 
Ingxenye 
yiqiniso 
Partly 
True 
Iqiniso 
True 
5a. Uma udakwa utshele abangani 
bakho bangacasuka baphoxeke. / If 
you got drunk and you told your friends, 
they would be angry and disappointed. 
    
5b. Abangani bakho bakhuluma 
kakhulu ngokungabinesidingo 
sokuphuza utshwala. / Your friends 
talk a lot about the need to not drink 
alcohol. 
    
5c. Wena nabangani bakho 
niyagqugquzelana ukuthi 
ningaphuzi (utshwala). / Your friends 
and you encourage each other not to drink. 
    
5d. Ucabanga ukuthi akulungile 
ukudakwa. / You think it’s bad to get 
drunk. 
    
5e. Uma udakwa abangani bakho 
bangakukhathalela baqiniseke 
ukuthi uphephile. / If you got drunk, 
your friends would care and make sure you 
were safe. 
    
5f. Wake wadakwa /You were once drunk.     
5g. Ungathanda ukuthi uke udakwe /You 
would like to get drunk. 
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I. Izidakamizwa / Drugs 
1. Ingabe abangani bakho bayazisebenzisa izidakamizwa? yebo cha 
angazi / Do your friends use drugs? (Yes, no, DK) 
2. Uyazisebenzisa izidakamizwa? yebo cha / Do you use drugs?(Yes, no) 
 
3.Wake wasebenzisa 
okunye noma 
okungaphezulu kwalokhu 
okulandelayo? / Have you 
ever used one or more of the 
following 
Insangu 
dagga 
 
 
 
 
 
Yebo 
Cha 
Yiglue 
glue 
 
 
 
 
 
Yebo 
Cha 
Yibensin 
bensin 
 
 
 
 
 
Yebo 
Cha 
umgwinyo 
ecstacy 
 
 
 
 
 
Yebo 
Cha 
Okunye 1 
Other 1 
(specify) 
Okunye 2 
Other 2 
(specify) 
 
 
 
J. Ukuziphatha ngokocansi / Sexual behaviour 
Imibuzo elandelayo ingokuziphatha ngokocansi nokucabangayo wena 
nabangani bakho ngocansi. / Ngiyazi eminye yalemibuzo inzima ukuyiphendula 
kodwa ngicela usize wenze okusemandleni akho. /The next questions are about sexual 
behaviour and what you and your friends think about sex. I know some of these questions are hard to 
answer, but please do your best. 
 
1. Umbono kabani owazisa kakhulu mayelana nokuziphatha kwezocansi ? 
abazali umkhulu   ogogo u   bheki u owenu uda  ewenu 
umngani  omuny muntu (ubuhlobo nengane) / Whose opinion do you value most 
with regards to your sexual behaviours? (parent, grandparent, guardian, brother, sister, friend, other 
person,(relationship with the child) 
 
 
2. Hloboluni locansi owake walwenza? / What kind of sex have you had? 
2a Ukuphathaphatha isitho sangasese kuphela / Petting Yebo Cha 
2b Ukusoma / Thigh sex Yebo Cha 
2c Olokukhotha isitho sangasese / Oral Yebo Cha 
2d Olwasesithweni sowesifazane / Vaginal Yebo Cha 
2e Olwasembotsheni yokuzikhulula / Anal Yebo Cha 
2f Alukho / None Yebo Cha 
 
Uma kungu YEBO yiya kuQ3/If Yes go to Q3 
Uma kungu CHA kwelesitho sangasese sowesifazane noma olwesitho sokuzikhulula 
yeqela embuzweni 10 / If no vaginal or anal, jump to question 10. 
 
3. Wawungakanani ngesikhathi wenza ucansi lwesitho sowesifazane okokuqala 
ngqa? (iminyaka) / How old were you when you had vaginal sexual intercourse for the first 
time?(age) 
4. Empilweni yakho usuwenze ucansi nabantu besilisa abangaki? 
(inamba) / During your life, with how many males have you had sexual intercourse?(number) 
5. Ezinyangeni ezintathu ezedlule usuwenze ucansi nabantu besilisa abangaki? 
|__|__|(abesilisa)/ During the past 3 months, with how many males did you have sexual intercourse? 
(males) 
6. Uke waphuza uphuzo oludakayo noma izidakamizwa ngaphambi kokuba 
wenze ucansi ngesikhathi ugcina?  ebo cha NA / Did you drink alcohol or use 
drugs before you had sexual intercourse the last time?(Yes, no, NA) 
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7. Esikhathini sokugcina wenza ucansi ikhona indlela owayisebenzisayo 
ukuvikela ukukhulelwa? (khetha impendulo ibe yinye) / The last time you had sexual 
intercourse, did you use a method to prevent pregnancy? 
 
7a Ayikho indlela eyasetshenziswa No method was used Yebo Cha 
7b Amaphilisi okuhlela Birth control pills Yebo Cha 
7c Amakhondomu Condoms Yebo Cha 
14d Depo-Provera (umjovo wokuvikela inzalo) Depo-Provera (injectable) Yebo Cha 
14e Ukukhipha (ngaphambi kokuqeda) Withdrawal Yebo Cha 
14f Ezinye izindlela (yisho) Other method (specify) Yebo Cha 
14g Anginasiqiniseko Not sure Yebo Cha 
 
 
 
8. Wake wakhulelwa? yebo cha /Have you ever been pregnant? (Yes, no) 
9. Uma kunguyebo: If yes: Usumasu/khulelwe kangaki [_     ] / How many pregnancies 
have you had? (number) 
10. Ingabe kukhona owake wakunika imali, izinto noma wakwenzela okuthile 
ngokwenza ucansi?yebo cha /  Has someone ever given you money, things or favours 
for having sex? 
11. Ingabe kukhona owake wakuphoqa ukuba wenze ucansi? yebo cha 
/Has someone ever forced you to have sex? (Yes, no) 
Uma kunguYEBO: Ngiyadabuka ukuzwa ukuthi kukhona owake wakuphoqa 
ukuba wenze ucansi naye. Okuningi sizokhuluma ngaloku kamuva 
engxoxwenimbuzo yethu. /If yes: I’m sorry to hear that someone has forced you to have sex. 
We will talk more about this later in the interview. 
 
Yikuphi kulezizitatimede ezilandelayo mayelana nemibono yezocansi okuxhaswa 
ngabangani bakho? Siza ukhethe isitatimende ESISODWA / Which of the following 
statements regarding sexual ideas is supported by your friends? Please choose one statement: 
Uma wenza ucansi akumele usebenzise ikhondomu NOMA /If you do have sex, 
you should not use a condom at all OR 
Uma wenza ucansi kumele usebenzise ikhondomu kuphela nomuntu 
ongamazi NOMA /If you do have sex, you should use a condom only with someone you 
do not know OR 
Uma wenza ucansi kumele usebenzise ikhondomu ngasosonke isikhathi 
NOMA / If you do have sex, you should use a condom every time OR 
Akumele nhlobo wenze ucansi / You should not have sex at all 
 
 
 
 
Imibuzo elandelayo ingawe nabangane bakho indlela abayiyo ngokwenza 
ucansi oluphephile. Ngizokufundela izitatimende ungaphendula ukuthi 
akukona, ingxenye ayikona, ingxenye iyiqiniso, iqiniso. /The following questions are 
about you and your friends’ attitudes towards practicing safe sex. I will read out a statement and 
you can answer if it’s false, partly false, partly true or true. 
 
 
12. Isitatimende /Statement Akukona 
False 
Ingxenye 
Ayikona 
Partly 
false 
Ingxenye 
yiqiniso 
Partly 
True 
Iqiniso 
True 
12a. Uma wenze ucansi ngaphandle 
kwekhondomu utshele abangani 
bakho bangacasuka baphoxeke. / If 
you had sex without a condom and you told 
your friends, they would be angry and 
disappointed. 
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12b. Abangani bakho baxoxa kakhulu 
ngokuzithiba noma ukwenza ucansi 
oluphephile njengokusebenzisa 
ikhondomu. /Your friends talk a lot about 
the need to abstain or practice ‘safe’ sex  i.e. 
use a condom. 
    
12c. Wena nabangani bakho 
niyagqugquzelana ngokuzithiba noma 
nenze ucansi oluphephile 
njengokusebenzisa ikhondomu. / Your 
friends and you encourage each other to 
abstain or practice ‘safe’ sex i.e. use a 
condom. 
    
12d. Uma umngani wesifazane azi ukuthi 
wenze ucansi uzikhiphile angeke 
abanandaba ukuthi uyisebenzisile 
noma awuyisebenzisanga 
ikhondomu. / If a female friend knew that 
you had sex on a date, she wouldn’t care if 
you had used a condom or not. 
    
12e. Uma umngani wesilisa azi ukuthi 
wenze ucansi uzikhiphile angeke 
abanandaba ukuthi uyisebenzisile 
noma awuyisebenzisanga 
ikhondomu. / If a male friend knew that 
you had sex on a date, he wouldn’t care if 
you had used a condom or not. 
    
12f. Uma ucabanga ukuthi omunye 
wabangani bakho angase alingeke 
enze ucansi ungabagqugquzela 
ukuthi bazithibe noma basebenzise 
ikhondomu. / If you think that one of your 
friends may be tempted to have sex, you 
would encourage them to abstain or use a 
condom. 
    
 
 
K. Wena nekusasa lakho / You and your future 
Imibuzo elandelayo ingendlela ozizwa ngayo ngekusasa. /The following questions are 
about your feelings and attitude towards the future. 
1. Ezinyangeni ezingu 12 ezedlule uke wazizwa udangele uphelelwa yithemba 
cishe zonke izinsuku amasonto amabili noma ngaphezulu kulandelana 
ingangokuthi wayeka ukwenza ojwayele ukukwenza? yebo cha 
akwenzeki / During the past 12 months, did you ever feel so sad or hopeless almost every day 
for two weeks or more in a row that you stopped doing some usual activities? 
 
2. Manje ngifuna sikhulume ngemizwa yakho esontweni eledlule. 
Ngizokufundela izitatimende kumele uphendule uma kungekona, ingxenye 
ingekona, ingxenye iyiqiniso noma iqiniso. / Now I want to talk about your feelings the 
last week. I will read out a statement and you have to answer if it’s false, partly false, partly true or true. 
 
 
 
 
 Isitatimende/Statement Akukona 
False 
Ingxenye 
Ayikona 
Partly 
false 
Ingxenye 
yiqiniso 
Partly True 
Iqiniso 
True 
2a Ungamane udele ngoba akukho 
ongakwenza ukuzenzela izinto 
kangcono. / You might as well give up 
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 because there is nothing you can do about 
making things better for yourself. 
    
2b Uma izinto zizimbi uyasizwa ukwazi 
ukuthi angeke zahlala zinjalo 
unomphela/When things are going badly, 
you are helped by knowing that they cannot 
stay like that forever. 
    
2c Ulindele ukuphumelela ngokufunayo 
ngengomuso. /In the future, you expect to 
succeed in what you want. 
    
2d Ikusasa lakho kuwena libukeka 
limnyama lingenathemba. / Your future 
seems dark and hopeless to you. 
    
2e Ikusasa lakho kuwena linokungacaci 
futhi liyakungabazisa . /The future seems 
vague and uncertain to you. 
    
2f Ulilangazelele/phokophelele/ ikusasa 
lakho. / You look forward to your future. 
    
2g Akusizi ukuzama ukuthola noma yini 
oyifunayo ngoba vele angeke 
uyithole/There’s no use in really trying to get 
anything you want because you probably 
won’t get it. 
    
 
3. Imibuzo elandelayo ingendlela ozizwa ngayo ngawe. Ngizofunda 
isitatimende kumele uphendule ukuthi akukona, ingxenye ayikona, ingxenye 
iyiqiniso noma iqiniso. / The following questions are about how you generally feel about 
yourself. I will read out a statement and you have to answer if it’s false, partly false, partly true or true. 
 Isitatimende/Statement Akukona 
False 
Ingxenye 
Ayikona 
Partly false 
Ingxenye 
yiqiniso 
Partly True 
Iqiniso 
True 
3a Uzizwa ungumuntu obalulekile. / 
You feel you are a person of worth. 
    
3b Uzizwa ungumuntu onezinto 
ezinhle zeqophelo (izenzo). / You 
feel you have many good qualities. 
    
3c Kukonke uzizwa ukuthi 
uyisahluleki 
/All in all, you feel that you’re a failure. 
    
3d Uzwa ukuthi uyakwazi ukwenza 
izinto njengabanye abantu 
abaningi. / You feel you are able to do 
things as well as most other people. 
    
3e Uzwa ukuthi awunakho 
okungakanani ongabaneqholo 
ngako. /You feel you do not have 
much to be proud of. 
    
3f Sekukonke ugculisekile ngawe. / 
On the whole you are satisfied with 
yourself. 
    
3g Ufisa sengathi ungaba 
nokuzihlonipha okuthe xaxa./You 
wish you could have more respect for 
yourself. 
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4. Izitatimende ezilandelayo zingendlela owenza ngayo uma ubhekene 
nezingqinamba. Emva kokuba sengizifundile lezizitatimende, siza uphendule 
uma kungekona, ingxenye ingekona, ingxenye iyiqiniso noma iqiniso./The next 
statements are about how you react when facing difficulties./ After I’ve read the statement, please 
answer if it’s false, partly false, partly true or true. 
 
 Isitatimende/Statement Akukona 
False 
Ingxenye 
Ayikona 
Partly 
false 
Ingxenye 
yiqiniso 
Partly 
True 
Iqiniso 
True 
4a Uma unenkinga ucabanga ukuthi 
ungayixazulula. / When you have a 
problem, you think you can solve it. 
    
4b Uma omunye ekuphikisa ungazithola 
izindlela zokuthola okufunayo. / If 
someone opposes you, you can find the 
ways to get what you want. 
    
4c Kulula kuwena ukugxila 
ezinhlosweni zakho futhi ufeze 
izinjongo zakho. / It is easy for you to 
stick to your aims and accomplish your 
goals. 
    
4d Uyazethemba ukuthi ungamelana 
nezimo ongazilindele. / You are 
confident that you could deal efficiently with 
unexpected events. 
    
4e Ungaxazulula izinkinga eziningi uma 
ungenza imizamo efanele. / You can 
solve most problems if you invest the 
necessary effort. 
    
4f Ungabeka umoya phansi uma 
ubhekene nezinkinga ngoba 
ungathembela ekwazini ukubukela. / 
You can remain calm when facing 
difficulties because you can rely on your 
coping abilities. 
    
4g Uma ubhekwe yinkinga ujwayele 
ukuthola izixazululo eziningi. / When 
you are confronted with a problem, you can 
usually find several solutions. 
    
 
 
L. Okunye ukubamba iqhaza / Further participation 
Sithanda ukukubonga ngokubamba kwakho iqhaza kulokhu. Sizama ukusiza 
abanye ngalolucwaningo. / We want to thank you for participating in this. We are trying to help 
others by this research. 
2. Singathanda ukuba sithintane nawowonke amantombazane 
ngokuzayo.Ungasisiza ukugcina umkhondo wabangani bakho? yebo cha 
NA / We would like to contact all the girls in the future. Would you help us keep track of your friends? 
(Yes, no, NA) 
 
3. Ingabe uyathanda ukungenela olunye ucwaningo lapho sikuhlola khona 
futhi? Lokhu kuzosisiza sifunde okuningi ngesichenene bo cha NA 
/ Are you interested in joining an extra project where we take a few more tests from you? This will help 
us to learn more about Bilharzia.(Yes, no, N/A) 
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Summery of questions with a star attached: (Read only the part(s) that corresponds 
with what the participant mentioned earlier on) 
Ngesikhathi sengxoxombuzo ngikubuze imibuzo enzima ukuba uyiphendule. 
Ngiyabonga ngezimpendulo zakho ezithembekile. Ungitshele ukuthi:/During the 
interview I’ve asked you questions that are hard to answer. I thank you for your honest answers. You 
told me that: 
 
 
   4. Wahlolwa watholwa unegciwane lengculazi futhi neCD4-count 
ayibhekwa. Ingabe lokhu kuyiko?/ You have been tested positive for HIV and your 
CD4-count is not monitored. Is this correct? 
 
Uma kunguYEBO: Sifuna ukuthi umbheki wakho azi ngalokhu, sibonisa 
ukuthi uhlolisiswe ngokushesha okukhulu. Ngakhoke, uzothola incwadi 
evela kithina ezokusiza wena nombheki wakho ukuba nithintane 
nomtholampilo./If yes: We want your caregiver to know about this, and we recommend 
that you have a thorough investigation as soon as possible. Therefore, you will receive a letter 
from us that will help you and your caregiver to contact a clinic. 
 
   5. Usuke wahlangabezana nokungaphatheki kahle esithweni sakho 
sangasese. Singathanda ukukusiza ngaloko. Lokho kusho ukuthi 
kumele uthintane nomthalampilo uthole okokwelashwa ukuze kuphele 
lokhu kungaphatheki kahle./You have experienced discomfort in your private parts. 
We would like to help you with this. That means you should get in contact with a clinic and get 
the necessary treatment to take away the discomfort. 
 
   6. Uye waphoqwa ukwenza ucansi. Akekho onemvume yokuba 
akuphoqe ukuthi wenze ucansi naye, futhi ngiyadabuka kakhulu ukuzwa 
ukuthi usuke wahlangabezana nalokho. Uyafisa ukukhuluma ngalokho 
nomunye osebenza nathi? Uma ungakakulungeli ukuba ukhulume 
ngako, ungathola inombolo yocingo ongasithinta kuyo uma ushintsha 
umqondo./You have been forced to have sex. No one is allowed to force you to have sex 
with them, and I’m sorry to hear that you’ve experienced this. I know it is very difficult for you to 
talk about this. It’s a very heavy load to have to carry on your own. And I wonder if you would 
like some help from somebody… We would like to offer you ……… If you’re not ready to talk 
about it now, you can get a phone number that you can call if you change your mind. 
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LIST OF ORAL/POSTER PRESENTATIONS 
 
 
 
BRIGHT Scientific Day: Ramsgate Durban. South Africa. 12/11/2015. An oral presentation entitled: 
Liquid Based Cytology as a diagnostic tool for a more precise risk- assessment of schistosomiasis 
and  cervical squamous  cell atypia among young women  from Schistosoma  and HIV endemic 
populations in South Africa.  Pillay P, Taylor M, Galappaththi-Arachchige HN, Zulu SG, Roald B, 
Kjetland EF. Durban University of Technology, South Africa, 2 University of KwaZulu Natal, South 
Africa, 3 Oslo University Hospital, Norway 
 
 
 
International Scientific Workshop on Neglected Tropical Diseases: Female Genital Schistosomiasis 
and its impact on HIV/AIDS. Magaliesburg, South Africa. 28/01/2015. An oral Presentation entitled: 
Cytology and PCR as diagnostic tools for Female Genital Schistosomiasis in a population of young 
women aged 16-21years from rural South Africa. P Pillay1, 2, M Taylor2, SG Zulu2, SG Gundersen3, 
E Kleppa 4, K Lillebo4, EF Kjetland2, 4, L van Lieshout5, B Roald 4. Durban University of Technology, 
South Africa, 2 University of KwaZulu Natal, South Africa, 3 University of Agder, Norway 4 Oslo 
University Hospital, Norway, 5 Leiden University Medical Center, The Netherlands 
 
 
 
16th International Congress on Infectious Diseases held in Cape Town, South Africa from April 2 
to 5, 2014. Poster Presentation title: Schistosoma PCR among high school girls in South Africa as a 
complimentary diagnostic tool for Female Genital Schistosomiasis (FGS) Authors: P Pillay1,2, M 
Taylor2, SG Zulu2, SG Gundersen3, E Kleppa 4, K Lillebo4, EF Kjetland2,4 , EAT Brienen5 , L van 
Lieshout5 Affiliations: 1 Durban University of Technology, South Africa, 2 University of KwaZulu 
Natal, South Africa, 3 University of Agder, Norway 4 Oslo University Hospital, Norway,  5 Leiden 
University Medical Center, The Netherlands 
 
 
9th  Public Health Association of South Africa (PHASA) 25-27TH  September 2013. Poster 
Presentation title: The use of PCR and extensive urine microscopy in the diagnosis of Schistosomiasis 
among schoolgirls in KwaZulu Natal. 1P Pillay, 2M Taylor, 2SG Zulu, 3J.J. Verweij, 
3P Hoekstra, 3EAT Brienen3, 4,5SG Gundersen, 6E Kleppa, 6E F Kjetland, 3L van Lieshout. 
Affiliations: 1 Durban University of Technology, South Africa, 2 University of KwaZulu Natal, South  
Africa, 3  University  of  Agder,  Norway 4  Oslo  University  Hospital,  Norway,    5  Leiden University 
Medical Center, The Netherlands 
 
8th European Congress on Tropical Medicine and International Health, Copenhagen, Denmark, 
September 10-13, 2013. Oral Presentation title: Real-time Schistosoma PCR in vaginal lavage and 
urine of high school girls in South Africa as an indicator of Female Genital Schistosomiasis (FGS) 
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P Pillay1,2, M Taylor2, SG Zulu2, SG Gundersen3, E Kleppa 4, K Lillebo4, EF Kjetland2,4 , EAT 
Brienen5 , L van Lieshout5 
 
 
 
VIBE Scientific Day on the 10TH January 2013 at UKZN. Oral Presentation title: PCR for 
Schistosomiasis of vaginal lavage in young women. Feasibility and usefulness. P Pillay1,3, M 
Taylor3, J Verweij 5, G van Dam 5, SG Gundersen4, EF Kjetland2,3, E Brienen5, SG Zulu 3, E 
Kleppa 2, L van Lieshout5 
 
 
VIBE Scientific Day on the 9th of March 2012 at UKZN. Oral Presentation title: "Bilharzia in the 
urinary and genital tracts detected by PCR" P Pillay, M Taylor, J Verweij, G van Dam,SG 
Gundersen, EF Kjetland, E Brienen,S Zulu, E Kleppa, K Lillebo, L van Lieshout 
 
 
 
American Society of Tropical Medicine and Hygiene, 61ST Annual Meeting Oral Presentation, - 
11-15 /11/12: Presented a paper entitled: Comparing high-throughput quantitative detection of 
Schistosoma-DNA using real-time PCR and extensive microscopy in urine samples from primary 
school girls in coastal KwaZulu Natal. P Pillay1,3, M Taylor3, J Verweij 5, G van Dam 5, SG 
Gundersen4, EFKjetland2,3, E Brienen5, S Zulu 3, E Kleppa 2, L van Lieshout5 
 
 
American Society of Tropical Medicine and Hygiene, 59th Annual Meeting Oral Presentation, 3-7 
/11/10: Presented a paper entitled: The role of pap smears in young females from a 
Schistosomaisis endemic area. P Pillay1,3, M Taylor3,  SG Gundersen4, EF Kjetland2,3, SG Zulu 3, 
E Kleppa 2 
 
 
 
 
 
Public Health Association of South Africa, 6th Conference Poster Presentation, 29/11/10: 
Presented a poster entitled: Female genital schistosomiasis (FGS) as an epidemiological risk 
factor for squamous cell atypia and genital disease in a longitudinal cohort of young women in 
KZN. 1,3 P Pillay, 2E Kleppa, 3 CC Jinabhai , 4,5SG Gundersen,3 M Taylor, 2,6 EF Kjetland. 
 
 
 
Society for Medical Laboratory Technologists South Africa. Oral Presentation, 7/09/09, Cervical 
screening in urban clinics in the eThekwini Municipal Area, Pillay P, Knight S, Rmiah WNS. 
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